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Summary of Thesis 
 
Type 2 diabetes mellitus is associated with a significant increased morbidity and 
mortality resulting from microvascular and macrovascular complications, in particular 
diabetic nephropathy and cardiovascular disease. Treatment of these conditions has 
involved improving diabetic control, reducing blood pressure and addressing other 
cardiovascular risk factors. Dietary fibre has wide reaching health benefits, including 
improvement of diabetic control and blood pressure, potentially by alterations in 
colonic bacterial populations that result in changes in serum short chain fatty acids. 
An open labelled study with a washout period was undertaken to examine the potential 
effects of Gum arabic on blood pressure and renal function.  
A daily supplement of gum arabic (25g), a soluble dietary fibre, was administered for a 
period of 12 weeks. An initial pilot study was conducted in healthy subjects (n=10) and 
subjects with overt nephropathy (n=14). A follow on study investigated subjects with 
incipient nephropathy (n=23) in more detail. Measurements of renal function, including 
isotope GFR and ERPF, blood pressure and vascular stiffness (follow on only), and 
short chain fatty acids were measured. A significant drop in GFR was seen in the 
healthy individuals with no associated change in filtration fraction, which could convey 
some renal protective effect. No changes were seen in the diabetic subjects. Significant 
drops in blood pressure were seen each of the individual groups. Results of pulse wave 
analysis and central blood pressure measurements suggest this is not as a result of 
changes in vascular stiffness. Significant changes in short chain fatty acid production 
were seen, in particular an increase in acetate (p=0.033) in the incipient nephropaths 
and butyrate (p=0.03) in the healthy subjects.  
This study suggests that Gum arabic has beneficial effects on blood pressure but no 
immediate beneficial effects on renal function in either diabetic cohort.   
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1.1 Aims 
 
There are currently numerous medications that have been proven to improve outcomes 
in patients with diabetes mellitus by reducing cardiovascular and renal complications, 
but the actual targets of treatment are limited.  
Dietary fibre has been documented to have several health benefits and I aim to look at 
the effects of supplementing the diet with Gum Arabic, a soluble fibre and examine 
outcomes on renal function and blood pressure. This was carried out firstly in two 
populations, namely healthy individuals and patients with advanced diabetic 
nephropathy, and secondly in a population of patients with type 2 diabetes and incipient 
nephropathy. 
 
1.2 Diabetes Mellitus 
 
Diabetes Mellitus is a disorder affecting blood glucose regulation resulting in chronic 
hyperglycaemia that in turn can have many serious complications including a 
significant increase in cardiovascular disease.  
 
1.2.1 Definition 
 
The World Health Organisation and National Diabetes Data Group first recommended 
uniform diagnostic criteria for diabetes in the late 1970s. This was updated and 
modified by the World Health Organisation in 1999 [1] and then further in 2006. The 
criteria now states that a diagnosis of diabetes mellitus is made on a fasting blood 
glucose of ≥7.0 mmol/L or a blood glucose of ≥ 11.1 two hours after an oral challenge 
of 75g of glucose [2].  
The classification of diabetes is then further split in to Type 1 Diabetes and Type 2 
Diabetes depending on the underlying pathogenesis. 
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1.3 Diabetes Mellitus – Type 1 and Type 2 
 
Type 1 diabetes mellitus, previously referred to as insulin-dependent diabetes (IDDM), 
is characterised by an absence of insulin production by the beta islet cells of the 
pancreas, and is usually caused by autoimmune destruction of these cells. The time of 
onset of Type 1 Diabetes is often, but not always more clearly defined, usually 
indicated by the presence of polydypsia, polyuria and ketosis. 
Type 2 diabetes mellitus, formerly referred to as non insulin dependent diabetes 
(NIDDM) is a disorder characterised by peripheral insulin resistance and 
hyperinsulinaemia. The precise time of the onset of type 2 Diabetes is more difficult to 
define and tends to have a rather insidious onset. During this time, which can last 
several years, there is hyperglycaemia, leading to organ damage even before the 
diagnosis of diabetes is made. It is also associated with impairment of fat and protein 
metabolism as a result of defects of insulin secretion, its action or a combination of the 
two [3]. Patients are not entirely dependent on administered exogenous insulin, unlike 
those with Type I Diabetes. However, long term hyperinsulinaemia may ultimately 
result in a relative impairment of insulin due to pancreatic beta cell “burnout”, 
necessitating the use of exogenous insulin. 
Importantly, both type 1 diabetes and type 2 diabetes are often associated with 
hypertension, hyperlipidaemia and an increased risk of cardiovascular disease. 
The vast majority of patients with diabetes have type 2 diabetes and therefore the focus 
of this thesis will be on patients with type 2 diabetes, it’s renal and cardiovascular 
complications and ways of modifying the course of the disease. However, I will refer at 
times to data that corresponds to type 1 diabetes to illustrate certain points. 
 
1.4 Epidemiology of Type 2 Diabetes mellitus  
 
1.4.1 Prevalence 
 
Type 2 diabetes mellitus accounts for approximately 90 percent of all diabetes 
worldwide and is most prevalent in the developed world. Currently there is massive 
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growth in the number of patients with type 2 diabetes in both the developed and 
developing world. Engeglau [4] reported in 2004 the increasing prevalence of patients 
with diabetes in the United States, as shown in Figure 1-1. In 1995 there was an 
estimated worldwide type 2 diabetes prevalence of 4%. This was expected to rise to 
5.4% over the following 30 years. This equates to an increase in absolute numbers from 
135 million people in 1995, to approximately 300 million in 2025 [5] as shown in 
Figure 1-2. The major part of this increase is occurring in developing countries with a 
170% increase, from 84 to 228 million. By the year 2025, 75% of people with diabetes 
will therefore reside in developing countries, as compared with 62% in 1995 [5].  
The National Health Interview Survey has shown a 4 to 8 fold increase in the number of 
patients receiving a diagnosis of diabetes over the last 50 years [6]. By 2002 an 
estimated 6.3% of the US population had diabetes, this has grown to 8.3% in 2011[7] 
and this number will continue to grow. 
The prevalence of type 2 diabetes in British men has been increasing significantly over 
the last 3 decades. Thomas et al have suggested that the crude prevalence of diabetes 
has risen from 1.2% in 1978-1980 to 12.1% in 2005 [8]. This was however in a selected 
age group of 40-59 year old males. Diabetes UK state the UK prevalence of type 2 
diabetes to be 4.26% as of 2010 [9].  
Figure 1-1. US Prevalence of Diabetes 1958-2000 
Adapted from Engeglau et al [4] 
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Figure 1-2. Predicted increase in Prevalence of Diabetes 
Adapted from King et al [5] 
 
 
1.4.2 Geographical variation 
 
There is wide global variation in the prevalence of the condition. In the main, Type 2 
diabetes mellitus is currently less prevalent in non-Western countries where the diet 
contains fewer calories and caloric expenditure is higher. Some of these non-Western 
populations are beginning to adopt Western lifestyles and hence weight gain and type 2 
diabetes mellitus are becoming virtually epidemic. Obesity and a lack of exercise are 
strongly linked to the development of type 2 diabetes [10]. Much of Southern Africa 
and China have the lowest rates which stand at less than 3%. Europe as a whole has a 
similar prevalence to Australasia and South America, in the region of 3 to 5%. North 
America, India and the Philippines have a higher prevalence of 6 to 8%. The highest 
prevalence areas with rates greater than 8% include parts of North Africa, much of the 
Middle East and Papua New Guinea [11]. 
In the UK, as already stated the prevalence of type 2 diabetes is slightly lower. As of 
2009, there are an estimated 2.6 million people with the condition, equating to 
approximately 4.0% of the population. In addition it is estimated there are a further 
500,000 people with the condition undiagnosed, due to the known time lag in people 
presenting with the condition [12]. 
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1.5 Pathogenesis of type 2 diabetes 
 
Hyperglycaemia as defined in Chapter 1.2.1 is as a result of a deficiency of endogenous 
insulin, either absolute as in Type 1 diabetes or relative as in the case of Type 2 
diabetes. The fundamental underlying problem in type 2 diabetes is that of insulin 
resistance which can be as a result of abnormal insulin molecules [13], an increase in 
the amount of circulating insulin antagonists or resistance to insulin in target tissues, the 
latter being by far the most common cause of type 2 diabetes. 
In obesity related insulin resistance, the normal response of the β cells of the pancreas is 
insulin hypersecretion in a process called β cell compensation. Rodent studies suggest 
there is an increase in β cell mass and enhanced β cell function with increased insulin 
synthesis. Type 2 diabetes occurs only when the subjects are unable to sustain this 
compensatory response. Early β cell failure is likely to be caused by numerous 
mechanisms including mitochondrial dysfunction, oxidative stress and dysfunctional 
triglyceride cycling amongst others. A self-fulfilling process then takes place in which 
the hyperglycaemia itself results in processes such as islet cell inflammation, amyloid 
deposition and O-linked glycosylation as a result of glucotoxicity. This leads to a loss 
of β cell mass by apoptosis [14]   
Environmental factors undoubtedly play a role in its prevalence and known 
environmental diabetogenic factors include obesity, pregnancy and intercurrent illness. 
These largely cause insulin resistance. Obesity is one of the most important factors 
associated with the development of type 2 diabetes and is also increasing in prevalence 
in the Western World and developing world. It is now reaching epidemic levels [15]. 
There are however also genetic factors and genetic susceptibility to type 2 diabetes. 
This is best demonstrated by studies in monozygotic twins which have shown 
concordance rates of 96% for an abnormality of glucose metabolism [16]. The Pima 
Indian people have also been extensively studied. They have the highest prevalence of 
type 2 diabetes of any group in the world. This is thought to be as a result of genetic 
differences, a so-called “thrifty genotype” which has now been exposed to a Western 
diet. These genetic factors however are not fully understood but are likely to be related 
to multiple genes. Increasing age is also an accepted important factor for the 
development of type 2 diabetes. 
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Free fatty acids have more recently been implicated in the development of type 2 
diabetes mellitus and obesity by mediating insulin resistance. One hypothesis put 
forward is that increased concentrations of plasma FFA induce insulin resistance in 
humans through inhibition of glucose transport activity, which appears to be a 
consequence of decreased insulin receptor substrate-1-associated phosphatidyl inositol 
3 kinase activity[17]. 
 
1.6 Complications of diabetes 
 
The major complications of diabetes can be broadly split in to those which are either 
macrovascular or microvascular in origin and are related to glycaemic control. As a 
result of these complications, particularly cardiovascular disease and diabetic 
nephropathy, there is an associated significant increase in mortality.  
Type 2 diabetes is commonly associated with a triad of medical disorders, these being 
obesity, hyperlipidaemia and hypertension, which have collectively become known as 
the “metabolic syndrome” or “syndrome X”. This term has been used for many 
decades, dating back to at least the 1950s but became increasingly used in the 1970s 
and was described by Haller in 1977 as a condition that obesity, type 2 diabetes 
mellitus, hyperlipoproteinemia, hyperuricemia and steato hepatis [18]. 
 
1.6.1 Macrovascular complications 
 
The macrovascular complications of diabetes include cardiovascular disease, 
cerebrovascular disease and an increased incidence of peripheral vascular disease. 
Macrovascular disease is a major cause of mortality and morbidity in patients with 
either type 1 or type 2 diabetes. Stamler et al, looked at cardiovascular mortality in the 
MRFIT study, between 1973 and 1975. The overall risk of cardiovascular mortality was 
3 times higher in the diabetic group compared to matched non diabetic subjects. The 
impact of other risk factors such as hypertension, hypercholesterolaemia and smoking 
have a larger effect on cardiovascular death rate in the diabetic population than in the 
non diabetic control group [19]. 
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Data analysed from the NHANES 1 Study shows that ischaemic Heart disease is the 
major cause of death associated with diabetes [20] in the United States, with a rate two 
to six times that of the general population, and an age adjusted prevalence of coronary 
heart disease twice that of the population without diabetes [21]. There has been a 
decline in the age adjusted mortality from heart disease in the US with time but this 
decline has not been shown in patients with diabetes. This correlates with a 2-fold 
increased risk for coronary heart disease in diabetic men, and a 3- to 4-fold increased 
risk in diabetic women [20] 
There is epidemiological evidence to show that there is a correlation between increased 
rates of cardiovascular disease and chronic hyperglycaemia [22-24].  
Selvin et al performed a meta analysis of largely type 2 diabetic patients and 
demonstrated an increase in relative risk for a cardiovascular event of 1.18 for every 
percentage point increase in HbA1C [24]. The evidence however on the treatment of 
blood glucose control on macrovascular outcomes is mixed. In patients with established 
diabetes, large studies such as the ACCORD study and ADVANCE study [25, 26] have 
failed to demonstrate that improved glycaemic control is associated with improved 
macrovascular outcomes. The ACCORD trial enrolled 10,251 patients with 
longstanding type 2 diabetes, randomising patients to an intensive treatment group, 
aiming for HBA1C of <6.0%, or to a standard arm aiming for HbA1C of 7.0 to 7.9%. 
The trial was brought to a halt in 2008 after 3.5 years, due to a higher number of 
cardiovascular deaths in the intensive treatment group [27]. No significant difference in 
non fatal cardiovascular events was shown between the groups. Similarly, the 
ADVANCE trial enrolled 11,140 patients with type 2 diabetes, with an intensive 
treatment (HbA1C <6.5%) group and a standard treatment group. There was no 
increased risk of death but also there was no reduction in macrovascular events or death 
from cardiovascular causes. Both of these studies have looked at intervening in patients 
with longstanding diabetes. In patients with newly diagnosed diabetes, there may be 
benefit from stricter control of HbA1C.  
The UKPDS 33 study [28] randomised 3867 newly diagnosed patients with type 2 
diabetes to either an intensive management group, treated with either a sulphonylurea or 
insulin aiming for a blood sugar of < 6 mmol/L, or to a conventional group treated with 
diet aiming for the best achievable blood sugar. The study continued for 10 years and 
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demonstrated a risk reduction of 10% for any diabetes related endpoint and a 10% 
reduction for any diabetes related death (NS) for the intensive treatment group. Most of 
the reduction in diabetes related events however came from the significant reduction in 
microvascular events. There was a 16% risk reduction in myocardial infarction in the 
intensive management group but this did not reach statistical significance (p=0.052). 
The authors postulate that a 10 year follow up may be too short to demonstrate 
significant differences in macrovascular events. 
 
1.6.2 Microvascular Complications 
 
The microvascular complications of diabetes are diabetic retinopathy, diabetic 
neuropathy, and diabetic nephropathy. The UKPDS 35 showed that HbA1c is strongly 
associated with microvascular events and that a 1% reduction in HbA1c was associated 
with a 37% reduction in microvascular complications [29].  
All of the microvascular complications are as a result of microangiopathy, as a result of 
thickening of the capillary basement membrane, resulting in increased vascular 
permeability. Metabolism of glucose to glucose alcohol (sorbitol) via the polyol 
pathway is thought to be key in the process. High glucose levels as a result of diabetes 
increase the flux of sugar molecules through the polyol pathway, which causes sorbitol 
accumulation in cells. Accumulation of sorbitol is thought to be an important 
underlying mechanism in the development of diabetic microvascular complications, 
including diabetic retinopathy. In animal models, sorbitol accumulation has been linked 
to microaneurysm formation, thickening of basement membranes [30], glycation of 
structural proteins and the production of advanced glycation end (AGE) products which 
become deposited in tissues underlies the structural and functional abnormalities of 
these diabetic complications [31].  
 
1.6.2.1 Diabetic Retinopathy  
 
Diabetic retinopathy is the leading cause of blindness in the US in persons aged 20 to 
64 years [4]. 20% of patients have established retinopathy at the time of diagnosis of 
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their type 2 diabetes. The earliest, but not macroscopically visible changes of diabetic 
retinopathy are changes in the capillary bed. With time, and poor diabetic control these 
progress through the following stages: 
• Microaneurysms 
• Retinal Haemorrhages 
• Hard exudates 
• Soft Exudates 
• Intraretinal microvascular abnormalities 
• Neovascularisation pre-retinal haemorrhage 
• Vitreous haemorrhage 
• Fibrosis 
 
Good glycaemic control, particularly early on in the disease is vital to reduce the 
development and progression of retinopathy. The UKPDS 33 study as described above, 
showed a 29% risk reduction (p=0.0031) in the incidence of photocoagulation for 
retinopathy with intensive control of blood sugar [28].   
 
1.6.2.2 Diabetic neuropathy 
 
The underlying pathogenesis of diabetic neuropathy is common to all of the 
microvascular complications. It predominantly affects the somatic nervous system, 
resulting in complications such as polyneuropathies and mononeuropathies, but also 
involves the autonomic nervous system resulting in complications such as gastroparesis 
and postural hypotension. The complication tends to occur relatively early in diabetes 
and affects up to about 30% of patients. The Diabetes Control and Complications Trial 
Research Group showed in 1993, albeit in patients with type 1 diabetes, that intensive 
glycaemic control was associated with a reduction in the incidence of neuropathy by 
60% compared to those in the standard treatment group [32]. 
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1.6.3 Diabetic Nephropathy 
 
It was previously a common belief that patients with Type 1 diabetes were at a higher 
risk of developing nephropathy than those with Type 2 diabetes. It is now widely 
accepted that the risk is similar [33]. 
Diabetic nephropathy is a slow and often progressive process, ranging from early 
glomerular hyperfiltration to overt diabetic nephropathy and end stage renal failure. It is 
recognised though that about 30% of patients with incipient nephropathy will regress 
back to normal with an absence of microalbuminuria. The earliest sign of diabetic 
nephropathy is glomerular hyperfiltration. This is related to glycosuria but does not 
seem to show any relationship to the development of more advanced diabetic 
nephropathy. Blood pressure and albuminuria are usually normal. Even at the time of 
diagnosis of type 2 diabetes, approximately 30 to 40% of patients have an elevated 
glomerular filtration rate (GFR) [34]. Estimated renal plasma flow (ERPF) however 
remains unchanged meaning that there is an increased filtration fraction 
(FF=GFR/ERPF). This would imply that there is glomerular hypertension, which is 
thought to be an important factor in the progression of diabetic nephropathy. Population 
based studies also suggest that there is a 5-10% prevalence of nephropathy even at the 
time of diagnosis of Type 2 Diabetes, due to the lag in making the diagnosis of diabetes.  
There is often a latent period during which glomerular filtration rate is at the upper limit 
of normal, but albumin excretion remains in the normal range. The development of 
microalbuminuria is often termed “incipient nephropathy”.  These patients have a Urine 
albumin excretion rate (UAER) between 30 and 300mg/day. This occurs approximately 
5 to 15 years after the diagnosis of diabetes. Glomerular filtration rate remains within 
the normal range. 
Twenty four hour urine collections have long been, and remain the gold standard for 
assessment of urine protein or albumin excretion. However they are cumbersome for 
patients to perform and are often inaccurately collected or incomplete. More recently 
the level of albumin has been defined by measurement of an Albumin : Creatinine ratio 
(ACR). The urinary albumin : creatinine ratio is measured using the first morning urine 
sample where practicable and is a much simpler test for patients to provide a sample 
for. 
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Microalbuminuria is diagnosed when there is an albumin: creatinine ratio of: 
≥ 2.5 mg/mmol (men) or ≥ 3.5 mg/mmol (women).  
Proteinuria is diagnosed by an albumin: creatinine ratio of ≥ 30 mg/mmol. 
 
As the disease progresses there is an increase in albuminuria, along with a progressive 
fall in glomerular filtration rate and a rise in blood pressure. The decline in GFR is 
generally quite predictable in a particular patient but varies quite considerably between 
patients. In untreated diabetic nephropathy the mean rate of decline is 5-10 ml/min/year 
but the overall range is quite considerable with a rate between 1 and 20 ml/min/year. 
The patients that decline more rapidly are more likely to have poorer glycaemic control, 
higher blood pressure, higher albumin excretion rates, hypercholesterolemia and are 
more likely to be smokers [35]. Overt nephropathy develops between 10 and 15 years 
after the diagnosis of diabetes and is defined as a UAER of >300mg/day, also termed 
“proteinuria”. This is equivalent approximately to a 24 hour urine protein excretion of 
0.5g/24 hours. 
In the group of patients who develop nephropathy, end stage renal failure occurs 
between 15 and 30 years after the diagnosis of diabetes has been made, normally some 
5 years after the onset of proteinuria [36]. There is however a state of flux between the 
stages of diabetic related renal disease. For example, some of the patients who progress 
to have microalbuminuria can revert back to the normal state.  
Approximately 20 years after a diagnosis of type 2 diabetes has been made 25% of 
those patients will have nephropathy. Of those patients, 20% will require renal 
replacement over the next 10 years. Type 2 diabetics make up a significantly higher 
proportion of patients with nephropathy compared to Type 1 diabetics, as type 2 
diabetes is 10 to 15 times more common [35]. 
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1.6.3.1 Pathology 
 
The changes within the kidney are the same whether the underlying diagnosis is either 
type 1 or type 2 diabetes. 
The normal kidney consists of approximately 1-1.5x106 nephrons, the basic functioning 
unit of the kidney. A nephron is made up of a glomerulus, which possesses an afferent 
arteriole, efferent arteriole and a capillary tuft, and a number of tubules lined with 
epithelial cells. The glomeruli occupy the outer part of the kidney referred to as the 
cortex and the tubules traverse from the cortex to the inner part of the kidney referred to 
as the medulla. Tubules in turn become collecting tubules and drain urine in to the renal 
pelvis [37]. 
The earliest histopathological change seen is renal hypertrophy, with kidney mass 
increasing by approximately 15%. Renal hypertrophy is thought to be due to tubular 
hypertrophy and hyperplasia and an expansion of the tubulointerstitium.   
Thickening of the glomerular basement membrane is a common feature of diabetic 
nephropathy and is almost always a feature of the disease in patients with a history of 
diabetes of more than 15 years [36]. The thickening of the basement membrane 
progresses through the course of disease in to the later stages of diabetic nephropathy 
[38] 
Expansion of the mesangium within the Bowman’s capsule leads to the pathological 
hallmark of diabetic nephropathy. This nodular glomerular lesion was originally 
described by Kimmelstiel and Wilson in 1936. These nodules on light microscopy are 
well-demarcated, eosinophilic, Periodic acid-Schiff (PAS) positive masses located in 
the central regions of peripheral glomerular lobules. They are virtually pathognomic, 
but do not necessarily have to be present to make a diagnosis of diabetic nephropathy. 
The prevalence of these lesions on renal biopsies occurs in about 20% [38] but in some 
series suggest they may be present in up to 47% [39]. 
Diffuse glomerular lesions are more frequent than nodular lesions and occur in 
approximately 25-50% of patients with type 2 diabetes for more than 10 years. The 
incidence is higher in patients with type 1 diabetes and nephropathy, at over 90%. 
These diffuse lesions involve expansion of the mesangium due to accumulation of 
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matrix. As the disease progresses, glomeruli become progressively sclerosed. This 
occurs as a result of mesangial expansion and from ischaemic injury. This ischaemic 
injury is either as a result of hyalinosis of the afferent arteriole, resulting in a reduction 
in glomerular blood flow or as a result of the mesangial expansion causing capillary 
occlusion [40]. Hyaline material progressively replaces the entire arteriolar wall of both 
efferent and afferent arterioles and is a common feature of diabetes. Involvement of the 
efferent arteriole is a highly specific finding to diabetic nephropathy, in contrast to the 
changes seen in hypertension in which only the afferent arteriole is affected. 
Hypertensive changes in the kidney often co-exist in patients with type 2 diabetes. 
Early data suggested that it was the glomerular abnormalities that resulted in 
progressive renal disease, but study data now suggests that the rate of decline in renal 
function is more closely related to the degree of tubulointerstitial damage rather than 
that of glomerulosclerosis [41, 42]. Although the aetiologies of progressive renal 
diseases such as chronic glomerulonephritis and diabetic nephropathy are different there 
is a final common pathway that results ultimately in glomerulosclerosis, tubular atrophy 
and interstitial fibrosis as a result of accumulation of extracellular matrix. An 
inflammatory cell infiltrate is seen within the tubulo-interstitium which is similar to that 
seen in many other chronic glomerulonephritides. This infiltrate consists of 
macrophages and monocytes [37].  
 
1.7 Pathogenesis of Diabetic Nephropathy 
 
The underlying cause for the pathological findings described above is multifactorial and 
are described below. 
 
1.7.1 Glycaemia 
 
In both type 1 and type 2 diabetes it has been shown in observational studies that poor 
glycaemic control is a significant risk factor for the development of nephropathy.  
Hyperglycaemia, or more specifically an elevated glycosylated haemoglobin (HbA1c) 
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has been shown to correlate with a reduction in GFR in patients with type 1 diabetes 
[43] and the development of proteinuria in patients with type 2 diabetes [44].  
Hyperglycaemia is associated with mesangial cell proliferation, mesangial cell matrix 
production and mesangial cell apoptosis. Mesangial cells play an important role in 
modulation of glomerular filtration. Mesangial cell expansion seems to be in part as a 
result of an increase in mesangial cell glucose concentration [45]. 
Thickening of the glomerular basement membrane is not directly related to the duration 
of diabetes, urinary albumin excretion or hypertension, but to hyperglycaemia [46].  
 
1.7.2 Hypertension 
 
Diabetes and hypertension occur together at a frequency higher than one would expect 
by chance. Patients with diabetes are at increased risk of developing hypertension and it 
is an important factor in both the development of, and progression of diabetic 
nephropathy. As a result control of hypertension is an important target for treatment. 
Both type 1 and type 2 diabetics have an increased incidence of hypertension, it being 
most marked in type 2 diabetics however, presenting earlier as part of the metabolic 
syndrome.  It has been shown in the Pima Indians, a group at increased risk of diabetes, 
that blood pressure before the onset of diabetes predicted the UAER after the onset of 
type 2 diabetes [47].  The Hypertension in Diabetes Study studied 3648 newly 
diagnosed type 2 diabetic patients found that 39% of patients were hypertensive, or on 
antihypertensive medications, 2 and 9 months after the diagnosis of type 2 diabetes. 
They also noted that this same group of patients were more at risk of a cardiovascular 
event prior to the diagnosis of diabetes [48].  
Not only is the risk of developing hypertension increased in a diabetic population but 
the hypertension is also independently associated with a progressive decline in GFR. In 
a cohort of 41 type 1 diabetic patients with persistent microalbuminuria, the rate of 
decline in GFR rose with increasing diastolic blood pressure with an r value of 0.52 
(p<0.0001) [49]. Hovind et al demonstrated in a population of type 1 diabetics, that an 
increase in mean arterial blood pressure, systolic or diastolic blood pressure was 
significantly associated with a worsening of GFR [50]. In a study of 227 type 2 diabetic 
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patients, a rise in systolic blood pressure of more than 10mmHg was associated with an 
increased rate of decline in GFR [51].  The occurrence of hypertension in a diabetic 
individual also increases the risk and accelerates the course of cardiac disease, 
peripheral vascular disease, cerebrovascular disease and retinopathy [52].   
The following three major factors are thought to contribute to the development of 
hypertension.  
 
• Hyperinsulinaemia 
Randeree at al retrospectively studied 80 patients with type 2 diabetes, whom had failed 
to reach target glucose levels with dietary measures and oral hypoglycaemic agents. 
After the commencement of insulin, they noted a statistically significant rise in both 
systolic (131.8 ± 1.7 to 148 ± 1.9 mm Hg, p<0.05) and diastolic (80.9 ± 0.9 to 89.2 ± 
1.0 mm Hg, p<0.02) blood pressure. A control group showed no such rises [53]. The 
underlying pathophysiology of this is not well understood and has not been 
demonstrated in all studies. The rise in blood pressure may be related to the associated 
weight gain caused by hyperinsulinaemia or due to an inherent prohypertensive effect 
of insulin itself. 
 
• Intravascular volume expansion 
It is accepted that sodium retention has a role in the pathophysiology of hypertension in 
humans. Sodium reabsorption occurs in the kidney, by reabsorption at the distal or 
proximal tubule, as a result of increased serum glucose and insulin concentrations. 
Insulin plays a role in the transportation of cations across the cell membrane resulting in 
increased levels of intracellular sodium.  Nosadini et al showed that impaired insulin 
sensitivity is associated with sodium retention and that insulin resistance is linked with 
slight elevations in blood pressure and albumin excretion rates [54]. The effect of salt 
retention on hypertension can be reversed by dietary salt restriction. 
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• Arterial stiffness 
Cruickshank et al studied a population of 397 type 2 diabetic patients and a control 
group for 10 years. Brachial blood pressure was studied and measures of vascular 
stiffness were obtained using doppler derived aortic pulse wave velocity (PWV). Mean 
systolic but not diastolic blood pressure and aortic PWV rose progressively with 
declining glucose tolerance. Pulse wave velocity was higher, indicating less compliant 
arteries, in the diabetic population for any given systolic blood pressure. This was 
associated with a doubling in mortality risk (hazard ratio 2.34, 95% CI 1.5 to 3.74) [55]. 
 
1.7.3 Proteinuria 
 
Work initially carried out in animal models suggested that proteinuria was not only a 
marker of renal disease in diabetes but may actually be responsible for causing 
progression of the disease.  
This has now been confirmed in humans with diabetes mellitus. Early work published 
by Rossing et al showed that in patients with type 1 diabetes there was a significant 
correlation between rate of decline in GFR with both diastolic blood pressure and 
albuminuria [49]. More recent studies have confirmed these findings. Hovind et al have 
shown in a population of type 1 diabetics that albuminuria has a significant positive 
correlation with decline in GFR. Univariate analysis in this study of 301 patients, 
showed that albuminuria had a correlation with decline in GFR of r=0.41(p<0.001) 
[50]. This relationship also seems to be true of patients with type 2 diabetes. In an 
average follow up time of 6.5 years, both higher baseline albuminuria and elevated 
mean albuminuria were associated with a significantly higher rate of decline in renal 
function [51]. Parving et al have shown that patients with the lowest rates of urine 
albumin excretion had a rate of decline in GFR less than half that of patients with 
higher levels of albumin excretion [56]. This data is also supported by the UKPDS 64 
study that studied 5097 patients with type 2 diabetes. This showed that patients 
progressed from a no nephropathy group, to microalbuminuria, to macroalbuminuria to 
a raised plasma creatinine or RRT at rates shown below [57]. The effect of treatments 
targeted at urine protein excretion are discussed in Chapter 1.10.3. 
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Figure 1-3. Annual Transition Rates (95% CI)[57] 
 
Excessive and sustained protein trafficking has been shown experimentally in both 
animals and humans to result in progressive renal parenchymal damage [58]. In animal 
models a reduction in the total nephron mass sets up a series of adaptive events to 
maintain renal function. The resultant haemodynamic changes are potentially damaging 
in the long term. As a result of increased glomerular pressure, proteins are filtered and 
reach the proximal tubule. These proteins then need to be reabsorbed from the proximal 
tubule and this can lead to interstitial injury by activating intracellular events, including 
upregulation of vasoactive and inflammatory genes. As a result an interstitial 
inflammatory reaction is set up which precedes any renal scarring but correlates with a 
decline in renal function [59]. 
Albuminuria has therefore become a target for the treatment of diabetic nephropathy 
and will be discussed later in this chapter.  
It has long been recognised that both microalbuminuria and proteinuria are significant 
independent cardiovascular risk factors, associated with an increase in mortality and 
morbidity [60, 61]. However, the concept of there somehow being a difference between 
microalbuminuria and overt proteinuria in terms of progression of renal disease and its 
associated complications is now being challenged. Ruggenenti et al have shown that the 
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risk of progression of kidney disease is a continuum even within the nomoalbuminuric 
range and suggest that we should abandon the concept of microalbuminuria and should 
view levels of albuminuria in a similar fashion to levels of cholesterol [62] 
 
1.7.4 Genetic susceptibility 
 
The level of risk of developing diabetic nephropathy cannot be explained solely by 
duration of diabetes or hypertension or by the adequacy of glycaemic control. The 
chance of developing diabetic nephropathy is significantly increased in individuals who 
have a sibling or parent with diabetic nephropathy [45, 63]. Further evidence comes 
from Pettitt et al who have demonstrated that in Pima Indian families with two 
successive generations of members with type 2 diabetes the risk of the offspring 
developing proteinuria was 22.9% if one parent had proteinuria and 45.9% if both had 
proteinuria [64]. Genetics must therefore have an important role.  
Advances in molecular genetics and genotyping have now enabled researchers to 
identify susceptibility genes for microvascular complications of diabetes and for 
diabetic nephropathy [45]. Loci on chromosomes 3, 7, 9 and 20 have been identified in 
Pima Indians as being important in microvascular complications and chromosomes 
7q21.3, 10p15.3, 14q23.1 and 18q22.3 (cited in [45]).  
Numerous studies have looked for candidate genes involved in the development and 
progression of diabetic nephropathy. Candidate genes that have attracted most interest 
are those that involve the renin-angiotensin system. In particular the DD (homozygous 
deletion) polymorphism of the ACE gene has been associated with an increase risk of 
developing diabetic nephropathy, severe proteinuria, progressive renal failure and 
mortality in dialysis subjects, in patients with type 2 diabetes [45]. Similar effects have 
been shown in patients with type 1 diabetes [65].  
Other genes encoding the aldose reductase gene, angiotensin II receptor, cytokines, 
proteins involved in glucose or lipid metabolism and extracellular matrix proteins have 
also been studied demonstrating the multifactorial nature of the genetic determinants of 
diabetic nephropathy [45, 66].  
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1.8 Morbidity and Mortality associated with diabetic nephropathy 
 
There are significant differences in survival of diabetics who develop nephropathy, 
compared to those who do not. Andersen et al demonstrated that in a follow up of 1471 
patients with type 1 diabetes, the 40 year survival of patients (249 patients) who had 
developed nephropathy was 10%, compared to those who had no evidence of 
nephropathy whose survival was 70% [67] (See Figure 1-4 ). This however was prior to 
the use of angiotensin converting enzyme (ACE) inhibitors, the impact of which will be 
discussed later.  
 
Figure 1-4. Survival Comparison with or without Nephropathy 
 
The presence of either overt proteinuria or microalbuminuria is associated with an 
excess of cardiovascular mortality and morbidity. The United Kingdom Prospective 
Disease Study (UKPDS 64) looked at this in detail in a cohort of over 5000 patients 
with type 2 diabetes. As patients progressed through stages of nephropathy there was a 
statistically significant (p<0.0001) increase in the risk of cardiovascular death [57]. 
The annual mortality rates as shown below. 
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Figure 1-5.Annual Mortality Rates with progression of Diabetic Nephropathy 
 
Gerstein studied data from the HOPE study looking at 1963 patients demonstrated to 
have microalbuminuria, 1140 of whom had diabetes. In the diabetic group the risk ratio 
for major cardiovascular events was 1.97 (1.68-2.31, p<0.001) and for all cause 
mortality was 2.15 (1.78-2.60, p<0.001). [68] 
The hypertension that occurs in association with diabetic nephropathy is further 
associated with an increased mortality and morbidity, and tends to be more difficult to 
control than that which occurs in non-diabetic subjects [69]. 
 
The World Health Organisation Multinational Study of Vascular Disease in Diabetes 
looked at the increased risk of cardiovascular mortality in both type 1 and type 2 
diabetes, and its relation to hypertension and proteinuria. Over 4700 diabetic patients 
were included in the study between the ages of 35 and 55. Standardised mortality ratios 
(SMR) were shown to be higher in the patients with type 1 diabetes compared to those 
with type 2 diabetes. SMR increased with duration of diabetes. The most significant 
data to emerge from the study was the increased mortality risk in those patients with 
both hypertension and proteinuria. In this sub group the increased risk was 11x for men 
with type 1 diabetes and 18x for women with type 1 diabetes compared to controls. The 
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risks for patients with type 2 diabetes were not as marked but still greatly increased 
with a 5 times increased risk for men with type 2 diabetes and 8 times for women with 
type 2 diabetes [61].  
 
1.9 Economic Impact of Type 2 Diabetes and Diabetic Nephropathy 
 
Type 2 diabetes is associated with significant morbidity and mortality which in turn 
carry a large financial cost.  
The National Health Interview Survey indicates that people with diabetes have a 
prevalence of physical disability twice that of people without diabetes (66% vs. 29%; P 
<0.001)[70]. 
The overall financial burden that this brings to countries is huge although exact cost is 
very difficult to pin down precisely, but broadly speaking derives from three categories.  
• The direct costs of diabetes care itself, such as the cost of insulin and 
medications. In 2005, the estimated cost in the US of diabetes is $132 billion, 
$92 billion of which is from direct medical costs.[71] In the UK it has been 
estimated that diabetes accounts for 9% of the annual NHS expenditure [72]. In 
2000, this equated to about £5.2 billion.  
• The costs of the complications of diabetes are harder to quantify, but arise from 
the cost of care of conditions such as ischaemic heart disease and peripheral 
vascular disease, conditions that are far more common in the diabetic compared 
with the general population.  
• Finally, and perhaps the hardest to put a cost on are the costs associated with its 
impact on the ability to work and quality of life issues. 
 
The cost to the health service attributable to diabetic nephropathy, again is difficult to 
quantify.  Nichols et al have shown that the healthcare costs associated with diabetes 
increase with increasing levels of proteinuria [73]. Worldwide an estimated 61 million 
people undergo renal replacement therapy. Patients with diabetic nephropathy represent 
the fastest growing group of patients in the US receiving dialysis or requiring 
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transplantation. More than 100,000 diabetic patients require renal replacement therapy 
or transplantation each year, accounting for more than 40% of the new cases of end 
stage renal disease[4]. The UK Renal Registry Data shows that the commonest specific 
cause of patients starting renal replacement therapy is diabetes. Of all adults 
commencing renal replacement therapy in 2005, 20% had diabetes as their cause of 
renal failure. This figure has continued to rise and 2010 Renal Registry data shows that 
25.3% of patients have diabetes as their primary cause of end stage renal failure [74, 
75] 
In the UK there are 49,080 patients undergoing renal replacement therapy. This is 
distributed amongst the modalities shown in Table 1-1 [74]. The cost of established 
renal failure (ERF) to the UK NHS amounts to approximately 1-2% of the entire NHS 
budget, despite ERF only representing 0.05% of the population [76]. For reference the 
annual costs of haemodialysis and of continuous ambulatory peritoneal dialysis (CAPD) 
are £35,032 and £15,570 respectively [76].   
 
Haemodialysis Peritoneal Dialysis Dialysis Transplant Renal Replacement 
21,850 3,946 25,796 23,284 49,080 
 
Table 1-1. UK prevalent patients per treatment modality – 2009 
 
 
1.10 Current Therapeutic Options 
 
The current consensus is that patients with persistent proteinuria will inevitably 
progress to end stage renal failure if they survive the associated increased 
cardiovascular risk. Treatment options for diabetic nephropathy are limited and are 
targeted at both slowing progression of renal disease principally by control of protein 
excretion and control of blood pressure. It is also important to address any associated 
cardiovascular risk factors. Current strategies can be viewed in terms of primary, 
secondary and tertiary prevention or at the targets of treatment. 
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• Primary prevention will be those treatments targeted at diabetic patients who 
have not yet developed nephropathy 
• Secondary prevention is those treatments aimed at patients who have early signs 
of being at risk for developing overt nephropathy, such as those with 
microalbuminuria. 
• Tertiary treatment is those treatments in patients who already have nephropathy 
and aim to reduce or slow progression to end stage renal failure. 
 
 
1.10.1 Control of blood glucose 
 
There is evidence to show that intensive control of blood glucose reduces the risk of 
developing incipient nephropathy. The Diabetes Control and Complications Trial 
(DCCT) was set up to look at both primary and secondary prevention of renal 
complications in patients with type 1 diabetes. There was a reduction in albumin 
excretion of 15% (p<0.001) after one year of intensive treatment of blood glucose and a 
mean adjusted reduction in risk of the cumulative incidence of microalbuminuria of 
34% (p=0.04). In the secondary prevention group, consisting of patients with early 
complications of diabetes, there was a reduction of mean adjusted risk of cumulative 
incidence of microalbuminuria of 43% (p<0.0001). The risk of developing a more 
advanced level of microalbuminuria (>70µg/ml) was also significantly reduced [77]. 
One of the largest studies specifically designed to look at the impact of glycaemic 
control on the complications in type 2 diabetes is the UKPDS 33 (United Kingdom 
Prospective Diabetes Study). Patients were randomised to either intensive treatment 
(sulphonylurea or insulin) or the conventional therapy group (diet control alone) 
Although not specifically designed to look at progression of albuminuria, development 
of microalbuminuria was reduced in the intensive treatment group with a relative risk 
reduction of approximately 0.8 for each of the 3 year study periods. This reduction in 
progression of albuminuria seems to have been accompanied by a reduced risk for the 
development of renal failure (Serum creatinine >250 µmol/l or dialysis) [78].  
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Shichiri et al, showed in a population of 110 Japanese type 2 diabetic patients that 
intensive control of blood sugar, compared to standard treatment, showed lower rates of 
progression of nephropathy (microalbuminuria to macroalbuminuria) in the intensively 
treated group [79]. 
There have however been some more recent studies that have shown a possible higher 
mortality in patients with intensively controlled blood glucose. One such study, the 
ACCORD study published in 2008, showed an increase in mortality in a population of 
patients with type 2 diabetes randomised to an intensive glucose control treatment 
group with no reduction on major cardiovascular events [27].  
Partly as a result of the concern raised in the ACCORD trial, Hemmingsen et al carried 
out a meta analysis. Despite the number of patients included, from 14 different trials, 
the authors were not able to either refute or confirm the fears of an increased 
cardiovascular mortality in patients with type 2 diabetes, randomised to intensive blood 
glucose lowering. The analysis failed to show any reduction in the risk of progressive 
nephropathy [80].  
 
The choice of hypoglycaemic agent may play a role in the reduction in progression of 
nephropathy.  In a 2005 meta analysis of trials using metformin it was found that 
patients on metformin monotherapy had improved outcomes for glycaemic control, 
weight, dyslipidaemia and diastolic blood pressure. In obese patients allocated to 
intensive blood glucose control using metformin, outcomes were better when compared 
to chlorpropamide, glibenclamide or insulin, for any diabetes related outcome and all 
cause mortality, and greater benefits than what was seen overweight patients [81].  
Rosiglitazone has now been shown in several studies to reduce albuminuria, although 
some of this effect may have been as a result of rosiglitazone’s apparent effect on 
reducing blood pressure. Two studies, one comparing rosiglitazone to glyburide and the 
other comparing these two drugs in addition to metformin, showed an increased 
reduction in urine albumin excretion in the rosiglitazone treated group compared to 
glyburide [82, 83]. 
The ADVANCE Trial aimed to see if intensive glycaemic control could improve major 
macrovascular and microvascular events including new or worsening nephropathy. 
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Patients were randomised to either a “standard” treatment group or an intensive 
treatment group to lower blood glucose to 6.5% or lower. After 5 years of follow up, 
there was a significant reduction in combined major micro and macrovascular events. 
There was also a reduction in microvascular events alone, largely attributable to the 
reduction in incidence of nephropathy. There was a reduction in new or worsening 
nephropathy. The reduction in development of microalbuminuria accounted for much of 
this improvement. There was also a reduction in new onset microalbuminuria (HR 0.91, 
p=0.02). There was no reduction in the doubling of serum creatinine [26]. 
By the time that overt diabetic nephropathy has developed, particularly in type 2 
diabetics, there is little evidence to show that tight glycaemic control affects renal 
outcome, although it may impact on other microvascular complications [56]. Wu et al 
showed that poor diabetic control prior to dialysis was associated with worse outcomes 
including mortality and cardiovascular morbidity [84].  
 
1.10.2 Treatment of Hypertension 
 
Overwhelming evidence shows that treatment of hypertension slows the progression of 
diabetic nephropathy and that it reduces albuminuria.  
Hypertension is closely linked to the development of diabetic nephropathy and has an 
impact on the rate of progression to overt nephropathy as previously discussed. 
Hypertension also tends to be more difficult to control in this population and is 
associated with a higher mortality than in a population without diabetes.  
Early work carried out by Parving et al in patients with Type 1 Diabetes clearly showed 
that by reducing blood pressure, using metoprolol, hydralazine and frusemide (or a 
thiazide), reduced the urine albumin excretion and also the rate of decline in GFR [85, 
86].  
The UKPDS 38 (United Kingdom Prospective Diabetes Study) [87] demonstrated that 
strict blood pressure control, using captopril or atenolol, to an average of 144/88 mm 
Hg, when compared with less tight control (154/87 mmHg) lead to a 30% reduction in 
microvascular complications including nephropathy. The UKPDS 39 studied 1148 
patients with type 2 diabetes and hypertension. They were again randomised to 
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captopril or atenolol. They showed that captopril and atenolol lowered blood pressure 
equally effectively. They were also both equally effective at reducing microvascular 
endpoints that included retinopathy and development of albuminuria [88]. This early 
study in to the effects of antihypertensives therefore suggested that it was the treatment 
of hypertension that prevented the development of albuminuria and not a specific 
characteristic of the medication used, a fact that would be debated and disproven in 
years to come and demonstrated in the next chapter. 
The current targets for the treatment of hypertension in this population are set lower 
than the normal population at <130/80 mmHg, reflecting the need for aggressive 
treatment [89]. The latest Chronic Kidney Disease guidelines from the National 
Institute for Health and Clinical Excellence (NICE) published in 2008 recognise the fact 
that many guidelines, including the British Hypertension Society’s, suggest a target 
blood pressure of <130/80 mmHg. However, NICE go on to explore possible negative 
cardiovascular outcomes if blood pressure is lowered too far (<120 mmHg systolic) and 
therefore suggest a target blood pressure of <130/80 mmHg in patients with diabetes 
and CKD or those with a urine PCR>100 mg/mmol and a blood pressure of 140/90 
mmHg in those without significant proteinuria [90]. 
 
1.10.3 Control of proteinuria 
 
Control of proteinuria and control of hypertension are closely linked. There is evidence 
to show that control of proteinuria and hypertension by blockade of the renin 
angiotensin system has benefits over and above that seen in control of hypertension 
with other classes of drugs. 
The first such work carried out by Lewis et al showed a renoprotective effect of 
captopril independent of its effect on blood pressure, as evidenced by a significant 
reduction in risk of doubling of serum creatinine in patients with Type 1 diabetes. The 
reasons for this renoprotective effect were not understood at the time but in the authors’ 
discussion they explore that amelioration of the proteinuria may have been linked to the 
improved renal survival [91].  
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One of the first primary prevention studies was carried out by Ravid et al in type 2 
diabetic patients with normoalbuminuria and normotension. It was shown that during a 
6 year follow up of 156 patients, transition to microalbuminuria occurred in 19% of 
placebo recipients compared to 6.5% of enalapril recipients [92]. 
In a meta-analysis by the ACE Inhibitors in Diabetic Nephropathy Trialist Group, of 12 
placebo controlled trials, ACE inhibitors have been shown to reduce the risk of 
progression from microalbuminuria to proteinuria in patients with type 1 diabetes. In 
those patients receiving an ACE inhibitor there was a decreased risk of progression 
from microalbuminuria to proteinuria with an odds ratio of 0.38 (CI 0.25 to 0.57). At 2 
years the albumin excretion rate was 50.5% lower in the treatment group (p<0.001), but 
this was compared to placebo. When this was adjusted for change in blood pressure 
there was still a significant change in albumin excretion, that was 45.1% lower than the 
placebo group[43, 93].  
The RENAAL Study [94] investigated renal and cardiovascular outcomes in type 2 
diabetics with nephropathy using the angiotensin II receptor antagonist (ARB) 
Losartan. Proteinuria was reduced by 35%. This was associated with a risk reduction of 
16% in reaching primary endpoint (doubling of serum creatinine, reaching end stage 
renal disease or death) and a 25% risk reduction in doubling of serum creatinine alone.  
The Irbesartan in Diabetic Nephropathy Trial (IDNT) looked at type 2 diabetic patients 
with hypertension and established nephropathy. Proteinuria was reduced by 33% in the 
Irbesartan group compared to a reduction of 10% and 6% in the placebo and amlodipine 
groups respectively. Compared to either placebo or amlodipine there was a risk 
reduction of 33% and 37% respectively in doubling of serum creatinine, and a 23% 
reduced risk of developing end stage renal disease compared to either group [95].  
The MICRO-HOPE study showed that the use of ramipril reduced the risk of 
progression from microalbuminuria to overt nephropathy (proteinuria) by 24% in 
diabetic patients compared to placebo. It also lowered the primary outcome risk of 
myocardial infarction, stroke or cardiovascular death by 25% [96].  
Most recently researchers from the PREVEND Study Group have shown in an 
observational study that the efficacy of blood pressure lowering agents in reducing 
cardiovascular events is dependent on the baseline level of urine albumin excretion, the 
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higher the level of albuminuria the greater the risk reduction in cardiovascular events. 
The results also suggest that drugs that affect the renin angiotensin system such as ACE 
inhibitors and ARBs may have an even more beneficial effect than other classes of 
antihypertensive [97].  
 
1.10.4 Modification of serum cholesterol 
 
Despite the potential link between lipids and diabetic nephropathy there is as yet no 
good trial data to show that reduction of serum lipids impacts on the development or 
progression of diabetic nephropathy. The renoprotective effects of HMG CoA reductase 
inhibitors in patients with either type 1 or type 2 diabetes, with microalbuminuria or 
macroalbuminuria is highly variable  [43].There is some data from the Heart Protection 
Study that suggests simvastatin use was associated with a smaller fall in estimated 
glomerular filtration rate compared to placebo in diabetic patients. Treatment with 
simvastatin was associated with a smaller fall in eGFR (5.9ml/min in simvastatin group 
vs 6.7ml/min placebo in group, p=0.0003). Although a small difference it was greater in 
those with diabetes than in those without [98]. The TNT study, using atorvastatin, 
showed that after a period of 5 years, there was a statistically significant increase in 
eGFR. However this study was not carried out purely in patients with diabetes [99]. It is 
well recognised that HMG-CoA reductase inhibitors have anti-inflammatory effects and 
the possible improved renal outcomes in these trials may not be as a direct result of 
lipid lowering but associated with these anti inflammatory properties. 
 
1.10.5 Non-pharmacological interventions 
 
Empowering patients to make a difference to their health can be an important 
mechanism to improve outcomes [100]. Several approaches are available and discussed 
in the following chapters. 
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1.10.5.1 Smoking cessation 
 
Smoking is universally accepted as a major risk factor for the development of 
cardiovascular disease and that cessation of smoking reverses a significant amount of 
that risk with time. The data in patients with diabetes has been mixed, with some trials 
failing to show an association between smoking and poor cardiovascular outcomes in 
diabetic smokers [101, 102]. There is now good evidence from a large meta analysis to 
show that there is an increase in cardiovascular mortality in diabetic smokers compared 
to non smoking diabetics with a risk ratio of 1.36 [103].  
There is also an as yet unexplained association between smoking and the risk of 
developing type 2 diabetes. A meta analysis by Willi et al demonstrated an increased 
risk in all groups of smokers, with a higher risk in heavy smokers (>20 cigarettes per 
day, RR 1.61, 95% CI 1.43-1.80) compared to lighter smokers (<20 cigarettes per day, 
RR 1.29, 95% CI 1.13-1.48) [104]. 
Christiansen [105] first proposed it as a risk factor for diabetic nephropathy in 1978. 
Several epidemiological and pathophysiological studies now support the association of 
smoking with both the onset and progression of diabetic nephropathy in patients with 
Type 2 diabetes [106]. In 1990, Ekberg et al studied a population of type 1 diabetics and 
showed that GFR was negatively related to the number of cigarettes smoked per week 
[107]. 
Smoking is a promoter of progression of proteinuria in patients with Type 1 or Type 2 
diabetes [51, 108]. Sawicki et al showed in a population of type 1 diabetics, progression 
of nephropathy was less common in non smokers compared to smokers [109].  
Not only does smoking increase the risk of progression of renal disease in both diabetic 
and non-diabetic renal disease, but also in those populations with high cardiovascular 
risk, and normal renal function, such as the elderly, those with diffuse atherosclerosis 
and severe hypertension [110].  
There is evidence to support cessation of smoking leads to some improvement in renal 
disease or slowing of progression. Progression of renal disease in patients with type 1 
diabetes has been shown to slow in patients who have stopped smoking, and that 
albuminuria decreases significantly in patients with type 1 diabetes in those who have 
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stopped smoking (cited in [111]). In a study of 91 patients with type 2 diabetes it was 
shown that quitting smoking reduced progression to macroalbuminuria and reduced 
decline in eGFR [112]. 
 
1.10.5.2 Modification of protein intake 
 
Dietary manipulation may also impact upon urine albumin excretion and progression of 
nephropathy. 
Gross et al studied 28 patients with type 2 diabetes. They were given either a chicken 
based diet or a low protein diet, in a crossover design. Results showed that the patients 
on the chicken diet and low protein diet had lower isotope GFRs compared to the 
normal diet and patients taking the chicken diet had reduced urine albumin excretion 
rates compared to the low protein and normal diets (34.3 µg/min vs 52.3µg/min vs 
63.8µg/min – P<0.05) [113]. 
There have been concerns though that in restricting protein intake in these patients, 
there is a risk of these patients becoming malnourished. A Cochrane review, carried out 
in 2009 included patients with both type 1 and type 2 diabetes. It showed that a non-
significant reduction in decline of GFR in type 1 diabetics and one trial in type 2 
diabetics demonstrated a small non significant improvement in the rate of decline in 
GFR. No data was given on level of proteinuria. One study demonstrated the 
development of malnutrition [114]. 
Given the lack of evidence that dietary protein restriction has any benefits in diabetes 
and that there are concerns over it causing malnutrition it is not currently a 
recommended treatment strategy. 
 
1.10.5.3 Weight loss and Exercise 
 
Many patients with type 2 diabetes are overweight and it is well recognised as a major 
risk factor for the development of type 2 diabetes.  
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Both obesity and low fitness levels are associated with worse cardiovascular outcomes. 
Church et al have shown significantly higher cardiovascular mortality in diabetic 
patients (type 1and 2 included in the study) with a low fitness level and increasing 
levels of obesity compared to those with a normal weight and high fitness level (HR 2.8 
in the class 1 obese group) [115]. 
Obesity in diabetes is associated with early onset of glomerulopathy and increased 
albuminuria [116].  Weight loss by diet has been shown to stabilise renal function and 
reduce urinary protein excretion in non diabetics and in patients with diabetes [117]. 
There is currently no good evidence to show that this translates in to improved 
outcomes such as slowing progression to end stage renal disease [115]. 
 
1.10.5.4 Dietary Salt restriction 
 
A recent Cochrane review on dietary salt restriction has improved our understanding of 
its role [118]. Sodium restriction has been recognised as an important factor in 
improving blood pressure control in the general population.  
By reducing salt intake to an average of 8.5 g/day, blood pressure was reduced in 
patients with type 1 or type 2 diabetes by 7/3 mmHg. Blood pressure control was 
improved by an average of 6.9/2.87 mmHg in patients with type 2 diabetes. No 
convincing change in renal function (Creatinine clearance or GFR) or ERPF was 
shown. One cited study demonstrates that dietary sodium restriction in type 2 diabetic 
subjects on Losartan reduced urinary albumin excretion, although this may in part have 
been as a result of improved blood pressure control in that group [119]. 
 
Public health guidelines recommend restricting dietary salt intake to less than 5-6g per 
day and in patients with diabetes to a level at least as low as this although firm evidence 
to support a further reduction does not exist [118]. 
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1.11 Dietary fibre intake 
 
My interest in this thesis is focussed on another aspect of dietary manipulation, that of 
dietary fibre. Dietary fibre as a term was adopted between 1972 and 1976 by Burkitt et 
al, and Trowell and Painter, but was originally described by Hipsley in 1953 [120]. The 
term was used to describe the remnants of plant components that were not broken down 
by hydrolysis in the gastrointestinal tract. Dietary fibre received a formal definition in 
December 1999 
“Dietary fibre is the edible parts of plants or analogous carbohydrates that 
are resistant to digestion and absorption in the human small intestine with 
complete or partial fermentation in the large intestine. Dietary fibre 
includes polysaccharides, oligosaccharides, lignin, and associated plant 
substances. Dietary fibres promote beneficial physiological effects 
including laxation, and / or blood cholesterol attenuation, and / or blood 
glucose attenuation”[121] 
 
The term 'dietary fibre' is commonly defined as plant material that resists 
digestion by the secreted enzymes of the human alimentary tract but which may 
be fermented by microflora in the colon [120]. As such, it includes most 
hydrocolloids, which are hydrophilic polymers, of vegetable, animal, microbial or 
synthetic origin. These are naturally present or added to control the functional 
properties of foodstuffs. Hydrocolloids include agar, gelatin, guar gum, locust 
bean gum and of interest to this thesis, gum arabic.  
 
1.12 The health benefits of dietary fibre 
 
There is a lot of epidemiological data to support that dietary fibre intake has many 
health benefits. Much of the research in to the use of dietary fibre has specifically 
looked at its beneficial effects on bowel health. There is an increasing number of 
studies published looking at additional effects such as lipid lowering, reduction of 
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cardiovascular risk and on improving blood sugar control in diabetics. These will 
be discussed in the following chapters. 
 
1.12.1 Fibre and Colorectal Cancer 
 
Colorectal cancer is a major cause of cancer death in the developed world. Hereditary 
factors, lifestyle and diet all contribute to the disease process. Fibre from grain, cereals 
and fruit has been shown to reduce the risk of colorectal adenoma [122]. Dietary fibre 
intake was assessed in a total of 33,971 participants of the Prostate, Lung, Colorectal 
and Ovarian (PLCO) Cancer screening trial. The risk of colorectal adenoma was 
inversely related to dietary fibre intake. Participants in the highest quintile group of 
dietary fibre intake, had a 27% lower risk than those in the lowest quintile of fibre 
intake. 
The European Prospective Investigation into Cancer and Nutrition (EPIC) [123] looked 
at the association between dietary fibre intake and colorectal cancer incidence. The 
authors demonstrated a hazard ratio for colorectal cancer for those with the highest 
quintile intake of dietary fibre, of 0.75 (95% CI 0.59-0.95). They also showed a trend in 
reduction in hazard ratio across the quintile groups of dietary fibre intake showing an 
8% reduction in risk for each quintile increase in dietary fibre.  
However, not all studies have confirmed the association between increased fibre intake 
and a reduction in colorectal cancer risk. A pooled analysis of 725,628 individuals from 
13 studies did show the associated reduction in colorectal cancer risk with increasing 
fibre intake but it failed to show a statistically significant association when other risk 
factors were taken into account except at very low dietary fibre intake [124]. 
 
1.12.2 Fibre and risk of developing Type 2 Diabetes Mellitus 
 
In three prospective studies that looked at over 160,000 men and women, studying the 
relationship of whole grain or cereal-fibre intake, the risk for incident type 2 diabetes 
was markedly lower in those with a higher fibre intake. In two of the studies, that 
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focussed on health care professionals, the risk for incident type 2 diabetes was 21-27% 
lower in the highest quintile of whole-grain intake and 30-36% lower in the highest 
quintile of cereal fibre intake even when adjusted for lifestyle factors – i.e. physical 
activity, BMI, waist : hip ratio, smoking, alcohol intake and education [125].  
The Nurses Health Study demonstrated a reduction in the incidence of type 2 diabetes 
of 28% (95% CI 0.53, 0.71, p<0.0001) in the group with the high intake of wholegrains 
over a 10 year follow up period. There was however an associated increased risk of 
developing type 2 diabetes with increasing quintile intake of refined grain, with a 
hazard ratio of 1.31 (95% CI 1.36, 1.82, p<0.0001) [126]. Similarly, the Health 
Professionals Study showed that after risk factor adjustment, the relative risk of type 2 
diabetes was 0.58 (95% CI: 0.47, 0.70; P for trend < 0.0001) comparing the highest 
with the lowest quintile of whole-grain intake [127]. 
The underlying mechanism by which an increased intake of wholegrain may translate in 
to a decreased risk of developing Type 2 diabetes is not fully understood but there are 
several accepted hypotheses. 
Whole grain products contain more viscous fibre than refined grain products and are 
digested more slowly. Increased dietary fibre intake has been shown to decrease 
postprandial glucose and insulin levels in diabetic and non diabetic subjects. Ordinarily, 
higher levels of postprandial glucose results in increased pancreatic β-cell production of 
insulin. This hyperinsulinaemia will maintain glucose homeostasis but with time the β-
cells become unable to keep up with demand and clinical diabetes results.  
 
Dietary fibre may play a role in reducing oxidative stress that has been associated with 
reduced insulin dependent glucose disposal and diabetic complications [126]. During 
the refining process of wholegrains, not only is the outer bran layer removed, but 
various individual antioxidants, nutrients, and phytochemicals, as well as the 
interactions between them are also removed which may go some way to explaining the 
differences between refined grain and whole grain. 
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1.12.3 Fibre and Effects on Blood Glucose in diabetic subjects 
 
One of the major ways that dietary fibre may impact upon blood glucose levels is by 
influencing the rate and degree of starch degradation within foods. Soluble fibre in 
particular has been shown to decrease the rate of starch breakdown and also the rate at 
which glucose is absorbed [128]. 
Other than its effect on lowering the risk of developing diabetes there are several papers 
showing that an increase in dietary fibre intake (and foods with a low glycaemic index) 
lowers post prandial glucose levels and HbA1c in diabetic and non diabetic populations 
[129-131].  
Data from a meta-analysis of fifteen studies investigated patients with type 2 diabetes 
randomised to either an increased dietary fibre intake or placebo. Results show a 
reduction in fasting blood glucose of 0.85 mm/L and a mean decrease in HbA1c of 
0.26% [132]. 
Guar gum is extracted from the Guar bean, and is used extensively in the food industry. 
It has also been used as a soluble dietary fibre to reduce post-prandial glucose 
absorption. The method by which either the addition of a fibre such as Guar gum, to the 
diet, or by actually adding it to food products such as pasta and breads reduces glucose 
absorption is not fully understood. Brennan suggests that in part it is due to their 
viscosity altering ability in the small intestine but also by altering the structure of foods 
and making them less amenable to breakdown by amylase, and therefore effectively 
reducing their glycaemic index [128]. 
 
1.12.4 Fibre and Lipids 
 
Soluble fibres are effective in reducing serum cholesterol by both reducing absorption 
of fat and cholesterol from the small intestine and absorption of bile acids from the 
terminal ileum [133]. Another potential mechanism by which serum cholesterol levels 
may be lowered is as a result of colonic fermentation of dietary fibre. Illman et al 
showed that in a rat model, feeding with oat bran (a soluble fibre) raised levels of serum 
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short chain fatty acids, in particular propionate. Propionate in turn can inhibit hepatic 
cholesterol synthesis [134].  
Gerhardt et al have shown that soluble fibre can reduce low density lipoprotein (LDL) 
cholesterol to a similar extent. In a small study of 44 subjects soluble dietary fibre 
reduced both total and LDL cholesterol in 78% of the individuals [135].  
Similar results have been demonstrated by Haskell et al using water soluble fibres. 
Individuals with a total cholesterol of greater than 5.17 mmol/L were given 
supplements of either acacia gum as a sole or primary source, a combination of 
psyllium, pectin, guar gum and locust bean gums or guar gum alone for a period of 4 
weeks. Acacia gum (Gum arabic) alone did not alter serum lipids, however the 
combination supplement lowered total cholesterol by 8.3% and LDL cholesterol by 
12.4%. Similar changes were seen with guar gum [136]. In a longer term study 
statistically significant sustained reductions in both total cholesterol and LDL 
cholesterol of 6.4% and 10.5% respectively were seen in a group taking a mixture of 
psyllium, pectin, guar gum and locust bean gum, compared to the control group that 
was given acacia gum [137]. 
 
1.12.5 Fibre and Cardiovascular Disease 
 
In a review by Liu et al, of data, again from The Nurses Health Study, 729,472 person-
years of follow up were studied. Between the highest and lowest quintiles of whole 
grain intake there was a relative risk reduction of coronary heart disease of 33% when 
adjusted for age and smoking [138]. 
A meta-analysis of 11 studies of wholegrain fibre intake shows there is a 17% reduction 
in cardiovascular risk for each 10g of fibre added to the diet. Much of this effect seems 
to be associated with insoluble cereal fibre, but less so with soluble fruit or vegetable 
fibre [139, 140]. 
Liu et al have provided further evidence to support that a high fibre diet is 
cardioprotective. With over 230,000 patient follow up years, those patients in the 
highest, compared to the lowest quintile of fibre intake (26.3g vs 12.5g) had an adjusted 
relative risk of 0.79 for all cardiovascular disease, and a relative risk of 0.68 for 
myocardial infarction [140].  
 
 
52 
Despite the known positive metabolic effects of soluble fibre there is only limited 
evidence that they have the same beneficial effects on cardiovascular disease that whole 
grains do. This is most likely as a result of the lack of other metabolically important 
substances such as minerals, vitamins and antioxidants which are present in bran and 
the germ [139]. 
Chronic kidney disease (CKD) is widely recognised as an inflammatory state. CKD is 
an independent risk factor for cardiovascular disease [141]. An elevation of CRP in 
patients with CKD is a strong predictor of cardiovascular morbidity and mortality.  
Research has shown that a high dietary fibre intake is associated with a decrease in 
inflammation in the general population. [142].  
By studying data from the NHANES III trial Krishnamurthy et al have shown an 
association and possible causal link between levels of dietary fibre intake, inflammation 
and mortality. This link between fibre and inflammation was demonstrated in both the 
general population and a population with CKD but the link with mortality was only 
shown in those with CKD. For each 10g/day increase in fibre intake the hazard ratio for 
overall mortality was 0.83 for total fibre, 0.77 for insoluble fibre and 0.67 for soluble 
fibre [142].  
 
1.12.6 Fibre and Blood Pressure Control 
 
Early trial data looking at the effects of dietary fibre showed a reduction in blood 
pressure in diabetic patients who were placed on a high fibre, high carbohydrate diet. 
However, there has been much criticism of these papers as the diets, although being 
high in fibre, were also higher in complex carbohydrate and lower in fat than the diets 
they were compared with [143].  
Whelton carried out a meta-analysis of 25 randomised controlled trials to assess the 
effect of dietary fibre on blood pressure control. The greatest improvements in blood 
pressure were in those patients with existing hypertension with a reduction of 
5.95mmHg (95% CI -9.50 to  -2.40) in systolic blood pressure and a reduction in 
diastolic blood pressure of  4.20 mmHg (95% CI -6.55 to -1.85) [144]. 
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The DASH (Dietary Approaches to Stop Hypertension) Collaborative Research Group 
published important data in 1997 [145]. The “combination diet” led to a reduction in 
systolic blood pressure of 5.5mmHg (p<0.001) and 3.0mmHg (p<0.001) in diastolic 
blood pressure, more than in the control group. The “fruit and vegetables diet” led to 
reductions of 2.8mmHg (p<0.001) and 1.1mmHg (p=0.07) respectively more than the 
control group. These reductions in blood pressure were seen in the first 2 weeks of 
commencing the diet and were maintained for the remaining 6 weeks. 
The PREMIER Clinical Trial investigated the effects of combining the diet used in the 
DASH Trial with further lifestyle modifications and demonstrated further 
improvements in systolic and diastolic blood pressure [146]. 
In a meta-analysis of 24 randomised controlled trials by Streppel et al, fibre 
supplementation of 11.5g/day reduced systolic blood pressure by 1.13mmHg and 
diastolic blood pressure by 1.26mmHg. They hypothesise that soluble fibre, which has 
been shown to have beneficial effects on mineral absorption from the gastrointestinal 
tract, may have indirect beneficial effects on blood pressure [147]. 
 
1.12.7 Fibre and Renal Function 
 
Studies that date back more than 20 years suggest that modification of dietary fibre may 
have beneficial effects on renal function. Locust bean gum is a non digestible polymer 
of mannose and galactose derived from the seeds of the ceratonia siliqua tree. It has 
been shown to be an efficient sorbent that binds many of the potential toxic metabolites 
in patients with chronic renal failure [148].  
In a case report by Yatzidis, albeit of only 2 patients, serum creatinine was reduced and 
blood pressure improved with locust bean gum [149]. 
An increase in dietary fibre intake has been shown to increase the excretion of faecal 
nitrogen. Stephen and Cummings were amongst the first to show this. In a small study 
of 6 patients, taking a controlled diet that included 22g of dietary fibre, they were able 
to show an increase of faecal nitrogen excretion from 1.5g per day to 2g per day. Wheat 
fibre was shown to alter colonic function by retaining water and increasing the bulk of 
colonic contents, and thus decreasing transit time. However, they were also able to 
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show that as a result of fibre being a source of carbohydrate, there was an increase in 
bacterial composition of the faeces. The bacteria in turn are able to digest nitrogenous 
(that is, urea forming) compounds to the quantity of about 0.4g per day [150].  
Ispaghula husk is a hemicellulosic fibre that may also have a beneficial effect on renal 
function beyond the associated increased faecal bacterial loss. Rampton showed that a 
diet supplemented with ispaghula reduced plasma urea by 19% and increased faecal 
nitrogen excretion by 39% [151].  
Experimental data has shown that indoxyl sulphate and p-cresyl sulphate contribute to 
the progression of renal disease in CKD patients, cardiovascular disease and bone 
disease, with both of these compounds rising in parallel with decline of renal function. 
Dietary fibre has been shown to reduce colonic generation of these compounds (by 
shifting colonic microbial activity from a proteolytic one to a saccharolytic one) and 
increase short chain fatty acid production , thereby offering up another possible 
pathway by which dietary fibre may improve renal and cardiovascular outcomes [152]. 
 
 
1.13 Gum Arabic 
 
The specific focus of interest in this thesis will be the dietary supplementation with a 
modified form of Gum Arabic. 
 
1.13.1 Background 
 
Gum Arabic, otherwise known as Acacia Gum is a naturally occurring gum that is 
prepared from an exudate from Acacia trees. These trees are harvested predominantly in 
Sub Saharan Africa. The production of the gum, in a process known as gummosis, is a 
natural response of the tree to injury of bark. The gum exudes as nodules which are then 
removed by farmers as a raw product. Generally there are two varieties of the acacia 
tree that it is harvested from, these being Acacia senegal and Acacia seyal.  
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Gum Arabic is a complex and variable mixture of arabinogalactan oligosaccharides, 
polysaccharides and glycoproteins. The molecular parameters and resulting 
functionality can vary greatly for different commercial samples [153]. Acacia Senegal 
tends to have a greater relative proportion of D-galactose compared to L-arabinose. It 
consists of a lower molecular weight polysaccharide and a higher weight 
hydroxyproline rich arabinogalactan. As such it belongs to the hydrocolloid group of 
compounds. 
Gum Arabic in a more refined form has many diverse commercial uses including use as 
a watercolour thickener for artists, in the pharmaceuticals industry and in cosmetics 
amongst many others. However, its main uses are as an emulsifier in the food industry, 
and in carbonated drinks to reduce the surface tension of fluids and increase fizzing. 
Being almost completely soluble in water it makes it an ideal product for use as a 
stabiliser, emulsifier and thickening agent in foodstuffs.  
The Federation of American Societies for Experimental Biology prepared a report for 
the United States food and Drug Administration in March 1973, looking at the safety 
profile of Gum Arabic [154].  This committee looked at the safety of Gum Arabic when 
used in food. A review of the then available literature recommended that Gum Arabic 
should be “Generally Regarded as Safe” – GRAS. It is accepted as a food additive in 
the European Union (E414) (Directive 99/77/EC) and by Codex Alimentarius 
(INS414). Gum arabic is now also officially recognised as a dietary fibre in the EU 
directive 2008/100/EC [155].  
Gum Arabic also has a prebiotic action. A prebiotic is defined as: 
“non-digestible food ingredients which beneficially affect the host by selectively 
stimulating the growth and / or activity of one or a limited number of bacteria in the 
colon and thus improve the host health”. 
Gum Arabic is a non digestible polysaccharide that has been shown to retard glucose 
absorption. It has a low glycaemic index and reduces plasma glucose concentrations in 
healthy individuals [156].   
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1.13.2 Potential Renal benefits of Gum Arabic 
 
As already discussed, dietary fibre, including soluble fibre, has wide ranging beneficial 
health effects. To date gum arabic has not been investigated extensively as a product 
beneficial to health. There is anecdotal evidence to support the use of Gum Arabic to 
prolong the time needed to commencing renal replacement therapy, particularly in a 
paediatric population [157, 158]. The mechanisms of this are not fully understood but 
are at least in part likely to relate to the associated increase in faecal urea nitrogen 
excretion, with a concomitant decrease in urinary nitrogen excretion [159]. 
 
1.13.3 Potential Actions of Gum Arabic in Nephropathy 
 
To date there has been no published work on the use of Gum Arabic in earlier stages of 
chronic kidney disease, but there are theoretical reasons behind benefits of its use. The 
areas in which I would like to concentrate are those looking at non renal clearance of 
urea that is seen with dietary fibres, its effects on glomerular filtration rate and effective 
renal plasma flow and its potential for affecting  transforming growth factor beta (TGF-
β) expression that could provide longer term benefits. The action of Gum Arabic on 
TGF-β may also be of benefit in the shorter term as well as long term by its effects on 
blood pressure homeostasis. 
The use of Gum Arabic in an end stage renal failure population has not been studied in 
a randomised controlled trial. However, accessibility to renal replacement therapy in the 
developing world is limited and other treatment modalities that can postpone the time to 
initiation of renal replacement therapy are of great value. Al-Mosawi describes 4 
paediatric patients [157, 158] who had reached end stage renal disease, and in whom 
access to renal replacement therapy was difficult. All patients’ diets were supplemented 
with powdered acacia gum (Gum Arabic). This was at a dose of 1g/kg in 3 of the 
patients and 0.5g/kg in the other patient. Intermittent peritoneal dialysis (IPD) was used 
as an adjunctive therapy if the patients became overtly symptomatic of uraemia. Three 
of the 4 patients showed stability of their renal function and a probable improvement in 
urea and creatinine. In one patient, its effect on blood pressure was also considered and, 
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although only anecdotal evidence appears to show an improvement in blood pressure 
that was reversed on cessation of treatment. 
Nasir showed that gum arabic treatment in mice was associated with an increase in 24 
hour urinary creatinine clearance. The mechanism is unclear but suggests a remote 
effect of gum arabic on the kidney and not that of non renal nitrogen clearance [159]. 
In a study of patients with CKD, the concentrations of creatinine, urea, phosphate and 
uric acid have been reported to be significantly lower in subjects give gum arabic at a 
dose of 50g/day for 3 months Possible mechanisms whereby Gum arabic may have 
these beneficial effects are discussed in the chapters following. 
 
1.13.3.1 Non renal clearance of nitrogen 
 
Bliss et al conducted a prospective, randomised, placebo controlled, single blinded 
study of a crossover design in 20 patients with chronic renal failure. The non placebo 
arm received 25g of Gum Arabic twice daily. They clearly showed that the mean 
nitrogen content of stool was significantly greater when taking Gum Arabic as 
compared to placebo or to baseline. In addition, serum urea nitrogen was also lower 
when compared to placebo or baseline [160]. This effect is dependent on an increase in 
colonic bacterial growth. These bacteria produce ureases that hydrolyse urea to 
ammonia and carbon dioxide. The ammonia that is produced is then used by the 
bacteria and incorporated in to bacterial proteins which are then excreted in the 
bacterial mass fraction of the faeces [156]. Renal function per se is of course not 
directly affected, the result being non renal clearance of urea via the bowel. 
 
1.13.3.2 Antioxidant properties 
 
Several studies have also shown a potentially protective effect of Gum Arabic against 
gentamicin nephrotoxicity in rats [161, 162], possibly in part through inhibition of the 
production of oxygen free radicals that cause lipid peroxidation. 
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The renoprotective effect of Gum Arabic seems to be independent of any effects that it 
may have on faecal bacterial ammonium metabolism [161, 163], although in one of 
these studies the improvements in serum urea and creatinine did not reach significance.  
There is however evidence that contradicts the theory that Gum arabic has significant 
antioxidant properties. Ali et al demonstrated in a rat model that administration of 
varying concentrations of Gum arabic in the drinking water did not change significantly 
levels of free radical scavengers [163]. 
 
1.13.3.3 Production of short chain fatty acids 
 
A common feature of all mammals is extensive microbial fermentation of 
polysaccharides in the hindgut. Large amounts of short chain fatty acids (SCFA) are 
produced, with concentrations of SCFA generally about 100 mmol/l [164]. Bacterial 
fermentation of dietary fibre-rich substrates in the colon results in the production of a 
variety of short chain fatty acids. The proportions of the different SCFAs produced is 
dependent on the type of dietary fibre ingested. Bourquin et al showed that in human 
subjects, ingestion of different dietary fibre rich substrates produced different quantities 
of SCFAs in the faeces. The fibre rich substrates that they tested, in 3 human 
volunteers, were two varieties of oat hull fibre, Gum Arabic, carboxymethylcellulose 
(CMC), soy fibre, psyllium, and six blends containing oat fibre, Gum Arabic, and CMC 
in various proportions. Production of SCFA was directly proportional to the content of 
Gum Arabic in the substrates and overall, proportions of the SCFAs were acetate, 
propionate, and butyrate, produced in the molar proportion of 64:24:12 [165].  
Gum Arabic when given to caecostomised pigs, has also shown increased levels of 
short chain fatty acid production, in particular acetate and butyrate. This further 
supports its potential as a prebiotic agent [166]. 
Short chain fatty acid production has been shown to have certain health benefits, 
particularly improved bowel health. Butyrate in particular plays a central role in 
maintaining the mucosal barrier in the gut. A lack of SCFA may be the cause of 
ulcerative colitis and other inflammatory conditions. Butyrate has also been shown to 
increase wound healing and reduce inflammation in the small intestine. Importantly 
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butyrate is the dominant energy source for epithelial cells and affects cellular 
proliferation and differentiation by yet unknown mechanisms [167]. It may also reduce 
the risk of colon cancer, and substrates that can decrease the acetate: propionate ratio 
may reduce serum lipids and possibly cardiovascular disease risk [168]. 
 
Gum arabic is able to selectively raise the proportions of different bifidobacteria in 
human intestinal microbiota, depending on the exact preparation of Gum arabic used. 
As a result levels of the short chain fatty acids butyrate and propionate are seen to rise 
[169]. 
Kishimoto et al have shown that SupergumTM (a specific preparation of Gum arabic) is 
fermented to short chain fatty acids by intestinal bacteria and that the dominant bacteria 
which is likely to be responsible is Prevotella ruminicola [170]. 
The possible health benefits of fibre as a result of short chain fatty acid production are 
clear but evidence currently only shows some benefit in the GI tract and possible 
cardiovascular benefits. It is possible that dietary fibre, including Gum arabic has health 
benefits beyond the GI tract which could impact on diabetic nephropathy. 
 
1.13.4 Effects of Gum Arabic on TGF-β activity 
 
TGF-β is a key growth factor involved in the development and pathophysiology of 
blood vessels and increased circulating levels of TGF-β have been found in 
hypertensive patients.  Different isomers of TGF-β are generated but only a small 
amount of the TGF-β produced by the cells is made available for signalling. Therefore 
the balance between maturation, sequestration and presentation of TGF-β serves as a 
regulatory step.  
Butyrate has been shown to be a direct inhibitor of the generation and of the signalling 
of TGF-β1 in a renal epithelial cell line. An in vitro study by Matsumoto et al has 
shown that the addition of butyrate at increasing doses to renal epithelial cells, 
suppressed the basal TGF β1 production by these cells. Glucose dependent stimulation 
of TGF-β1 is also inhibited by butyrate [171]. This of particular interest to diabetic 
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nephropathy as the glucose dependent alterations in cell function are a well established 
pathogenic mechanism. 
By dietary supplementation with Gum arabic, it may be possible to increase short chain 
fatty acid production, in particular butyrate, by bacterial fermentation. This increase in 
serum butyrate may in turn inhibit the production of TGF-β1.  
Until relatively recently it was thought that the underlying pathogenesis of essential 
hypertension was largely as a result of abnormal function of smooth muscle and 
endothelial cells. Faury et al however have shown that there are other components 
involved in the cause of essential hypertension. In the murine model they were able to 
demonstrate that ELN+/- (hemizygous for the elastin gene) mice, had a mean arterial 
pressure that was 30-40% higher than the wild type heterozygous mice. They concluded 
that vessel wall proteins, particularly elastin should be considered as causal genes for 
essential hypertension [172]. 
Zacchigna et al have studied the role of Emilin 1 (elastin microfibril interface-located 
protein 1) in the pathogenesis of hypertension in mice. Emilin 1 is a protein of the 
extracellular matrix of blood vessels, and may be responsible for anchoring smooth 
muscle cells to elastic fibres, and may also be involved not only in the formation of the 
elastic fibre, but also in the processes that regulate vessel assembly. Deficiency of 
Emilin 1 causes systemic arterial hypertension. Emilin 1 only binds to immature 
proTGF-β and prevents its maturation. The group studied Emilin 1 knockout mice. This 
inactivation of Emilin 1 leads to increased TGF-β signalling in the vessel wall. These 
animals had elevated systemic blood pressure, increased peripheral vascular resistance 
and reduced vessel size, independent of cardiac output. Furthermore, blood pressure 
returned to normal levels by inactivation of a single TGF-β allele [173]. 
Modification, by down regulation, of TGF-β expression may therefore play a role in 
controlling BP and could be a target for treatment with dietary supplements of Gum 
arabic. 
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1.13.5 Choice of Gum Arabic preparation 
 
One of the major problems with Gum Arabic is that most commercially available forms 
have an inherently variable mass due to the fact that it is a natural product. 
Traditionally, the two widely available forms of Gum Arabic, each from the tree Acacia 
senegal, have been A.senegal var. Senegal and A.senegal var. karensis. Both of these 
are approved as food additives by the FAO Joint expert Committee on Food Additives 
and the Codex Alimenarius Commission. Al-Asaaf et al showed that in 67 
commercially available samples there was an extensive variation between individual 
samples, despite the fact that they were all marketed as “Gum Arabic”. Multi angle 
laser light scattering was used to determine the average molecular mass of the samples 
which varied from 4.6 to 10.2x105  [153].  
This wide variation in properties of different types of Gum Arabic could be of major 
importance when carrying out a clinical study, as the biochemical properties of the 
different products may well vary. Therefore a product with a consistent molecular make 
up is required. SupergumTM is a specially produced form of Gum Arabic that is well 
characterised and can be produced to specific molecular dimensions. The average 
dietary fibre Supergum is 91% (cited in [156]). The Supergum comes as a dried powder 
that is stable at room temperature and can be easily dissolved in water to make it an 
easily ingested product, ideal for use in a human clinical trial.  
 
1.14 The Role of Arterial Stiffness 
 
1.14.1 Historical viewpoint 
 
The measurement of brachial blood pressure with a sphygmomanometer provides a 
simple recording of systolic and diastolic blood pressure and has been accepted practice 
in medicine for over 100 years. As a result, measurement of the brachial blood pressure 
has been used as the gold standard in hundreds of clinical trials and seems to have an 
impact on outcomes in human trials. Previously little notice has been taken of the actual 
shape of the pressure waveform and its potential relationship to disease. However, long 
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before the arrival of the sphygmomanometer, physicians studied the shape of the 
waveform and understood, to a degree its potential impact. 
As far back as Hippocrates, different pulse characters were described in different 
diseases [174]. In more recent history, Mahomed was one of the pioneers of this science 
and was able to demonstrate the differences in tracings of asymptomatic hypertension 
and those associated with nephritis. Mahomed placed great importance on these 
tracings: 
“Our old ally the pulse ranks the first amongst our guides; no Surgeon can despise its 
counsel, no Physician shut his ears to its appeal. Since then the information which the 
pulse affords is of so great importance and so often consulted, surely it must be to our 
advantage to appreciate fully all it tell us, and to draw from it every detail that it is 
capable of imparting”    
 
F.A. Mahomed, 1872 [175] 
Mahomed studied the shape of the pressure wave form rather than just isolating and 
ultimately simplifying a complicated physiological process in to a systolic and diastolic 
blood pressure. By using a device known as sphygmograph he was able to plot the 
waveform of a radial artery pulse. As a result of this he was able to describe and 
recognise the differences between a normal waveform and those generated by 
individuals with essential hypertension and those with renovascular hypertension. 
Richard Bright, regarded as the “father” of Nephrology also recognised its importance, 
identifying increased arterial hypertension from “hardness” of the arterial pulse, and 
attributed left ventricular hypertrophy and vascular damage to high arterial pressure 
[175]. 
With the introduction of the manual sphygmomanometer at the turn of the last century 
interest was lost in the study of the arterial waveform until recently. It is now becoming 
increasingly clear that a more complex measure of blood pressure, including an 
estimation of central blood pressure and shape of the pressure waveform may give a 
better indication of outcome.  
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The next major step forward in research was in the 1950s by John Wormersley, a 
Scottish mathematician who studied the equations of fluid motion [174]. His major 
collaborator at the time was Donald McDonald who went on to produce Blood Flow in 
Arteries [176], an important reference manual in this field. One of the most important 
principles to come out of the research was that of wave reflection. This refers to the 
outgoing pressure waveform from the heart which travels distally towards the 
peripheries, then at various bifurcations and narrowings of the arterial tree is reflected 
back towards the heart. This was first demonstrated experimentally in computer models 
by Taylor [177] who noted that the major factor influencing transmission along larger 
vessels was wall elasticity and only a minor factor was fluid viscosity, but in smaller 
peripheral vessels the major influence became fluid viscosity [177]. Futhermore, 
O’Rourke and Taylor went on to discover that approximately 90% of the outward 
pressure wave was reflected back towards the heart from the peripheral vascular bed. 
[178].  
More work carried out by McDonald, Wormersley and Taylor lead to the separation of 
the mean from the pulsatile components of pressure and flow waves within vessels. 
Instead of purely looking at changes in systolic and diastolic pressure their work 
explained how one could view an increase in mean pressure, indicating a change in 
peripheral resistance, and a change in pulse pressure which would indicate a change in 
the stiffness of arteries [176].  O’Rourke et al measured central aortic waveforms and 
recognised significant differences in the arteries of normal individuals from those with 
hypertension: 
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1 
2 
3 
Normal Hypertension 
 
Figure 1-6. Effects of Hypertension on the Ascending Aortic Pressure Wave 
[174]    
O’Rourke’s work then went on to look in animal studies at the shape of the aortic 
pressure wave in normals and in simulated hypertension using noradrenaline [174]. The 
resulting waveforms are demonstrated in Figure 1-7. 
 
 
1 Mean Pressure 
2 Initial pressure peak 
3 Late systolic peak 
 
 
 
 
Figure 1-7. Aortic Pressure Waveforms in Normals and in Hypertension 
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The presence of hypertension makes no difference to the blood flow, but as shown 
above, it does to the shape of the pressure wave. In Figure 1-7 an increase in peripheral 
resistance leads to an increase in mean pressure (arrow 1), and increased arterial 
stiffness leads to an increase in the amplitude of the initial pressure peak (arrow 2). 
Finally, an earlier return of reflected waves, due to decreased arterial compliance, 
results in the late systolic pressure peak occurring later (arrow 3). 
The peripheral pulse wave that is generated is as a result of the pressure wave that is 
generated with each contraction of the left ventricle. The size and shape of this wave is 
dependent on 3 factors: 
 
• The magnitude of the left ventricular contraction 
• The viscosity of the blood 
• Properties of the arterial tree 
 
The pressure wave travels distally during systole until it reaches areas of turbulent or 
stagnant flow, arterial branches or changes in vessel character. The wave is then 
reflected back proximally, toward the heart. This is an extremely important 
physiological point as the timing of this reflected wave impacts on the cardiovascular 
system greatly. Ordinarily the reflected wave, which itself is a summation of numerous 
smaller reflected waves, returns to the heart during diastole and increases coronary 
artery filling, which occurs during the diastolic phase of the cardiac cycle. In a disease 
state however, peripheral, elastic arteries stiffen and blood flow velocity through those 
arteries is increased. 
 
1.14.2 The Impact of Arterial Stiffness 
 
Vessel walls of larger conduit arteries undergo remodelling resulting in arteriosclerosis 
as a result from repeated stretch and relaxation. This in turn leads to reduced vascular 
compliance and as a result of this an increase of pulse wave velocity down the conduit 
artery. The impact of the reflected wave on the aortic waveform is best represented 
graphically and has several important clinical implications. These are described be 
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Figure 1-8. Simple Waveform 
 
This simple graph represents what the pressure 
waveform would look like if there were no 
reflection of the wave from the peripheries. 
 
 
 
                                                                                                                                                                                            
Figure 1-9. Simple Waveform and Reflected Wave 
 
 
As well as the waveform generated from LV 
contraction, represented here is the reflected 
waveform from the peripheries, returning in 
diastole. 
 
 
 
Figure 1-10. Composite Waveform 
 
 
The pressure wave (shown in red) in the 
aortic root is therefore composed of the 
outgoing and reflected waves and increases 
coronary artery perfusion during diastole 
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Figure 1-11. Reflected Waveform in Stiff Vessels 
 
In a subject with stiff peripheral vessels, 
transmission of the outgoing and returning 
waves will occur faster (shown in red). The 
reflected wave therefore returns quicker, 
during systole. 
 
 
 
Figure 1-12. Aortic Waveform in Stiff Vessels 
 
 
The sum of the 2 pressure waveforms at the 
aortic root now looks very different than 
previously and has 3 important clinical 
implications. 
                   Normal composite waveform 
     Abnormal composite waveform 
 
Figure 1-13. Increased Central Pulse Pressure 
 
 
1. There is an increase in central pulse 
pressure that can occur independently of 
peripheral systolic pressure 
 
 
 
ΔPP 
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Figure 1-14. Increased Left Ventricular Load 
 
2. There is an increase in Left Ventricular 
load, increasing the risk for Left Ventricular 
Hypertrophy. 
 
 
 
 
 
Figure 1-15. Decreased Coronary Artery Perfusion 
 
 
 
3. There is decreased coronary artery 
perfusion filling pressure in diastole, 
potentially leading to myocardial ischaemia. 
 
 
 
 
Adapted from [179] 
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Pulse pressure is a marker of vascular stiffness. Schram et al studied 2484 patients, of 
which 208 had type 2 diabetes. They demonstrated that pulse pressure was associated 
with increased cardiovascular mortality among the diabetic individuals with an adjusted 
relative risk of cardiovascular mortality (95% confidence interval) per 10 mmHg 
increase in pulse pressure of 1.27 (95% CI 1.00-1.61) . There was no associated 
increase in mortality in the non diabetic population [180]. 
The impact of vascular stiffness has been investigated using pulse wave velocity (PWV) 
[181-184] and augmentation index (AIx) [184, 185] as surrogate markers and have been 
shown to be associated with an increased cardiovascular risk. Many of these studies 
have been carried out in patients with end stage renal disease, a group of patients 
already with a high cardiovascular mortality.  
Smith et al studied the relationship between Aortic pulse wave velocity (Ao-PWV) and 
albumin creatinine ratio (ACR) in 134 patients with type 2 diabetes without overt renal 
impairment (serum creatinine <150 µmol/L). Patients with raised ACR (>/=3 
mg/mmol) were associated with a higher Ao-PWV, poorer diabetic control,  higher 
pulse pressure and systolic BP (all P < 0.05) than those with normal ACR. Ao-PWV 
was also negatively associated with GFR (P<0.01). They suggest that even modest 
decline in renal function may affect the viscoelastic properties of arteries [186]. 
However not all studies have shown similar results. Diabetic patients have been shown 
to have increased pulse wave velocity, a measure of increased vascular stiffness, when 
compared to non-diabetic patients, but peripheral and central augmentation index were 
not different between the groups. Pulse pressure is a good marker of vascular stiffness 
and explains much of the widening of pulse pressure with ageing, it is also a good 
predictor of outcome, along with pulse wave velocity [187]. 
The greatest amount of evidence currently, for the role of vascular stiffness impacting 
on cardiovascular outcomes is from the measurement of carotid-femoral pulse wave 
velocity. This has been shown in several papers to be independently predictive for all-
cause and cardiovascular mortality, cardiovascular disease, fatal and non fatal coronary 
events and fatal strokes [55, 182, 188-191] 
Despite many studies showing equal control of brachial blood pressure using different 
antihypertensive agents, there have been differences in outcome. The outcome from 
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studies such as HOPE[192], ASCOT-BPLA[193] and CONSENSUS[194] have not 
been explained purely on the basis of brachial blood pressure and have often been 
attributed to the “non BP lowering effect” of some of these classes of medication. The 
CAFÉ study[195], a sub-investigation of 2199 of the ASCOT Study [196] showed a 
poorer outcome in a beta blocker treated group compared to an amlodipine treated 
group. Despite similar brachial blood pressure control in each group, there were 
substantial reductions in central aortic systolic pressure and central aortic pulse pressure 
in the amlodipine treated group. In post-hoc analysis, central pulse pressure was shown 
to be associated with total cardiovascular events/procedures and the development of 
renal impairment. 
This reinforces previous studies, that have shown that different classes of 
antihypertensive agent have different effects on central blood pressure [197]. 
Due to the relative reduced effect of beta blockers on central blood pressure compared 
to other antihypertensives, as a class of antihypertensive they have recently fallen out of 
favour and are now not regarded as first line therapy in the management of 
hypertension, except in certain circumstances [198].  
 
 
1.15 Aim of the study 
 
I have shown Gum Arabic is a type of soluble dietary fibre for which there is at least 
theoretical evidence and some anecdotal evidence for it having a beneficial effect on 
renal function and blood pressure. Dietary fibre has been shown to have beneficial 
effects on cardiovascular outcome, blood pressure and diabetes. I have shown that 
patients with diabetes have a significantly increased cardiovascular risk, and have a 
high rate of decline in renal function.  
Gum Arabic, as a source of modified dietary fibre may lead to increased production of 
serum short chain fatty acids, in particular butyrate. This SCFA could potentially lead 
to a reduction in production of the profibrotic cytokine TGF-β1, and hence improve 
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renal function. By as yet undefined pathways, Gum Arabic may also improve blood 
pressure, which may also in turn impact on renal function. 
The current therapeutic options to improve cardiovascular risk and slow progression of 
renal failure are quite limited. From the data presented I have shown that Gum Arabic 
may well be a beneficial dietary addition to this group of patients. 
It was therefore hypothesised that by giving Gum Arabic to 3 groups of patients, renal 
function, blood pressure, and various other biochemical parameters may be improved.  
A pilot study was initially run to look broadly at the Healthy Individuals and the Overt 
Nephropaths. Following results from this smaller study, a larger more in depth study 
was set up to look at a high risk population of Incipient Nephropaths.  
 
The 3 groups investigated are : 
 
1. Healthy Individuals – Pilot Study 
2. Patients with Type 2 Diabetes and abnormal renal function (“Overt 
Nephropaths”) – Pilot Study 
3. Patients with Type 2 Diabetes and normal renal function (as calculated by 
Cockroft-Gault creatinine clearance) (“Incipient Nephropaths”) – Follow on 
Study 
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2 METHODS 
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2.1 Introduction 
 
The aims of the study were to examine the effects of modified Gum Arabic (SUPER 
GUM™) on renal and arterial function in addition to serological markers of 
cardiovascular risk and short chain fatty acid metabolism in individuals with type 2 
diabetes.  
 
A pilot study was carried out in normal healthy individuals and in patients with Type 2 
Diabetes and overt diabetic nephropathy. Healthy individuals were volunteers from the 
Department of Nephrology at the University Hospital of Wales. Patients with overt 
diabetic nephropathy were recruited from the Nephrology outpatients department at the 
University Hospital of Wales. 
 
Following the results of the pilot study, a follow up study was undertaken to investigate 
a group of patients who are well documented to have an increased cardiovascular risk, 
which may well be modifiable. These patients had type 2 diabetes and incipient 
nephropathy and were recruited from a Diabetes outpatients department. Patients who 
fitted the predefined entry criteria were invited to take part in the study during an 
outpatient visit. They were then provided with a patient information sheet (See 
Appendix). A follow up telephone call was made several days later. If the patient was 
willing to take part in the study they were then invited to attend the investigation unit 
for a further screening test.  
Approval for the study was gained from the local Ethics Committee, the local Research 
and Developments Committee and from the Medicines and Healthcare products 
Regulatory Agency (MHRA). 
Funding for this study was from a research grant provided by San-Ei Gen Inc, Japan, 
who manufacture SuperGum. 
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The objectives of the follow on study were as follows: 
 
• Primary objective: To assess effects of a diet supplemented with modified 
Gum Arabic on renal physiology and arterial function. 
• Secondary objective: To observe effects of modified Gum Arabic on serum 
lipids, short chain fatty acid production and glucose metabolism. 
 
2.2 Study Design 
 
The Pilot Study consisted of an initial study visit following which subjects were 
commenced on the gum arabic supplementation for a period of 12 weeks. Following 
this 12 week period the subjects returned for another study visit. An optional third post 
washout visit was also included.  
The Follow On study was a single centre, open labelled prospective study with a 
washout period.  The total duration of the study was 24 weeks and is described in detail 
in section 2.5. All measurements were recorded by DG 
A randomised placebo controlled double blind study design would have been ideal but 
was not carried out, largely due to the technicalities and cost of designing a robust trial 
of this design. 
 
2.3 Participants 
 
Patients with normal renal function were selected from a group of healthy volunteers. 
Urine dipstick was negative and had a creatinine clearance of >60 ml/min. The patients 
with overt diabetic nephropathy were selected from a specialist Nephrology clinic and 
had a creatinine clearance of <60ml/min and had overt proteinuria. Recruitment of 
patients with type 2 diabetes and incipient nephropathy for the follow on study was 
from a specialist diabetes clinic. Patients were identified with stable renal function and 
no overt proteinuria, microalbuminuria however was acceptable. 
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Renal function was calculated using the Cockroft and Gault formula for creatinine 
clearance [199] and used as a screening tool prior to formal testing of renal function 
with an isotope GFR. The Cockroft-Gault equation was used to assess this population as 
it is probably more accurate in this population than the now more widely used MDRD 
(Modifications of Diet in renal Disease) equation in patients with a GFR of greater than 
60 ml/min [200].  
The original Cockroft-Gault equation was derived from the measurement of the mean of 
two 24 hour urine creatinine clearances in 236 patients, aged 18-92, predominantly 
male. Mean creatinine clearances varied in each 10 year age group from 114.9 in the 
youngest to 37.4 in the oldest. 
The original formula is as follows [199]: 
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Ccr = Creatinine clearance 
Scr = Serum creatinine (mg/dl) 
wt = Weight (kg) 
 
This formula has been modified since to take account of differences in body 
composition between males and females and measurement of serum creatinine in 
µmol/l. 
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Cons = constant, where cons = 1.23 for men and 1.04 for women. 
Patients were accepted to the follow up study if the estimated creatinine clearance was 
> 60 ml/min, and this had been stable for a period of 6 months or more. 
Patients were identified as having or not having microalbuminuria, as previously 
described in Chapter 1.6.3. 
 
2.4 Study Settings 
 
All investigations were carried out in the Investigation Unit in the Institute of 
nephrology, University Hospital of Wales, Cardiff.  
 
2.5 Study Time Points and Interventions – Follow on Study 
 
Following study entry all patients had a 4-week run in period during which blood 
pressure was monitored. If necessary additional antihypertensive medication was added 
to maximise blood pressure control to a target blood pressure of 140-150 mmHg 
systolic and 75-90 mmHg diastolic. This was felt to be an achievable target in the 
period given, although not in line with current ideal targets. All groups of 
antihypertensive medication were allowed during the run in period with a preference for 
maximising angiotensin blocking drugs.  
Following the run in period subjects were invited back to the investigation unit for the 
commencement of the study – Test Point 1 (see Figure 2-1).Each of the Test Points 
were identical in the way in which they were carried out and the tests performed, which 
will be detailed later in this chapter. 
Patients were then commenced on the study treatment, Supergum for a period of 12 
weeks and then recalled to the investigation unit for Test Point 2. There was then a 
washout period of 8 weeks, followed by a further visit to repeat the previous 
investigations. 
All patients had baseline characteristics measured prior to the run in.  
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The overall design of the study is best represented graphically in Figure 2-1. 
 
 
 
 
 
 
Figure 2-1. Timeline of Study 
 
 
2.6 Investigations carried out 
 
The investigations performed at each of the test visits were very similar. At the initial 
screening visit the following investigations were performed: 
• Height 
• Weight 
• Sitting office blood pressure 
• Serum urea, creatinine, electrolytes, glucose 
• HbA1C 
• Serum Lipids  
• 24 hour urine protein 
 
These acted as baseline measurements and as a screening tool for patients to enter the 
study. 
 
 
 
4 Weeks 
Run in 
12 Weeks 
Gum Arabic 
 
8 Weeks 
Wash out 
Screening 
Test point 1 Test point 2 Test point 3 
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The following 3 visits, Test Points 1,2 and 3, had identical tests performed on each 
occasion, as follows. All data was recorded on a pro forma (See appendix) 
• Height 
• Weight 
• Sitting office blood pressure 
• Serum urea, creatinine, electrolytes, glucose 
• HbA1C 
• Serum Lipids  
• 24 hour urine protein 
• Urine for short chain fatty acid analysis   (Follow on study only) 
• Stool collection for bacterial DNA analysis (Follow on study only) 
• Pulse Wave Analysis    (Follow on study only) 
• Isotope GFR and ERPF    (Follow on study only) 
 
 
2.7 Treatment Formulation 
 
Cherbut et al have shown that gum arabic has a prebiotic action at a dose of 10g per day 
and that digestive tolerance was not different to that of sucrose up to a dose of 30g per 
day [201]. After the first test point, subjects were commenced on a daily 
supplementation of 25g of Gum Arabic, a dose at which it will have a prebiotic action 
and will be tolerable. This was supplied in pre-weighed sealed foil sachets that could be 
stored at room temperature. Subjects were asked to add a sachet of Gum Arabic to 
200ml of water in a small bottle of water and shake to mix. If needed, flavouring such 
as orange juice or orange squash was added to improve palatability. The solution could 
be drunk in one sitting but could also be kept in the fridge to be drunk throughout the 
day. Adherence was measured by patients returning all sachets, both empty and full at 
the end of the 12 week period. 
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2.8 Inclusion and Exclusion criteria 
 
Inclusion criteria 
 
1. Healthy individuals with normal renal function or subjects with type 2 diabetes 
with stable renal function in the 6 months prior to study start. 
2. Females of childbearing age must have had a negative pregnancy test prior to 
the inclusion period. Effective contraception must have been used during the 
trial. 
3. Patients who were willing and able to participate in the full course of the study 
and from whom written consent was obtained. 
 
Exclusion criteria 
1. Individuals with poorly controlled blood pressure (systolic > 160mmHg and/or 
diastolic>100mmHg).  
2. Individuals with overt proteinuria.   (For follow on study) 
3. Individuals intolerant of Gum Arabic. 
 
Patients were invited to attend the research facility for an 8:00am start. This enabled 
fasting samples to be tested and so that repeated measurements of vascular stiffness and 
blood pressure were performed at approximately the same time of day at subsequent 
visits in the follow on study. Patients were requested to fast from midnight the night 
before and abstain from smoking prior to attendance as this could interfere with the 
measurement of vascular stiffness. They were permitted water to drink on the morning 
of the investigations. 
 
2.9 Baseline demographics  
 
The following parameters were recorded on an initial screening visit pro forma (see 
Appendix) 
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2.9.1 Cardiovascular Risk 
 
A detailed history of the subjects’ diabetes history and cardiovascular risk data was 
recorded in the follow on study. The particular factors that were recorded were the 
following: 
• Date of diagnosis of diabetes 
• Presence of microalbuminuria and duration if known 
• History of ischaemic heart disease 
• History of myocardial infarction 
• History of coronary artery bypass graft (CABG) 
• Smoking history including number of pack years 
• Presence of hypertension 
• History of hyperlipidaemia 
• Family history of cardiovascular disease 
• History of cerebrovascular disease 
• Presence of peripheral vascular disease 
• Presence of diabetic neuropathy 
• Presence of diabetic retinopathy 
 
 
2.9.2 Other Parameters measured 
 
 
Height and Weight 
 
Each subject’s height and weight were recorded at each visit. Height was measured in 
metres using a Seca measuring rod (Seca gmbh and Co, Hamburg, Germany) and 
patients’ weight was recorded using a calibrated Seca Model 761 mechanical weighing 
scales, recorded in kilograms.  
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The Body Mass Index (BMI) was calculated using the following formula: 
 𝐵𝑀𝐼 =𝑊𝑒𝑖𝑔ℎ𝑡  (𝑘𝑔)𝐻𝑒𝑖𝑔ℎ𝑡  (𝑚!) 
  
 
Sitting office blood pressure 
 
Patients were sat in a chair to rest for 10 minutes prior to measurement of the brachial 
blood pressure. This was measured in the right arm with the patient seated using an A 
and D Medical UA-767 Plus, British Hypertension Society approved automated 
sphygmomanometer. Two recordings were taken and used if the readings were within 
10mmHg of one another and an average of the two then calculated. If they were not the 
recordings were repeated to ensure accurate results. 
 
 
Biochemical assays 
 
An intravenous cannula was placed in a suitable vein in the arm of the patient, 
preferably in the antecubital fossa. Blood was drawn from the cannula, using a 3 way 
tap, for all necessary biochemical investigations.  
 
Samples of venous blood taken from the cannula were placed in to appropriate 
Vacutainer (Beckton Dickinson, USA) bottles. The samples were analysed at the 
University Hospital of Wales biochemistry laboratory. All assays, apart from HbA1C 
were measured on an Abbott Aeroset Clinical Chemistry System (Abbott Industries, 
Illinois, USA). Coefficients of variation (CV)of the assays as stated by the manufacturer 
as given below. 
 
 
Sodium and Potassium 
These are measured by an indirect measuring electrode and expressed in mmol/l. 
Sodium CV 0.7% at 148.7 mmol/L, 1.1% at 133.0 mmol/L 
Potassium CV 2.0% at 4.3 mmol/L, 0.9% at 6.6 mmol/L 
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Urea 
This was measured by a urease reaction and expressed in mmol/L. 
Urea CV 1.8% at 5.5 mmol/L, 2.0% at 17.1 mmol/L 
 
Creatinine 
This was measured using a two part liquid format based on the Alkaline-Picrate Jaffe 
reaction. Units used are µmol/L. 
Creatinine CV 3% at 115 µmol/L, 2.6% at 592 µmol/L 
 
Lipids 
Cholesterol was measured using a cholesterol oxidase method and triglycerides by an 
enzymatic lipase method. Units are mmol/l. 
Total cholesterol CV 1.6% at 3.36 mmol/L, 0.8% at 6.95 mmol/L 
Triglycerides CV 1.1% at 1.20 mmol/L, 0.8% at 2.13 mmol/L 
 
Urine protein 
24 hour urine protein was measured using an aliquot from the sample using a 
turbidimetric method and expressed as g/24 hour. 
 
HbA1c 
This was measured using a Tosoh (Tosoh Corporation, Minato-Ku, Japan) automated 
glycohaemoglobin analyser using cation exchange high performance liquid 
chromatography. HbA1c has the units %. 
 
Stored samples 
 
Twenty millilitres of venous blood was taken and prepared for future analysis. The 
20ml sample was evenly divided in to two 5ml Vacutainer tubes containing a clot 
activator. The remaining 10 ml was placed in to two Lithium-heparin containing tubes. 
All 4 of these samples were then placed in a MSE Mistral 3000i centrifuge. The 
samples were centrifuged at 2500g, at 4OC, for a period of 10 minutes. Following this 
period the samples were removed from the centrifuge and the supernatant removed with 
a pipette and placed into four 2ml aliquots. The samples from the clot activator tubes 
provided serum, and those from the Lithium-heparin tubes provided plasma. The 
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samples were labelled and then stored in a Thermco Scientific Revco Ultima II 
temperature controlled freezer, at -80OC. 
 
24 hour urine protein 
To obtain an accurate measure of urinary protein excretion, patients were requested to 
bring a urine collection with them from the previous 24 hours. This was placed in a 
plain 2.5l container. Urine protein excretion is best measured with a 24 hour collection. 
The instructions provided to the patient are in the Appendix. 
 
2.9.3 Measurement of Renal Function 
 
To accurately assess renal function, isotopic measurements of both Glomerular 
Filtration Rate and Effective Renal Plasma Flow were undertaken. Both assays were 
undertaken with a single injection including 2 necessary isotopes. Blood samples were  
drawn from the intravenous cannula. The cannula was then flushed with 5ml of 0.9% 
sodium chloride solution. 
GFR 
Measurement of GFR was done using an injection of 51Cr-EDTA (Chromium 51 
labelled ethylenediaminetetraacetic acid). The injection contained a known quantity of 
the isotope that had been counted in the medical physics laboratory, this was nominally 
1MBq. Counting was undertaken in a Sodium Iodide scintillation well counter. The 
isotope was injected directly in to a suitable vein on the dorsum of the hand, preferably 
the one on the opposite side to the cannula used for blood sampling. A stopwatch was 
commenced at the time of injection, to enable accurate timing of the subsequent blood 
tests. The used syringe and needle were then placed in a plain tube which was placed in 
a lead lined transport box. 
GFR was calculated using a 3 time point method. Blood samples were taken at 2, 3 and 
4 hours following injection of the isotope. These samples were taken from the cannula 
by first withdrawing and discarding 10ml of blood. A further 10ml was then taken and 
evenly distributed in to 3 Vacutainer bottles and stored in the lead lined transport box. 
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The cannula was then flushed with 5ml of 0.9% sodium chloride to maintain its 
patency. 
 
All samples were sent to the medical physics department for calculation of glomerular 
filtration rate. The empty syringe and needle was counted again on the Panax manual 
well counter. The blood samples were then centrifuged and the plasma counted using 
the Wallac Compugamma automatic well counter, along with diluted aliquots from the 
standard. All counts are then background subtracted. The difference between the counts 
from the full syringe and the empty syringe is equal to the amount of isotope entering 
the patient’s circulation.  
 
The GFR was then corrected for body surface area and expressed as GFR per 1.73m2 
using the Mosteller technique [202] defined by the following formula: 
 
𝐻𝑒𝑖𝑔ℎ𝑡 𝑐𝑚 ×𝑊𝑒𝑖𝑔ℎ𝑡   𝑘𝑔3600  
 
The coefficient of variation of isotope GFR measurement is given as between and 8% 
and 10% [203, 204]. 
ERPF 
 
Renal blood flow accounts for approximately one fifth of cardiac output, despite the 
kidneys only accounting for about 0.4% of total body mass. On average therefore, renal 
blood flow is approximately 4ml/g/min [205].  
Measurement of renal plasma flow has been made possible by the availability of 
substances that have tubular secretion and glomerular filtration. Classically 
measurement of ERPF has been measured using Para-amino hippurate (PAH), an 
 
 
85 
inorganic acid that undergoes glomerular filtration and is actively secreted by the 
proximal tubule. It is completely removed from the plasma on a single pass through the 
kidney. Therefore the amount of PAH passing through the kidney in a given time period 
is equal to the amount of PAH that is present in the urine.  This can be expressed by the 
following: 
 
𝑅𝑃𝐹 = 𝑈!"#×𝑉𝑃!"#   = 𝑃𝐴𝐻  𝐶𝑙𝑒𝑎𝑟𝑎𝑛𝑐𝑒 
RPF = Renal Plasma Flow, U= Urine, V= volume, P= Plasma 
[35] 
  
However this method can potentially underestimate renal plasma flow as the actual 
extraction ratio of PAH is approximately 0.92, therefore underestimating RPF by about 
10% [206]. The method therefore used for this study was isotopic measurement of renal 
plasma flow using the radioiodine labelled PAH analogue ortho-iodo-hippuran. This 
technique was first described by Tauxe et al, using 123I-orthoiodohippurate [207]. 
Calculation of ERPF following a single injection, as described above, of 1MBq of I-
orthoiodohippurate, is taken from the measurement of 1 sample of blood taken at 44 
minutes. 
 
The original calculation used the formula: 
 𝐸𝑅𝑃𝐹   = 𝑎 + 𝑏𝑥 + 𝑐𝑥! 𝑥 = 1 𝐶! (a theoretical volume of distribution) 𝐶𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡𝑠  𝑎  𝑎𝑛𝑑  𝑏,𝑎𝑛𝑑  𝑐𝑜𝑛𝑠𝑡𝑎𝑛𝑡   𝑐 𝑤𝑒𝑟𝑒  𝑐𝑎𝑙𝑐𝑢𝑙𝑎𝑡𝑒𝑑 
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This method tends to underestimate high ERPF values, as the study population did not 
include individuals with a high ERPF. An expanded series of 116 subjects was studied 
resulting in a modified formula that is now used [208]. 
Leach et al have described the measurement of renal plasma flow using a three sample 
method. However they importantly demonstrated a close correlation of renal plasma 
flow using 3 different isotopes of I-orthoiodohippurate, these being 125I, 123I and 131I 
[209]. For the purposes of this study, due to availability of radioisotopes, 1MBq of 123I-
orthoiodohippurate was used. 
There is not widely published data on the coefficient of variation of ERPF. The medical 
physics laboratory at the University Hospital of Wales state a CV of ±	 5% (Personal 
communication with Dr Beth Jones, Principal Physicist, Medical Physics, University 
Hospital of Wales). In 2 papers by Tauxe et al the standard error of the tests were 30.7 
ml/min and 31.2 ml/min [207, 208]. Average ERPF in these studies was approximately 
600ml/min, giving a CV in the region of 5%. 
 
Filtration Fraction 
 
The filtration fraction (FF) is a measure of the proportion of fluid that is filtered and 
passes in to the renal tubules.  
Filtration fraction is simply calculated as  𝐹𝐹   = 𝐺𝐹𝑅 𝐸𝑅𝑃𝐹 
 
Plasma for short chain fatty acid analysis 
Plasma was stored as previously described. These samples were then sent to Japan for 
analysis of concentrations of short chain fatty acids. Following thawing of the samples, 
they were sub-sampled in to microfuge tubes and deproteinised by the addition of 0.1 
vol of perchloric acid (60% w/v). These were then centrifuged at 15000g for 5 minutes 
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at 4º C and subjected to High performance liquid chromatography (HPLC) analysis as 
detailed by Kishimoto et al [170]. 
 
Urine for 3-methyl histidine analysis 
3-methyl histidine, a product of protein metabolism was measured in a fresh early 
morning urine sample at each study visit. 
Approximately 20ml of urine was placed in a 30ml flask on a magnetic stirrer. An 
electronic pH metre probe was placed in the urine. Concentrated (38%) hydrochloric 
acid was then added to the urine until a pH of 2.0 was reached. This was to ensure that 
any bacteria present were killed. The sample was then placed in to a clean container, 
labelled and stored at -80OC. 
 
Stool collection for bacterial DNA analysis and SCFA Analysis 
A sample of faeces was an optional part of the study. Faeces were stored for bacterial 
DNA analysis and SCFA production. The faeces was prepared and stored in 2 separate 
ways. 
 
Storage in Acid 
Approximately 1ml of faeces was placed in to a 2.5m Eppendorf tube. Fours drops of 
concentrated hydrochloric acid were added to the faeces in the container. These samples 
were stored at -80OC to stop bacterial activity. The samples would be used for faecal 
SCFA analysis in Japan by first thawing them and then sub-sampling in to microfuge 
tubes and centrifuging at 15000g for 5 minutes at 4º C. The samples were then 
subjected to HPLC analysis. 
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Storage in Alcohol 
The remaining sample of stool was placed in a 50ml sealed container containing 40ml 
of 95.6% ethanol. The container was labelled and stored in a refrigerator at 4OC.  These 
samples would be used for faecal bacterial DNA analysis  at a future date. 
 
 
2.9.4 Measurement of the central waveform 
 
An invasive method of recording central pressure waveforms is not suitable for routine 
investigation of human subjects. O’Rourke therefore used a method known as 
applanation tonometry  [174], which provides an accurate calculation of central blood 
pressure and vascular stiffness. A tonometer, which is effectively a pressure transducer, 
was developed to enable measurement of the pressure waveform at either the radial 
pulse or the carotid pulse, by compressing, but not occluding, the artery against a firm 
tissue, such as the radius at the wrist (see Figure 2-2). When these surfaces are 
flattened, the circumferential pressures are equalised and an accurate waveform 
recorded [210]. 
 
Figure 2-2. Applanation Tonometry at the Radial Artery 
Tonometer 
Sensor 
Radial Artery 
Bone 
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There is amplification of the pressure between central and peripheral arteries, and 
therefore a pressure measured at the wrist would give an inaccurately high estimation of 
central pressure. Karamangolu et al therefore studied 14 patients and compared pressure 
recordings from cardiac catheterisation and those obtained from tonometry at the radial 
artery. A mathematical transfer function was then devised to calculate an aortic pressure 
from a brachial pressure [211]. The equation for the transfer function takes in to 
account the pressure waves at the two sites the frequency of the wave and the shape of 
the waveforms. 
Since the calculation of the original equation, more patients have been studied, to 
confirm its validity. The Association for the Advancement of Medical Instrumentation 
have set criteria that need to be met for systems measuring arterial pressures by 
different methods, set out in AAMI SP10. The values can be different by no more than 
5mmHg with a SD of 8mmHg or less in 25 or more patients. Pauca et al studied 62 
consecutive anaesthetised patients undergoing cardiac surgery. They demonstrated that 
the equation was valid for aortic systolic, pulse, mean and diastolic pressures [212] 
This formula has been implemented in the SphygmoCor system (AtCor Medical, 
Sydney, Australia), the equipment used for the purpose of measuring pressure 
waveforms in this study. 
 
2.9.5 The SphygmoCor System 
 
For the purposes of this study the SphygmoCor Vx system was used. This system is 
able to non-invasively measure both the shape of the aortic pulse waveform and the 
velocity of the pulse waveform. It uses a high fidelity micromanometer (SPC-301, 
Millar Instruments, Texas USA) to record a pulse waveform at an arterial site, usually 
the radial, femoral or carotid, depending on the parameter studied. Data is then 
automatically transferred in to the software for the system (SphygmoCor 2000 ver 7.1). 
There are several data series looking at the reproducibility of the data that can be 
acquired, which is very important given the time period over which this studied was 
carried out. Wilkinson et al have studied the system’s ability to produce reliable data for 
both Pulse Wave Velocity (PWV) and Augmentation Index (AIx). This study showed 
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there was no statistically significant intra- or inter-observer difference [210]. Savage et 
al carried out a study in a population of patients with renal impairment. In the 
population of 188 subjects they included 23 healthy controls, 71 pre-dialysis patients, 
67 dialysis patients and 27 renal transplant patients. Central aortic mean blood pressure, 
AIx, Time for reflected Wave (TR) and Subendocardial viability ratio (SEVR) were all 
shown to be reproducible with only small, statistically non-significant differences in 
inter and intra-observer measurements [213].  
Although this has been shown to be a reliable tool in other trials as outlined above, I 
carried out my own small study to make sure that my own intra-observer variation was 
not statistically significant. 
 
2.9.5.1 Using the SphygmoCor System 
 
The SphygmoCor system is attached to a laptop computer that runs the Sphygmocor 
2000 software. A Standard Operating Protocol (SOP) was developed to make sure that 
the measurements were carried out the same way, on each patient and at each visit to 
reduce variability. Inter-operator variability was eliminated as I was the only operator.  
All measurements were carried out in a quiet room. Patients were fasted from midnight 
the night before and had been asked to abstain from smoking. All studies were 
performed early in the morning to again reduce any variability that could be introduced 
if studies were repeated at different times of day. 
2.9.5.1.1 Carrying out Pulse Wave Analysis 
 
Patients were rested for approximately 10 minutes prior to the start of any 
measurements. They were in a semi recumbent position, with the forearm placed 
comfortably on an arm rest. The forearm was placed in a supine position with the wrist 
slightly extended, the aid of a rolled bandaged was sometimes used to make this easier. 
Baseline data was entered, including height, weight, date of birth and brachial blood 
pressure. The radial artery was palpated between 2 fingers and the tonometer placed 
between them over the artery, whilst applying slight downward pressure. Slight 
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adjustments were made until a clear recording of the pulse waveform was displayed on 
the monitor. Ten seconds of recording was necessary for the programme to analyse the 
data. Using the sequential waveforms recorded in that time, an average radial waveform 
is generated.  
 
 
 
Figure 2-3. Screen showing sequential radial waveforms (upper) and calculated aortic waveforms 
 
 
 
 
 
 
 
Figure 2-4. Screen showing overlaid individual radial waveforms and Quality Data 
 
 
The software has a quality control system, whereby it assesses the individual 
waveforms and looks for variability within them, and scores them on a scale of 0-100, 
termed the Operator Index. 
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Operator Index  
95-100% Excellent 
90-94% Good 
85-89% Acceptable 
75-84% Borderline 
<74% Unacceptable 
 
Table 2-1. Operator Index Measurements 
 
Data was rejected if the Operator Index was <74%, indicating unacceptably variable 
wave form measurements. If the Operator index was between 75% and 84% the raw 
data waveforms (see Table 2-1) were examined visually to look for similarities of the 
waveforms to decide if they were of acceptable quality. 
 
For the purposes of measurement the Augmentation index corrected for a heart rate of 
75 (AIx75) beats per minute was examined. The study was repeated to obtain 2 
recordings of AIx75 within ± 4% of one another and of acceptable quality as described. 
 
 
Figure 2-5. Screen showing averaged radial waveform (left) and calculated average aortic waveform 
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2.9.5.2 Measurements Obtained of the Pulse Waveform 
 
For the purposes of the study, data on the following parameters was collected and 
analysed. 
Central aortic pressures 
Having calibrated the radial pulse measurements by measuring brachial blood pressure 
using a sphygmomanometer, the software calculates, using the averaged aortic pressure 
waveform central aortic blood pressures. The recorded values are for central systolic 
blood pressure, central diastolic pressure and aortic pulse pressure – the difference 
between systolic and diastolic pressures.  
Augmentation index AIx 
Each arterial pulse waveform is generated by the sum of the forward pressure wave 
created by left ventricular ejection and a backward wave that is the summation of 
numerous reflected from peripheral sites. The time point at which these forward and 
backward waves merge and the amplitude of the reflected wave affect the level of 
central BP. Augmentation pressure (AG) is actually measured with the tonometer by 
calculating the contribution of the reflected wave to systolic pressure. Augmentation 
index is then calculated to give an indirect measure of arterial stiffness. Augmentation 
index is calculated by the following formula [214]: 
 
𝐴𝐼𝑥 = 𝐴𝐺𝑃𝑃   ×100 
PP = Pulse pressure 
 
Augmentation index is therefore expressed as a percentage. 
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Augmentation index corrected for heart rate Aix75 
Due to the possibility of numerous patients being on rate controlling medications such 
as Beta blockers, augmentation index corrected for a heart rate of 75 beats per minute 
was measured. Heart rate itself can impact upon augmentation index, due to an 
increased wave reflection at lower heart rates, leading to higher augmentation indices 
for lower heart rates [215] 
Subendocardial viability ratio SEVR 
SEVR is a measure of the arterial systems ability to supply the myocardium with 
sufficient blood. Buckberg et al first described a measurement – the SEVR to look at 
the perfusion of the subendocardium, thought to be more sensitive to ischemia than the 
subepicardium. The SEVR is the ratio of area of the diastolic phase to that of the 
systolic phase measured in the central aorta. This has been shown to correlate well with 
the blood supply to the subendocardium. A lower SEVR is indicative of poorer delivery 
of blood. Pulse rate and age have been shown also to be shown to correlate with SEVR 
[216]. 
Time for return of reflected wave Tr 
This is simply crude data recorded, showing the actual time for the reflected waveform 
to return from the peripheries to the central aorta. 
 
2.9.5.3 Carrying out Pulse Wave Velocity measurements 
 
Pulse wave velocity was measured using the carotid – femoral method. A standard 
operating protocol was written. After performing the pulse wave analysis, as described 
above, subjects were reclined in the chair. Blood pressure was repeated as previously 
described. Measurements from the femoral artery recording site to the umbilicus, from 
the umbilicus to the suprasternal notch and also from the carotid artery recording site to 
the suprasternal notch were made in millimetres (mm) and entered in to the 
Sphygmocor system.  Three ECG recording electrodes were applied to the patient. 
Recordings of the pulse waveform were made at the distal site initially. A good quality 
10 second recording was made. The Sphygmocor system indicated the quality of the 
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trace and whether this was suitable. The Sphygmocor system then calculates a Pulse 
Wave Velocity. All pulse wave analysis investigations were carried out by investigator 
DG.  
Wilkinson et al studied the reproducibility of this method. Reproducibility assessed 
through the Bland-Altman method with calculation of the repeatability coefficient was, 
following intraobserver comparison, for Brachial PWV: 1.64m/sec (for a mean value of 
8.65±1.58 m/sec); and for aortic PWV:2.34m/sec (for mean value of 8.15±3.01 m/sec) 
[210]. 
 
 
2.9.6 Statistical analysis 
 
Statistical analysis and data collection was carried out using SPSS version 15.0 (SPSS 
Inc. Illinois, USA). Data was analysed as a whole group and within individual groups of 
patients. Data was analysed for normality of distribution by means of inspection of a 
histogram. Further details of statistical methods will be discussed in the Results chapter.  
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3 RESULTS 
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3.1 Introduction 
 
This chapter will discuss the results of the investigations firstly carried out during the 
pilot study. Secondly it will present the results from the follow on study and look at the 
combined results of all subjects. As discussed in the introduction, diabetes has a strong 
association with cardiovascular disease and with this comes an associated morbidity 
and mortality. Dietary fibre intake has a wide range of health benefits, with evidence to 
show it can improve these cardiovascular outcomes. There are also theoretical ways by 
which it may improve renal outcomes.   
These results explore what happens in the three groups of subjects when they are given 
the dietary fibre supplement gum arabic in terms of changes in renal function, changes 
in blood pressure and cardiovascular risk, and other metabolic parameters. The results 
will be discussed in sections, determined by the study group populations, that is: 
Healthy Individuals and Overt nephropaths in the pilot study and finally the Incipient 
Nephropaths in the follow on study. 
 
3.2 Recruitment 
 
The initial pilot study recruited a total of 10 healthy volunteers with normal renal 
function from members of staff in the Institute of Nephrology. All individuals screened 
met the entry criteria for the study. Patients with known overt diabetic nephropathy 
were recruited from the University Hospital of Wales Hospital Nephrology clinics. 
Fourteen patients expressed an interest in taking part in the study and met the entry 
criteria. 
Following the pilot study a power calculation was undertaken to ascertain the sample 
size for the follow on study. In order to obtain an 80% chance of detecting a 10% 
difference in GFR at the 5% level it was calculated that 30 patients would need to be 
recruited in to the study. The standard difference in the GFR measurements calculated 
from the pilot study were used and applied to a nomogram to achieve the power 
calculation.  
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The subjects with incipient nephropathy were recruited from a diabetes clinic within the 
same trust. A total of 242 patients met the entry criteria of which 36 agreed to the initial 
screening visit. A total of 27 subjects agreed to commence the study following the 
initial screening. Four subjects withdrew from the study resulting in 23 incipient 
nephropaths completing the study. Recruitment for the study is shown in Figure 3-1. 
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Figure 3-1. Recruitment to Follow on Study 
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3.3 Demography 
 
The data presented in Table 3-1 shows baseline demographic data for all of the 3 
individual study groups and for all the groups as a whole. 
 
 Value  
Parameter Total Group Healthy Incipient 
Nephropath 
Overt 
Nephropaths 
n 47 10 23 14 
Sex (M:F) 40:7 8:2 18:5 14:0 
Age (years) 58.07 ± 12.68 39.74 ± 6.24 59.95 ± 8.74 68.09 ± 6.33 
Weight (kg) 90.21 ± 17.21 82.3 ± 14.40 88.63 ± 17.13 98.46 ± 16.82 
BMI (kg/m2) 29.42 ± 4.43 25.20 ± 2.42 29.83 ± 3.11 31.78 ± 5.39 
Systolic blood pressure 
(mmHg) 
138.5 ± 18.90 129.10 ± 8.23 141.52 ± 18.72 140.07 ± 23.18 
Diastolic blood 
pressure (mmHg) 
79.43 ± 12.13 75.5. ± 11.21 86.09 ± 7.26 71.29 ± 13.53 
 
Table 3-1. Baseline Demographics – All Groups 
 
All data is mean ± standard deviation. Mean age and weight were highest in patients 
with overt nephropathy and lowest in the healthy volunteers.  
 
3.4 Completion of Study and Side Effect Profile 
 
All subjects completed the 12 week period on the Gum arabic supplement and there 
were no withdrawals once the study had commenced. Side effects were minimal and 
tended to be gastrointestinal in origin. Four patients noted some bloating with the Gum 
arabic supplement and one subject noted an increased bowel frequency. Compliance 
with the supplement was measured by the number of full and empty Gum arabic sachets 
returned. Four full sachets of Gum arabic were returned suggesting good compliance. 
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3.5 Effects of Gum Arabic on Biochemistry and Renal Function 
 
3.5.1 Methods  
 
The data in Table 3-2 is baseline biochemical data taken at the first study visit. This 
includes measures of baseline electrolytes and renal function taken from simple blood 
measurements. All biochemical parameters were repeated at each study visit. Any 
significant changes in these measurements are discussed. The primary method of 
measurement of renal function in this study was by way of isotope GFR and ERPF, as 
detailed in the Chapter 2.9.3. 
The data for the biochemical results and isotopic measures of renal function was 
normally distributed so a paired samples t-test was carried out, comparing changes in 
the following parameters between Visit 1 and Visit 2 (pre and post administration of 
gum arabic), and Visit 2 and Visit 3 (post administration of gum arabic and post 
washout phase). Significance was taken to be a p value < 0.05. Data was analysed on 
subjects who had completed data rather than on an “intention to treat basis” as in some 
of the studies, data was limited for study visit 3 due to the limited numbers of patients 
returning for the third study point.  
It should therefore be noted that in some of the following tables, the values for 
measured GFR and ERPF at “visit 2” may be different when comparing them with 
values from visits 1 and 3. This is because data was not available for some patients at 
study visit 3.Therefore, when comparing measurements between visits 2 and 3, only 
patients who had both recorded values were included for analysis. 
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Parameter Healthy subjects Overt nephropaths 
 
N Mean SD N Mean SD 
Sodium 
(mmol/L) 10 140.7 1.16 14 139.93 2.97 
Potassium 
(mmol/L) 10 4.10 0.29 14 4.72 0.59 
Urea 
(mmol/L ) 10 6.01 1.13 14 18.68 7.93 
Creatinine 
(µmol/L) 10 87.10 10.56 14 214.14 64.45 
 
Table 3-2. Baseline Data 
 
3.5.2 Effects of Gum Arabic on electrolytes and simple measures of Renal 
Function 
 
Data on electrolytes and simple measures of renal function was normally distributed 
and therefore analysis was undertaken using a Student’s t-test. 
 
3.5.2.1 Healthy Individuals  
 
 Visit 1 Visit 2 n p Visit 2 Visit 3 n p 
Sodium 
(mmol/l) 
140.70 139.30 10 0.055 139.75 139.50 4 0.82 
Potassium 
(mmol/l) 
4.1 4.26 10 0.20 4.175 4.00 4 0.21 
Urea 
(mmol/l) 
6.01 5.63 10 0.21 5.87 6.14 7 0.58 
Creatinine 
(µmol/L) 
87.10 82.80 10 0.016 84.14 84.71 7 0.66 
 
Table 3-3. Changes in biochemistry - Healthy Individuals 
 
The only significant change in the simple biochemistry of the healthy individuals was a 
drop in serum creatinine from 87.1 µmol/l to 82.8 µmol/l (p=0.016). Only 7 of the 10 
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subjects had a third visit sample for urea and creatinine recorded, of those who did there 
was a no significant rise in creatinine after the washout period.  
 
3.5.2.2 Overt Nephropaths 
 
 
 Visit 1 Visit 2 n p 
Sodium 
(mmol/l) 
139.93 139.57 14 0.74 
Potassium 
(mmol/l) 
4.72 4.47 14 0.07 
Urea 
(mmol/l) 
18.68 16.99 14 0.21 
Creatinine 
(µmol/L) 
214.14 215.43 14 0.83 
 
Table 3-4. Changes in Biochemistry - Overt Nephropaths 
 
In the overt nephropath group, there was no change in the biochemical parameters after 
taking gum arabic. No subjects in the overt nephropath group in the pilot study returned 
for the third visit. 
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3.5.3 Effects of Gum Arabic on isotopic measures of renal function 
 
All patients had a baseline measurement of isotope glomerular filtration rate performed 
as previously described at the first study visit. Data was normally distributed and 
analysis was undertaken using a Student’s t-test. 
 
Table 3-5. Baseline Measures of Isotopic Renal Function 
 
The mean GFR of the healthy individuals was 113 ml/min compared to 32.1 ml/min in 
the overt nephropathy group. Only 11 of the overt nephropathy patients had an isotope 
ERPF as a result of difficulties obtaining the isotope as a result of manufacturing and 
supply problems. 
 
3.5.3.1 Healthy Individuals 
 
 Visit 1 Visit2 n P Visit 2 Visit 3 n p 
GFR 
(ml/min) 
113.00 99.40 10 0.016 97.00 106.86 7 0.030 
ERPF 
(ml/min) 
489.75 463.00 8 0.041     
FF (%) 24 22 8 0.21     
 
Table 3-6. Changes in Renal Function - Healthy Individuals 
 
   Units = ml/min 
Patient 
group 
  n Minimum Maximum Mean Std. 
Deviation 
Healthy 
 
GFR 10 100.0 141.0 113.0 13.33 
ERPF 10 381.0 541.00 474.6 47.96 
Overt 
nephropaths 
 
GFR  14 21.0 46.0 32.1 7.74 
ERPF  11 96.0 266.0 158.9 49.68 
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The healthy individuals demonstrated a statistically significant drop in GFR (113.0 
ml/min to 99.4 ml/min, p=0.016) following dietary supplementation with gum arabic. 
GFR then increased again from 97.0 ml/min to 106.9 ml/min following the washout 
period (p=0.03). A statistically significant fall in ERPF was also seen (489.75 ml/min to 
463.0, p=0.041) with no significant change in filtration fraction. 
 
3.5.3.2 Overt Nephropaths 
 
 
 Visit 1 Visit2 n P 
GFR 
(ml/min) 
32.07 33.50 14 0.55 
ERPF 
(ml/min) 
158.00 163.00 4 0.35 
FF (%) 19 19 4 0.85 
 
Table 3-7. Changes in Renal Function - Overt Nephropaths 
 
Glomerular filtration rate and ERPF both increased a small, non-statistically significant 
amount. GFR increased from 32.07 to 33.50 and ERPF from 158.00 to 163.00, but 
numbers were small for measurement of ERPF as the isotope was unavailable on the 
day of the study visit. There was no change in filtration fraction.  
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3.6 The Effects of Gum Arabic on Blood Pressure and Cardiovascular Risk 
 
3.6.1 Methods 
 
Baseline blood pressure measurements were recorded in all 3 groups of patients at 
baseline and at subsequent study visits. This chapter studies the effects that the 
administration of gum arabic had on the 3 groups of subjects.  
As previously, data was analysed for normality of distribution by means of inspection 
of a histogram. Peripheral blood pressure was normally distributed for the whole group 
and a paired samples t-test was used for statistical analysis. For individual group 
analysis, the data was not normally distributed and therefore non-parametric analysis of 
the data used a Wilcoxon Signed Ranks Test.  
 
3.6.1.1 Healthy Individuals 
 
Data for the individual groups of subjects blood pressures was not normally distributed. 
Therefore a Wilcoxon Signed Ranks test was undertaken.  
Variable Mean (mmHg) SD Significance 
Systolic BP Visit1 129.10 8.25 
0.038 
Systolic BP Visit 2 123.60 11.51 
Diastolic BP Visit 1 75.50 11.21 
0.86 
Diastolic BP Visit 2 74.60 10.54 
Pulse Pressure Visit 1 53.60 9.34 
0.39 
Pulse Pressure Visit 2 49.00 11.38 
MAP Visit 1 93.37 9.33 
0.11 
MAP Visit 2 90.93 9.46 
 
Table 3-8.Changes in Blood Pressure - Healthy Individuals 
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Mean arterial  
pressure 
Following administration of Gum Arabic there was a clinically and statistically 
significant drop in systolic blood pressure from 129.10 mmHg to 123.60 mmHg 
(p=0.038) in healthy individuals. Reductions in diastolic pressure, pulse pressure and 
mean arterial pressure were also seen but these did not reach statistical significance.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-2. Changes in Systolic Blood Pressure - Healthy Individuals 
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3.6.1.2 Overt Nephropaths 
 
Variable Mean (mmHg) SD Significance 
Systolic BP Visit1 140.07 23.18 
0.13 
Systolic BP Visit 2 131.07 12.13 
Diastolic BP Visit 1 71.29 13.52 
0.19 
Diastolic BP Visit 2 66.07 12.26 
Pulse Pressure Visit 1 68.79 22.28 
0.75 
Pulse Pressure Visit 2 65.00 12.10 
MAP Visit 1 94.21 13.81 
0.026 
MAP Visit 2 87.74 10.80 
 
Table 3-9. Changes in Blood Pressure - Overt Nephropaths 
 
 
Despite there being a clinically important drop in systolic blood pressure in the overt 
nephropath group from 140.07 mmHg to 131.07 mmHg, this did not reach statistical 
significance. There was also a fall in diastolic blood pressure but again this did not 
reach a level of statistical significance. The combined effect of reductions in both 
systolic and diastolic pressure resulted in a drop in mean arterial blood pressure from 
94.21 mmHg to 87.74 mmHg, reaching statistical significance (p=0.026). 
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Figure 3-3. Changes in MAP - Overt Nephropaths 
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3.7 Metabolic Parameters 
 
Baseline metabolic parameters are recorded in Table 3-10. Cholesterol is noted to be 
higher in the healthy individuals as compared to the overt nephropaths. This is likely to 
be due to the fact that these groups, with a recognised increased cardiovascular risk will 
be treated with a lipid lowering agent.  Urinary protein excretion was measured by a 24 
urine sample. 
 
 
Parameter Healthy Overt Nephropaths 
 N Mean SD N Mean SD 
Glucose visit 1 
(mmol/L) 10 5.22 0.54 14 9.26 4.19 
HbA1C Visit1 (%) 10 5.09 0.26 12 8.05 1.22 
Cholesterol 
(mmol/l) 8 4.81 0.99 14 3.94 0.68 
Triglycerides 
(mmol/L) 8 0.90 0.37 14 2.30 1.45 
24 hour urine 
protein (g/24hrs) 9 0.21 0.15 14 0.91 0.68 
 
Table 3-10. Baseline metabolic parameters 
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3.7.1 The effects of Gum Arabic on Metabolic Parameters 
 
Statistical analysis was carried out using a Students t-test.  
 
3.7.1.1 Healthy Individuals 
 
 
Table 3-11. Effects of Gum arabic on metabolic parameters - Healthy Individuals 
 
Following the study period on Gum arabic, no significant changes in metabolic data are 
seen in the group of healthy individuals. There was however a statistically significant 
drop in HbA1C following the washout period (5.14 to 4.97, p=0.02). The reasons for 
 N Value SD P 
HbA1C Visit 1 (%) 10 5.09 0.26 
0.67 
HbA1C Visit 2 (%) 10 5.12 0.27 
HbA1C Visit 2 (%) 7 5.14 0.32 
0.02 
HbA1C Visit 3 (%) 7 4.97 0.26 
Total Cholesterol Visit 1 (mmol/l) 8 4.81 0.99 
0.39 
Total Cholesterol Visit 2 (mmol/l) 8 4.68 0.94 
Total Cholesterol Visit 2 (mmol/l) 7 4.59 1.00 
0.18 
Total Cholesterol Visit 3 (mmol/l) 7 4.83 1.26 
Triglycerides Visit 1 (mmol/l) 8 0.90 0.37 
0.23 
Triglycerides Visit 2 (mmol/l) 8 1.00 0.47 
Triglycerides Visit 2 (mmol/l) 7 0.93 0.29 
0.26 
Triglycerides Visit 3 (mmol/l) 7 0.79 0.23 
24 hr urine protein Visit 1 (g/24hr) 8 0.22 0.16 
0.11 
24 hr urine protein Visit 2 (g/24hr) 8 0.12 0.08 
Weight Visit 1 (kg) 10 82.30 14.40 
0.83 
Weight Visit 2 (kg) 10 82.39 15.24 
Weight Visit 2 (kg) 7 81.64 16.60 
0.08 
Weight Visit 3 (kg) 7 80.89 16.03 
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this are not clear. Data for 24 hour urine protein excretion at visit 3 was not complete. 
Weight remained static during the study period. There was a drop in weight in the 
washout period that did not reach statistical significance. 
 
 
3.7.1.2 Overt nephropaths 
 
 
Table 3-12. Effects of Gum arabic on metabolic parameters - Overt Nephropaths 
 
There were no changes in the metabolic parameters in the overt nephropath group 
following the intervention period. A small but statistically significant rise in HDL 
cholesterol, from 0.79 to 0.86 mmol/l (p=0.05) was seen. A small and non-statistically 
significant rise in weight is seen (98.46kg to 99.14 kg, p=0.16). 
 
 
 N Value SD P 
HbA1C Visit 1 (%) 12 8.05 1.22 
0.24 
HbA1C Visit 2 (%) 12 7.68 1.32 
Total Cholesterol Visit 1 (mmol/l) 14 3.94 0.68 
0.41 
Total Cholesterol Visit 2 (mmol/l) 14 4.09 0.70 
HDL Cholesterol Visit 1 (mmol/l) 7 0.79 0.09 
0.05 
HDL Cholesterol Visit 2 (mmol/l) 7 0.86 0.08 
LDL Cholesterol Visit 1 (mmol/l) 7 2.10 0.57 
0.32 
LDL Cholesterol Visit 2 (mmol/l) 7 2.34 0.64 
Triglycerides Visit 1 (mmol/l) 14 2.30 1.45 
0.66 
Triglycerides Visit 2 (mmol/l) 14 2.34 1.60 
24 hr urine protein Visit 1 (g/24hr) 14 0.91 0.68 
0.46 
24 hr urine protein Visit 2 (g/24hr) 14 0.99 0.64 
Weight Visit 1 (kg) 14 98.46 16.82 
0.16 
Weight Visit 2 (kg) 14 99.14 16.56 
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3.7.2 The effects of Gum Arabic on Short Chain Fatty Acid Production 
 
3.7.2.1 SCFA Production in Normal Individuals 
 
Data on SCFA (butyrate and propionate) production was collected in the healthy 
individual group.  
Levels of serum butyrate increased significantly from baseline levels to post gum arabic 
ingestion levels, with no associated change in serum propionate levels. Levels of 
butyrate rose form a baseline of 0.49 ± 0.08 to 0.71 ± 0.11 µmol/l (P=0.03).  
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3.8 Extended Baseline Demographics 
 
The follow on study consisted entirely of subjects with incipient nephropathy. In 
addition to the baseline demographic data presented, data on the complications of 
diabetes and other cardiovascular risk data were also collected and are presented in 
Table 3-13. 
 
Risk factor Value Percentage 
Duration of diabetes 9.99 ± 8.39 years NA 
History of microalbuminuria recorded 9 39.1 
Duration of microalbuminura 1.33 ± 0.34 years NA 
Ischaemic heart disease 4 17.4 
Previous myocardial infarction 3 13.0 
Previous CABG 0 0 
Smoker 11 47.8 
Pack year history (years) 33.91 ± 22.87 NA 
Hypertension 16 69.6 
History of total cholesterol >5.00 
mmol/L 
19 
82.6 
Family history of cardiovascular 
disease 
10 
43.5 
 
Previous CVA 1 4.3 
Peripheral vascular disease 3 13 
Diabetic neuropathy 3 13.0 
Diabetic retinopathy 6 23.0 
 
Table 3-13. Baseline cardiovascular risk data  - Incipient Nephropaths 
 
Duration of diabetes was taken as the time as the period from diagnosis until the time of 
screening. This may underestimate the true duration of diabetes due to the time lag form 
onset to diagnosis. Average duration of diabetes was 9.99 ± 8.39 years.  
17.4% of this population had ischaemic heart disease, defined as any patient who had 
been given a clinical diagnosis of angina, which may or may not have been proven with 
cardiac investigations. 47.8% were smokers, defined as anyone who had smoked 
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regularly in the past or continued to do so. Pack year history (PYH) was defined as: 1 
pack year being equivalent to smoking 20 cigarettes daily for 1 year, the average PYH 
being 33.91 ± 22.87 years. 
All patients in the diabetes clinic undergo annual diabetic retinopathy screening. The 
most recent report was referred to, to make a diagnosis of diabetic retinopathy, showing 
that 23.0% had a diagnosis of diabetic retinopathy. 
39.1% of the population had a documented history of microalbuminuria with an average 
duration of 1.33 ± 0.34 years.   ACR measurement was not part of the study, 24 hour 
urine protein excretion was and all of the patients had levels of protein excretion that 
would make a diagnosis of “microalbuminuria”, and therefore incipient nephropathy.  
In the follow on study data was also collected regarding medications that were 
prescribed to the incipient nephropath subjects and is presented in Figure 3-4.  
 
 
 
Figure 3-4. Concurrent Medication - Subjects with Incipient Nephropathy 
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3.9 Baseline Data 
The data in Table 3-14 is data taken from the first study visit and includes simple 
measures of renal function and electrolytes. 
 
Parameter Incipient nephropaths 
 
N Mean SD 
Sodium (mmol/L) 23 140.13 2.14 
Potassium (mmol/L) 23 3.97 0.35 
Urea (mmol/L ) 23 5.94 1.18 
Creatinine (µmol/L) 23 78.30 13.18 
 
Table 3-14. Baseline Biochemical Data - Incipient Nephropath 
 
 
3.10 Effects of Gum Arabic on Biochemistry and Renal Function 
 
3.10.1 Incipient Nephropaths 
 
 Visit 1 Visit 2 n p Visit 2 Visit 3 n p 
Sodium 
(mmol/l) 
140.13 140.13 23 1.0 140.13 140.65 23 0.30 
Potassium 
(mmol/l) 
3.97 3.99 23 0.79 3.99 4.01 23 0.57 
Urea 
(mmol/l) 
5.94 6.13 23 0.53 6.13 5.85 23 0.30 
Creatinine 
(µmol/L) 
78.30 81.96 23 0.044 81.96 83.17 23 0.56 
Bicarbonate 
(mmol/l) 
26.09 24.50 22 0.011 24.50 23.00 22 0.03 
 
Table 3-15. Changes in Biochemistry - Incipient Nephropaths 
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Data was normally distributed and analysed using a Student’s t-test. All patients in the 
incipient nephropath group had the parameters measured at each visit. There was a 
statistically significant rise in creatinine from visit 1 to visit 2, from 78.30 to 81.96 
(p=0.044), the period during which Gum Arabic was taken.  Similarly there was a 
progressive and statistically significant decline in serum bicarbonate throughout the 
duration of the study. 
 
3.10.2 Whole group 
 
 Visit 1 Visit 2 n P Visit 2 Visit 3 n p 
Sodium 
(mmol/l) 
140.19 139.79 47 0.33 140.07 140.48 27 0.37 
Potassium 
(mmol/l) 
4.22 4.189 47 0.59 4.02 4.01 27 0.93 
Urea 
(mmol/l) 
9.75 9.26 47 0.25 6.07 5.92 30 0.52 
Creatinine 
(µmol/L) 
120.64 121.89 47 0.52 82.47 83.53 30 0.50 
 
Table 3-16. Changes in biochemistry - Whole group 
There were no significant changes in simple measures of renal function (urea and 
creatinine) or electrolytes following the intake of gum arabic or any changes following 
the washout period. Values stated for visit 2 are different in the comparisons with visits 
1 and 3 as not all patients had complete data for visit 3. 
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3.10.3 Effects of Gum Arabic on isotopic measures of renal function 
 
All subjects had a baseline measurement of isotope glomerular filtration rate performed 
as previously described at the first study visit. Data was normally distributed and 
analysis was undertaken using a Student’s t-test. 
 
Table 3-17. Baseline Measures of Isotopic Renal Function 
The mean GFR of the incipient nephropath group was 100.5 ml/min with an ERPF of 
382.0 ml/min. 
 
3.10.4 Incipient Nephropaths 
 
 Visit 1 Visit2 n P Visit 2 Visit 3 n p 
GFR 
(ml/min) 
100.68 98.23 22 0.34 98.23 99.05 22 0.79 
ERPF 
(ml/min) 
382.00 388.00 23 0.68 380.82 366.23 22 0.29 
FF (%) 27 26 22 0.58 26 27 22 0.20 
 
Table 3-18. Changes in renal Function - Incipient Nephropaths 
Amongst the incipient nephropaths GFR dropped from 100.68 ml/min to 98.23 ml/min, 
between visit 1 and visit 2 but this was non-significant (p=0.34). There was no 
significant change in ERPF or filtration fraction. One subject did not have data on GFR 
at visit 2 due to problems with analysis of the sample in the laboratory.  
 
   Units = ml/min 
Patient 
group 
  n Minimum Maximum Mean Std. 
Deviation 
Incipient 
nephropaths 
 
GFR 23 69.0 139.0 100.5 20.05 
ERPF  23 278.0 489.0 382.0 62.11 
 
Whole Group 
 
GFR 47 21.0 141.0 82.8 37.17 
ERPF 44 96.0 541.0 347.3 128.53 
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3.10.5 Whole Group 
 
 Visit 1 Visit2 n P Visit 2 Visit 3 n p 
GFR 
(ml/min) 
82.48 78.78 46 0.054 97.93 100.93 29 0.24 
ERPF 
(ml/min) 
381.03 379.42 35 0.87 380.81 366.23 22 0.29 
FF (%) 25 24 34 0.24 26 27 22 0.20 
 
Table 3-19. Changes in Renal Function - Whole Group 
 
Isotope GFR dropped from 82.48 ml/min to 78.78 ml/min in the whole group following 
the intake of gum arabic. This approached statistical significance (p=0.054). Following 
the washout period there was a small rise in GFR from 97.93 ml/min to 100.93 ml/min 
although this did not reach significance. Data was not complete for visit 3 or for ERPF 
data. This was due to difficulties in sourcing the radioisotope (particularly in the pilot 
study) and not due to withdrawals from the study. There were no significant changes in 
ERPF or filtration fraction. 
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3.10.6 Effect of Gum Arabic on Peripheral Blood Pressure 
 
The following analyses look specifically at the changes in peripheral blood pressure 
following administration of Gum Arabic.   
 
3.10.7 Incipient Nephropaths 
 
Variable Mean (mmHg) SD 
 
Significance 
Systolic BP Visit 1 
 141.52 18.72 0.26 
Systolic BP Visit 2 137.91 17.85 
0.93 Systolic BP Visit 3 
 138.70 15.94 
Diastolic BP Visit 1 
 86.09 7.23 0.044 
Diastolic BP Visit 2 82.57 9.43 
0.94 Diastolic BP Visit 3 
 82.74 10.89 
Pulse Pressure Visit 1 
 55.44 16.35 0.78 
Pulse Pressure Visit 2 55.35 14.68 
0.92 Pulse Pressure Visit 3 
 55.96 11.70 
MAP Visit 1 
 104.57 9.62 0.08 
MAP Visit 2 101.01 10.84 
0.96 MAP Visit 3 
 101.39 11.54 
 
Table 3-20. Changes in Blood Pressure - Incipient Nephropaths 
 
A small drop is observed in systolic pressure (141.52 mmHg to 137.91 mmHg) 
following the intervention period but this does not reach statistical significance. A 
statistically significant reduction in diastolic blood pressure is observed from 86.09 
mmHg to 82.57mmHg (p=0.044). No significant rise in diastolic blood pressure was 
seen following the washout period. Mean arterial pressure also fell from 104.57 mmHg 
to 101.01 mmHg but was not statistically significant. 
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Figure 3-5. Changes in Diastolic Blood Pressure - Incipient Nephropaths 
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3.10.8 Whole Group 
 
The whole group was analysed to look for changes in peripheral blood pressure on and 
off treatment with Gum Arabic. Statistical analysis was with a Student t-test. 
Variable Mean (mmHg) Std. Deviation Significance 
Systolic BP Visit 1 138.45 18.90  
0.024 
 
Systolic BP Visit 2 132.83 15.88 
Diastolic BP Visit 1 79.43 12.13 
0.071 
Diastolic BP Visit 2 75.96 12.60 
Pulse Pressure Visit 1 59.02 18.09 
0.34 
Pulse Pressure Visit 2 56.87 14.30 
Mean Arterial Pressure Visit 1 100.00 12.02 
0.023 
Mean Arterial Pressure Visit 2 94.91 12.03 
 
Table 3-21. Changes in Blood Pressure – Whole Group 
 
Statistically significant changes were seen in systolic and mean arterial blood pressure 
with a reduction in systolic blood pressure of nearly 6 mmHg (shown in Figure 3-6) 
from 138.45 mmHg to 132.83 mmHg after dietary supplementation with gum arabic 
(p=0.024). 
There was also a statistically significant drop in MAP of just over 5mmHg (p=0.023) 
shown in Figure 3-7.  
A clinically relevant fall in diastolic blood pressure in the whole group is seen after the 
study period on Gum Arabic which trended towards significance with a reduction from 
79.43 mmHg to 75.96 mmHg (p=0.071). 
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Figure 3-6. Changes in Systolic Blood Pressure - Whole Group 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-7. Change in Mean Arterial Pressure - Whole Group 
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3.10.9 The Effect of Gum Arabic on Central Blood Pressure and Cardiovascular 
Risk  
 
This chapter will discuss the effects that Gum arabic has on central blood pressure. 
Measurements of vascular stiffness are accepted to be markers of cardiovascular risk. 
Baseline data on other more traditional markers of cardiovascular risk and 
complications of diabetes were also recorded in this group and have been presented in 
Table 3-13. Central blood pressure and measures of vascular stiffness were calculated 
in the follow on study using the Sphygmocor system in the group of incipient 
nephropaths. 
Incipient nephropaths are a group of patients with an increased cardiovascular risk 
which is potentially modifiable and treatable. To further examine this group in detail the 
effects of dietary supplementation with Gum Arabic, the effects on central blood 
pressure and vascular stiffness were looked at in this sub group of incipient diabetic 
nephropaths taking part in the main study. Data for this group was normally distributed 
and statistical analysis was carried out using a comparison of means using a paired t-
test.  
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3.10.10 Central blood pressure 
 
 
Mean BP mmHg Std. Error Mean p value 
Aortic Systolic Pressure Visit 1 129.65 4.18 
0.62 
Aortic Systolic Pressure Visit 2 128.13 3.80 
Aortic Systolic Pressure Visit 2 128.13 3.80 
0.33 
Aortic Systolic Pressure Visit 3 126.89 3.52 
Aortic Diastolic Pressure Visit 1 86.52 1.60 
0.68 
Aortic Diastolic Pressure Visit 2 84.96 2.00 
Aortic Diastolic Pressure Visit 2 84.96 2.00 
0.38 
Aortic Diastolic Pressure Visit 3 83.80 2.36 
Aortic Pulse Pressure Visit 1 42.85 3.58 
0.89 
Aortic Pulse Pressure Visit 2 43.17 2.83 
Aortic Pulse Pressure Visit 2 43.17 2.83 
0.97 
Aortic Pulse Pressure Visit 3 43.09 2.31 
 
Table 3-22. Changes in Central Blood Pressure 
 
Following treatment with Gum Arabic, there were no statistically significant changes 
are observed in aortic (central) blood pressure. There is a small drop in aortic systolic 
and diastolic blood pressure following the study period on gum arabic but with no 
associated increase in these pressures following the washout period. 
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3.10.11 Effect of Gum Arabic on measures of Vascular Stiffness  
 
 Mean N SE Mean p value 
AIx @75bpm Visit1 (%) 22.07 23 2.49 
0.42 
AIx @75bpm Visit 2 (%) 23.11 23 2.11 
AIx @75bpm Visit 2 (%) 23.11 23 2.11 
0.89 
Aix @75bpm Visit 3 (%) 23.30 23 1.89 
AIx Visit1 (%) 24.24 23 2.45 
0.86 
AIx Visit 2 (%) 24.50 23 2.32 
AIx Visit 2 (%) 24.50 23 2.32 
0.41 
AIx Visit 3 (%) 25.87 23 1.76 
PWV Visit 1 (m/sec) 10.47 22 0.58 
0.61 
PWV Visit 2 (m/sec) 10.32 22 0.57 
PWV Visit 2 (m/sec) 10.32 22 0.57 
0.68 
PWV Visit 3 (m/sec) 10.53 22 0.71 
Tr Visit1 (ms) 136.48 23 2.67 
0.57 
Tr Visit 2 (ms) 135.24 23 2.4 
Tr Visit 2 (ms) 135.24 23 2.46 
0.51 
Tr Visit 3 (ms) 136.52 23 2.10 
SEVR Visit 1 (%) 159.52 23 6.59 
0.60 
SEVR Visit 2 (%) 157.89 23 6.47 
SEVR Visit 2 (%) 157.89 23 6.47 
0.42 
SEVR Visit 3 (%) 160.78 23 7.01 
 
Table 3-23.  Changes in Parameters of Vascular Stiffness 
 
The measures of vascular stiffness detailed in Table 3-23 show that there are no 
changes vascular stiffness following the administration of Gum arabic to subjects with 
incipient nephropathy. This would suggest that the blood pressure lowering effect that 
is seen is not as a result of changes to vascular compliance. 
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3.11 The Effects of Gum Arabic on Metabolic Parameters 
 
Baseline metabolic parameters are recorded in Table 3-24. Urinary protein excretion 
was measured by a 24 urine sample of urinary protein excretion.  
 
 
Parameter Incipient Nephropaths 
 N Mean SD 
Glucose visit 1 
(mmol/L) 22 9.13 2.16 
HbA1C Visit1 (%) 23 7.54 1.15 
Cholesterol (mmol/l) 23 3.97 0.86 
Triglycerides 
(mmol/L) 23 1.52 0.63 
24 hour urine protein 
(g/24hrs) 23 0.18 0.13 
 
Table 3-24. Baseline Metabolic Parameters - Incipient Nephropaths 
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3.11.1 The effects of Gum Arabic on Metabolic Parameters 
3.11.1.1 Incipient Nephropaths 
 
 
Table 3-25. Effects of Gum arabic on metabolic parameters - Incipient Nephropaths 
 N Value SD P 
HbA1C Visit 1 (%) 23 7.54 1.15 
0.25 
HbA1C Visit 2 (%) 23 7.73 1.30 
HbA1C Visit 2 (%) 22 7.71 1.33 
0.18 
HbA1C Visit 3 (%) 22 7.51 1.28 
Total Cholesterol Visit 1 (mmol/l) 23 3.97 0.86 
0.045 
Total Cholesterol Visit 2 (mmol/l) 23 4.13 0.89 
Total Cholesterol Visit 2 (mmol/l) 23 4.13 0.89 
0.66 
Total Cholesterol Visit 3 (mmol/l) 23 4.08 0.95 
HDL Cholesterol Visit 1 (mmol/l) 17 0.99 0.30 
0.33 
HDL Cholesterol Visit 2 (mmol/l) 17 0.97 0.27 
HDL Cholesterol Visit 2 (mmol/l) 19 0.95 0.19 
0.85 
HDL Cholesterol Visit 3 (mmol/l) 19 0.95 0.21 
LDL Cholesterol Visit 1 (mmol/l) 17 2.21 0.81 
0.43 
LDL Cholesterol Visit 2 (mmol/l) 17 2.28 0.80 
LDL Cholesterol Visit 2 (mmol/l) 19 2.24 0.84 
0.56 
LDL Cholesterol Visit 3 (mmol/l) 19 2.17 0.89 
Triglycerides Visit 1 (mmol/l) 23 1.52 0.63 
0.03 
Triglycerides Visit 2 (mmol/l) 23 1.70 0.58 
Triglycerides Visit 2 (mmol/l) 23 1.70 0.58 
0.69 
Triglycerides Visit 3 (mmol/l) 23 1.74 0.75 
24 hr urine protein Visit 1 (g/24hr) 23 0.18 0.13 
0.26 
24 hr urine protein Visit 2 (g/24hr) 23 0.21 0.12 
24 hr urine protein Visit 2 (g/24hr) 21 0.19 0.11 
0.56 
24 hr urine protein Visit 3 (g/24hr) 21 0.18 0.11 
Weight Visit 1 (kg) 23 88.63 17.13 
0.85 
Weight Visit 2 (kg) 23 88.59 17.28 
Weight Visit 2 (kg) 23 88.59 17.28 
0.50 
Weight Visit 3 (kg) 23 88.74 17.46 
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Statistical analysis was carried out using a Student’s t-test as data was normally 
distributed. No change in HBa1C is seen in the group of incipient nephropaths 
following the study period on gum arabic. Due to problems in the biochemistry lab, data 
for some subjects was only available for total cholesterol and triglycerides. There are 
however statistically significant increases in total cholesterol (3.97 mmol/l to 4.13 
mmol/l, p=0.05) and in serum triglycerides (1.52 mmol/l to 1.70 mmol/l, p=0.03). This 
could once again relate to a possible appetite stimulation effect. However, this is not 
supported by any change in weight of the subjects.  
 
3.11.1.2 Whole Group 
 
 
Table 3-26. Effects of Gum arabic on metabolic parameters - Whole Group 
 
 N Value SD p 
HbA1C Visit 1 (mmol/l) 45 7.13 1.52 
0.99 
HbA1C Visit 2 (mmol/l) 45 7.13 1.57 
HbA1C Visit 2 (mmol/l) 29 7.09 1.61 
0.09 
HbA1C Visit 3 (mmol/l) 29 6.9 1.57 
Total Cholesterol Visit 1 (mmol/l) 45 4.11 0.88 
0.15 
Total Cholesterol Visit 2 (mmol/l)  45 4.21 0.85 
Total Cholesterol Visit 2 (mmol/l) 30 4.24 0.92 
0.83 
Total Cholesterol Visit 3 (mmol/l) 30 4.26 1.06 
Triglycerides Visit 1 (mmol/l) 45 1.65 1.04 
0.02 
Triglycerides Visit 2 (mmol/l) 45 1.78 1.08 
Triglycerides Visit 2 (mmol/l) 30 1.52 0.62 
0.93 
Triglycerides Visit 3 (mmol/l) 30 1.52 0.78 
24 hr urine protein Visit 1 (g/24hr) 45 0.41 0.51 
0.54 
24 hr urine protein Visit 2 (g/24hr) 45 0.44 0.52 
24 hr urine protein Visit 2 (g/24hr) 21 0.19 0.11 
0.56 
24 hr urine protein Visit 3 (g/24hr) 21 0.18 0.11 
 
 
132 
Statistical analysis was done using a Students t-test. Gum arabic did not change levels 
of HbA1C in the whole group. There was no change in levels of total cholesterol either. 
Following the study period on Gum arabic, an increase in serum triglycerides (1.65 
mmol/l to 1.78, p=0.02) is seen. This could be as a result of improved appetite. No 
change in urine protein excretion was seen. 
 
 
 
3.12 The effects of Gum Arabic on Short Chain Fatty Acid Production 
 
3.12.1 SCFA Production in Incipient nephropaths 
 
Data on an expanded series of plasma short chain fatty acids was collected for 22 of the 
incipient diabetic nephropath group at all 3 study points. The following short chain fatty 
acids were quantified: 
Lactate Acetate 
Propionate Isobutyrate 
Butyrate Isovalerate 
Succinate Valerate 
Formate  
 
Statistical analysis was undertaken to ascertain whether there had been a change in the 
levels of SCFAs. A paired t-test was used for the total short chain fatty acids as the 
levels were normally distributed. A Wilcoxon Signed Ranks Test was used for the 
individual SCFAs as these levels were not normally distributed.  
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Table 3-27. Changes in Production of SCFAs – Incipient Nephropaths 
 
Only changes in the levels of plasma acetate, butyrate, formate and total SCFA were 
observed following administration of Gum Arabic with a subsequent fall towards 
baseline after the washout period. Data for the other SCFAs was complete but no 
clinically relevant or statistically significant changes were seen in their levels.  
 Mean (µmol/l) Std. Error Mean p value 
Plasma Acetate Visit 1 22.85 6.27 
0.033 
Plasma Acetate Visit 2 39.19 10.16 
Plasma Acetate Visit 2 39.19 10.16 
0.55 
Plasma Acetate Visit 3 32.21 6.52 
Plasma Succinate Visit 1 
 
24.51 4.03 
0.91 
Plasma Succinate Visit 2 
 
27.59 5.70 
Plasma Succinate Visit 2 
 
27.59 5.70 
0.90 
Plasma Succinate Visit 3 26.64 4.08 
Plasma Lactate Visit 1 3652.32 360.71 
0.31 
Plasma Lactate Visit 2 3816.12 406.97 
Plasma Lactate Visit 2 3816.12 406.97 
0.32 
Plasma Lactate Visit 3 3896.77 276.98 
Plasma Isobutyrate Visit 1 33.22 4.23 
0.73 
Plasma Isobutyrate Visit 2 36.61 5.96 
Plasma Isobutyrate Visit 2 36.61 5.96 
0.78 
Plasma Isobutyrate Visit 3 39.67 6.72 
Plasma Isovalerate Visit 1 33.07 4.87 
0.53 
Plasma Isovalerate Visit 2 33.00 6.93 
Plasma Isovalerate Visit 2 33.00 6.93 
0.71 
Plasma Isovalerate Visit 3 25.90 4.55 
Plasma Butyrate Visit 1 36.72 5.90 
0.031 
Plasma Butyrate Visit 2 23.79 4.79 
Plasma Butyrate Visit 2 23.79 4.79 
0.10 
Plasma Butyrate Visit 3 36.58 6.72 
Plasma Formate Visit 1 46.30 13.60 
0.64 
Plasma Formate Visit 2 83.66 28.45 
Plasma Formate Visit 2 83.66 28.45 
0.14 
Plasma Formate Visit 3 46.90 12.25 
Plasma Valerate Visit 1 27.55 4.28 
0.43 
Plasma Valerate Visit 2 34.65 6.16 
Plasma Valerate Visit 2 34.65 6.16 
0.76 
Plasma Valerate Visit 3 40.03 6.59 
Plasma Propionate Visit 1 50.86 11.19 
0.59 
Plasma Propionate Visit 2 51.92 15.92 
Plasma Propionate Visit 2 51.92 15.92 
0.14 
Plasma Propionate Visit 3 58.72 10.78 
Total SCFA Visit 1 275.04 24.86 
0.12 
Total SCFA Visit 2 330.37 39.42 
Total SCFA Visit 2 330.37 39.42 
0.56 
Total SCFA Visit 3 306.63 25.94 
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Plasma acetate rose from 22.85 to 39.19 (p=0.033) with a fall towards baseline after the 
washout period (p=NS).  Conversely plasma butyrate fell from 36.72 to 23.79 
(p=0.031) with a subsequent rise back to baseline (NS, p=NS). Plasma formate levels 
increased greatly after the study period on Gum Arabic, from 46.30 to 83.66, with a fall 
towards baseline but this did not reach statistical significance. There was an increase in 
total plasma SCFAs after administration of Gum Arabic from 275.04 to 330.37 with a 
drop towards baseline (306.63) following the washout period. Neither of these changes 
reached statistical significance. 
The original study design allowed for collection of faeces to measure both faecal short 
chain fatty acids and faecal bacteria composition. The collection was undertaken in a 
number of patients and stored for future analysis. This analysis has not yet taken place, 
in part due to cost limitations of the study. 
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3.13 Further data analysis 
 
Although many of the patients showed little or no change in the measurements 
presented, this could be for numerous reasons. One of the major compounding factors, 
particularly in the group of incipient nephropaths may be the fact that 78.3% of this 
group were taking an ACE inhibitor or ARB. This group of medications is well 
documented to have effects on GFR and vascular function and it may not have been 
possible to improve these parameters further by the addition of Gum arabic. Another 
unexplored confounding factor may have been that of pre-existing dietary fibre intake. 
No measurement of concurrent dietary fibre intake was recorded and it is feasible that 
some of the subjects were already on a high fibre diet. The addition of further fibre in 
the form of gum arabic may not have had any further impact on the parameters 
recorded. By looking for a group of subjects that may have responded to the Gum 
Arabic, by way of a reduction in blood pressure, it might be possible to see if this group 
has also had improvements in other parameters measured such as changes in renal 
haemodynamics or in measures of arterial stiffness. 
 
3.13.1 Blood Pressure Responders 
 
To further study the effects of gum arabic on blood pressure the data was analysed to 
see if there was a sub-group of patients who responded to gum arabic. This group was 
defined as any individual who had a fall in their mean arterial blood pressure. There 
was no significant difference in the number of responders in each group. 
 MAP Responder 
No Yes % responders 
Healthy Individuals 3 7 70 
Incipient Nephropaths 8 15 65.2 
Overt Nephropaths 3 11 78.6 
Total 14 33 70.2 
 
Table 3-28 Distribution of patients with significant fall in blood pressure - Classified by MAP response 
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As expected, these “responders” had a statistically significant drop in both peripheral 
systolic and diastolic blood pressure (p=0.000). When the 3 patient groups were 
analysed separately only the incipient nephropaths had a significant drop in both 
systolic and diastolic blood pressure (p=0.002 and p=0.001 respectively). The healthy 
individuals had a significant drop in diastolic blood pressure (p=0.027) and the overt 
nephropaths only in systolic blood pressure (p=0.013). These significant changes may 
be as a result of selection bias. 
 
3.13.1.1 Changes in Central Blood Pressure and Vascular Stiffness 
 
Central blood pressure was of course only measured in the group of incipient 
nephropaths using the Sphygmocor system, and I have already demonstrated that they 
had a significant drop in their peripheral diastolic blood pressure and a trend to a drop 
in systolic blood pressure but there was no associated drop seen in central blood 
pressure which may be a better marker of cardiovascular risk in these patients.   
 
Patient Group Ao Sys BP (pre) Ao Sys BP (post) P value 
Non-responders 124.38 ± 4.85 135.31 ± 5.19 0.032 
Responders 132.47 ± 5.85 124.30 ± 4.97 0.015 
 
Units are mmHg 
Table 3-29. Changes in Central Systolic Blood Pressure 
 
When the data is analysed further, comparing responders, that is those with a drop in 
MAP, and non responders some marked differences are seen. The responder group 
show a significant fall in central aortic systolic blood pressure with a fall from 132.47 
mmHg to 124.30 mmHg (p=0.015) compared with the non responder group who 
actually showed a significant rise in their aortic systolic pressure from 124.83 mmHg to 
135.31 mmHg (p=0.032). 
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Patient Group Ao Dias BP (pre) Ao Dias BP (post) p value 
Non-responders 84.63 ± 2.71 89.63 ± 3.39 0.031 
Responders 87.53 ± 2.00 82.47 ± 2.29 0.007 
 
Units are mmHg 
Table 3-30. Changes in Central Diastolic Blood Pressure 
 
Similar changes are demonstrated when aortic diastolic blood pressure is analysed. The 
responder group showed a significant fall in pressure from 87.53 mmHg to 82.47 
mmHg (p=0.007) and the non responders showed a significant rise in pressure from 
84.63 mmHg to 89.63 mmHg (p=0.031). Analysis of parameters of arterial stiffness 
failed to show any significant changes as demonstrated below in Table 3-31. 
 
 Pre SD Post SD  P value 
AIx (%) 24.87 12.95 25.27 12.47 NS 
AIx @75 (%) 22.47 12.30 23.30 11.77 NS 
PWV (m/sec) 10.07 2.86 10.14 2.84 NS 
 
Table 3-31 Analysis of Diabetic responders - Classified by MAP response 
 
 
3.13.1.2 Changes in Renal Function in responder group 
 
Looking at all of the subjects, data was analysed to see if there was any change in renal 
function within the groups of responders or non responders. As discussed earlier, there 
was a drop in GFR following administration of Gum Arabic in the whole group that did 
not quite reach statistical significance (p= 0.054). The non-responder group showed no 
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real change in the GFR (88.85 ± 9.91ml/min to 87.54 ± 10.14 ml/min). The MAP 
responder group show a greater drop in GFR (79.97 ± 6.69 ml/min to 75.33 ± 5.97 
ml/min) with a trend towards statistical significance (p= 0.053) which is likely to be 
directly related to the change in blood pressure. 
For the three separate patient groups the data was further analysed, looking at the 
responder and non-responder groups. There were no significant changes in renal 
function when the groups were split down in to these fairly small numbers, other than a 
significant drop in the GFR (p<0.05) in the sub-group of healthy “non-responders”. 
However this group consisted of only 3 patients and may be inappropriate to infer 
anything from this. 
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4 DISCUSSION 
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4.1 Baseline Demographics 
 
The vast majority of the patients recruited to the two studies were male. The reasons for 
this are not clear. There were no female patients in the overt nephropathy group.  
Comparison of age, weight and BMI was calculated using the One-way ANOVA 
method. Both age and weight were statistically significantly different (p<0.001 and 
p=0.038 respectively) between the 3 groups. This study will be unable to answer why 
this difference in weight existed but studies do show that obesity is an independent risk 
factor for progression and worse outcomes of kidney disease [116]. This difference in 
weight is also reflected in a statistically significant (p=0.001) difference in BMI 
between the groups. It is likely that the difference in age between the 2 diabetic 
populations is that it has taken time to progress to overt nephropathy and hence the 
greater age. The healthy population was younger as they were selected from a 
population who were of working age.  
 
 
4.2 The Effects of Gum Arabic on Biochemistry and Renal Function 
 
Baseline biochemical data for the group of healthy individuals and for the incipient 
nephropaths was very similar, with no statistically significant differences between them. 
Overall there was little in the way of change in the simple biochemical parameters 
following the ingestion of Gum Arabic when looking at the group as a whole.  
The results show that there is a drop in isotope GFR in the group as a whole, following 
the intake of gum arabic but this did not reach statistical significance (p=0.054). There 
was no associated change in filtration fraction which is important. It is likely that most 
of this change is as a result of the statistically significant change in GFR seen in the 
group of healthy individuals, with a drop in GFR of 13.60 ml/min (p=0.016). As a result 
of a drop in EPRF in the same period there was no change in filtration fraction. 
Following the washout period the GFR increased again suggesting a reversible effect 
that was likely to have been caused by the gum arabic. Despite this drop in GFR, the 
results show that there was actually a drop in serum creatinine in the group of healthy 
individuals (87.10 to 82.80 ml/min, p=0.016). This is difficult to reconcile given that a 
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decrease in GFR should lead to an increase in serum creatinine. One possible 
explanation is that there was an increase in the tubular secretion of creatinine during the 
gum arabic supplementation. This compensation by a tubular process could have led to 
these results. Similar changes are not shown in the group of incipient nephropaths. In 
this group there was climb in serum creatinine after taking gum arabic supplements 
(78.3 µmol/l to 81.96 µmol/l, p=0.044). There was no associated change in isotope 
GFR. A possible explanation is a potential effect on appetite, though this is not 
supported by a change in weight remained constant in the throughout the study. No 
food diary was recorded in the study to look at either fibre intake or protein intake. If 
there had been an increase in protein intake this may be sufficient to account for the 
change in serum creatinine. 
There was no significant change in either ERPF or GFR in either group of diabetic 
subjects although there did appear to be a trend towards a reduction in GFR in the 
incipient nephropath group following administration of Gum Arabic. The reasons for 
this are unclear but may relate to the poly pharmacy that these patients are taking, in 
particular drugs affecting the renin angiotensin system (see Figure 3-4). There may 
have also been an element of “self selection”. Many of the patients willing to take part 
in the study are likely to already be the type of patient who takes an interest in their 
health. This is reflected by relatively good diabetic control, good control of lipids and 
urine protein excretion. Blood pressure control in all 3 groups was also good (see Table 
3-1). It was not known what the subjects’ diets were as a food diary was not kept. It is 
quite possible that there was a subset of patients who were on a high fibre diet already 
and the addition of 25g of Gum Arabic would not have been able to alter bacterial short 
chain fatty acid production further. There may not therefore have been any scope for 
improving renal function further by the addition of gum arabic to the diet.  
The small changes that have been observed may be clinically important and may have 
been better demonstrated if the study period was longer and if more patients had been 
recruited to the study. In this particular study, a dose of 25g of Gum arabic was chosen. 
Ali et al [217] have however chosen a higher dose of 50g of gum arabic, for a similar 
time period, in a study of patients with chronic renal failure. A higher dose may have 
lead to an increased effect but may have worsened its side effect profile and 
compliance.  
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4.3 The Effects of Gum Arabic on Blood Pressure and Cardiovascular Risk 
 
Analysis of peripheral blood pressure at baseline demonstrates that the diastolic and 
mean arterial pressure in the group of incipient nephropaths were statistically higher 
than the healthy individuals and the overt nephropaths. Diastolic blood pressure was 
significantly higher at 86.09mmHg in the incipient nephropath group compared to the 
healthy individuals who had a mean diastolic BP of 75.50 mmHg (p=0.028) and the 
overt nephropaths who had a diastolic blood pressure of 71.29 mmHg (p=0.000).  It 
would not be unexpected that the blood pressure would be higher in the incipient group 
compared to the healthy group, due to the association of hypertension and diabetes. 
Given the association of high blood pressure and progressive diabetic nephropathy, it 
would be likely that the group of overt nephropaths would have higher blood pressures 
than those with incipient nephropathy [47]. One possible explanation is purely that the 
overt nephropath group have been more aggressively treated for their hypertension as 
their increased cardiovascular risk has been recognised in the specialist nephrology 
clinics treating them.  
By analysing the group as a whole Gum arabic is shown to have a clinically beneficial 
effect on peripheral blood pressure. There was nearly a 6 mmHg reduction in systolic 
blood pressure (p=0.024) and just over a 4mmHg drop in mean arterial pressure 
(p=0.023). Despite a potentially clinically important reduction in diastolic blood 
pressure of over 3 mmHg, it did not reach statistical significance (p=0.071). 
Looking at the individual groups of patients, there was a significant drop in the systolic 
blood pressure of healthy individuals, with some rise back towards baseline following 
the washout period. This partial rise back to baseline could indicate a prolonged effect 
of the Gum Arabic and that not a long enough washout time was used. 
The use of antihypertensive agents is seen extensively in the incipient nephropath 
group. As previously discussed there is good evidence for the use of drugs that block 
the renin angiotensin system and hence 78% of the patients were on either an ACE 
inhibitor or an angiotensin II receptor antagonist (Figure 3-4). Fourteen patients were 
on ACE inhibitors, 4 patients were on angiotensin II receptor antagonists but none of 
them were on dual therapy. A total of 18 or 78.3% of the patients were on a drug that 
inhibited the renin angiotensin system. Many other classes of antihypertensive agent 
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were also commonly prescribed as monotherapy or in combination other medication. 
The number of antihypertensive medications taken by individual patients is shown in 
Figure 4-1, with the majority of patients being on 2 drugs. 
 
 
 
Figure 4-1. Number of Antihypertensives - Incipient Nephropaths 
 
In the incipient nephropaths, there was a significant drop in the diastolic blood pressure, 
again with a possible trend to return to baseline following the washout period. There 
was a non-statistically significant drop in systolic and mean arterial pressure. A possible 
criticism of this study is that not large enough numbers of subjects were recruited. With 
greater numbers of patients there is a possibility this could be shown to be significant. 
These individuals had less than adequately controlled blood pressure despite being on 
multiple medications and were not reaching a target blood pressure of 130/80mmHg at 
the start of the study. The improvements in blood pressure following gum arabic 
suggest gum arabic could have an important role in lowering peripheral blood pressure 
further in this population of subjects. 
Despite some improvements in the peripheral blood pressure measurements of the 
incipient nephropaths, this did not translate in to changes in measures of central blood 
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pressure or measures of vascular stiffness. This would suggest that the blood pressure 
lowering effect of Gum arabic seen in this study is unlikely to be as a result in changes 
in endothelial function. This is similar to what was demonstrated in the CAFE study 
[195]. An antihypertensive regime of amlodipine ± perindopril versus atenolol ± 
thiazide showed similar reductions in peripheral blood pressure but the amlodipine 
based regime showed significant improvements in central blood pressure and 
improvements in cardiovascular outcomes. 
Looking at the overt nephropath group there was a clinically important drop in systolic 
blood pressure of 9 mmHg, but this was not statistically significant. Mean arterial 
pressure did improve, with a reduction of over 6 mmHg and this has clear clinical 
importance. 
The reasons for the differences between the groups are not entirely clear and cannot be 
explained on the basis of this study. Numbers in the different groups were markedly 
different and this may have an impact on the results and statistical analysis. Compliance 
is difficult to record accurately in a study design such as this. An attempt was made to 
record compliance in the incipient nephropath group by recording the number of sachets 
of Gum arabic used. A total of 4 unused sachets of Gum arabic were returned. This 
would suggest excellent compliance but unfortunately does not prove that study 
subjects actually took the supplements.  
By looking at the data available more closely a group of patients have been potentially 
identified who appear have responded to gum arabic. One potential limitation of the 
study is that a food diary was not obtained. Some of the subjects may have already been 
taking a high fibre diet, and therefore the addition of further fibre to the diet may not 
have shown any beneficial effect. By selecting a group of patients who have had an 
improvement in their blood pressure it is possible that we have selected subjects who 
were in some way able to respond to the effects of gum arabic. It was decided to select 
this group on the basis of a drop in their mean arterial pressure. Mean arterial pressure 
was taken to represent a change in “average” blood pressure, reflecting changes in 
either systolic or diastolic blood pressure. Lowering of mean arterial pressure has been 
shown to reduce cardiovascular risk [218]. This group did have significant changes in 
peripheral systolic and diastolic blood pressures as a whole and as individual groups 
with some changes in either systolic or diastolic blood pressure or both. This is likely to 
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be purely as a result of selection bias, in as much as they have been selected by the fact 
they had a change in blood pressure. In the group of incipient nephropaths, the group 
who had further assessment of vascular stiffness, this change also translated in to a 
change in central systolic and diastolic blood pressure but not in to a change in 
measurements of vascular stiffness. This would suggest that the changes in blood 
pressure seen are not as a result of alterations vascular stiffness.  
There are also other limitations of this study that need to be recognised. The design was 
unblinded and there was no placebo arm. It is possible that the blood pressure 
recordings were improved at the second study visit purely as a result of the subjects 
being more relaxed at this visit. All recordings using the Sphygmocor were taken by 
one investigator, but due to the unblinded nature of the study, a bias could also have 
been introduced. 
This study suggests that Gum Arabic may have beneficial effects on peripheral blood 
pressure that are not only statistically significant changes that could translate in to 
clinically relevant changes that might result in improved cardiovascular outcomes. 
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4.4 The Effects of Gum Arabic on Metabolic Parameters 
 
Although there is good evidence to show that an increased intake of dietary fibre can 
result in improved glycaemic control [129-132], use of Gum arabic in these populations 
has not shown any change in glycosylated haemoglobin. The average HbA1C of the 
incipient nephropaths was 7.54±1.15% at baseline, which would be regarded above 
target of 7%. Many of these patients were already on multiple medications. The most 
commonly prescribed oral hypoglycaemic agent was metformin. Twenty one of the 23 
patients in the group were on this as a single hypoglycaemic agent or in combination 
with insulin, gliclazide or a thiazolidinedione. Improving diabetic control further by the 
addition of dietary fibre in the form of Gum arabic has not been demonstrated in this 
study. The combinations of medication are shown Figure 4-2 
 
 
Figure 4-2. Number of hypoglycaemic medications used - Incipient Nephropaths 
1 = Sulphonylurea 
2 = Biguanide 
3 = Thiazolidinedione 
4 = Insulin 
  
Although there was a statistically significant fall in HbA1C in the washout period in the 
healthy subjects, who have normal physiological control of their blood sugars, this is 
not likely to be of clinical importance and the results remained within normal limits.  
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Measurements of serum lipids at baseline show that serum total cholesterol was higher 
in the healthy individuals compared to the incipient nephropaths and overt nephropaths 
(p=0.06 and p=0.035 respectively). The healthy individuals are not a population at risk 
of cardiovascular disease and have probably not been previously screened or treated for 
dyslipidaemia. The lower cholesterol value in the group of incipient nephropaths is 
likely to be due to the extensive use of lipid lowering agents in this group. Eighteen of 
the patients, due to their history of hyperlipidaemia were on a cholesterol lowering 
agent, 12 of them being on an HMG CoA reductase inhibitor. Only 2 of the patients 
were on a fibrate and 4 of the patients were on ezetimibe. This drug acts at the small 
intestine brush border and inhibits absorption of cholesterol from the diet.  
There was a clear rise in the serum total cholesterol of the incipient nephropath subjects 
and a rise in triglycerides in the same group and in the group as a whole. A rise in 
serum HDL is seen in the group of overt nephropaths. The changes in serum lipids are 
contrary to what much of the literature would suggest, as ingestion of fibre tends to 
have a lipid lowering affect as previously discussed [135]. However, it must be noted 
that Haskell et al showed that Gum arabic in particular resulted in no change on serum 
lipids [136]. This study of Gum arabic has shown a rise in cholesterol in this group. 
This could add evidence to the hypothesis that Gum arabic may have an appetite 
stimulatory effect which could explain the rise in serum creatinine also seen. Another 
possible cause for the rise in cholesterol in the incipient nephropath group is associated 
with the rise in serum acetate, discussed later in this chapter. 
Urinary protein excretion was higher in the healthy group (0.21g/24hr) compared to the 
Incipient Nephropathy group (0.18g/24hr).  However, this is not clinically significant in 
the healthy group and is regarded as within the normal range. It is however clinically 
significant in the incipient nephropath group and sufficient to make a diagnosis of 
microalbuminuria. 24 hour urinary protein excretion did not change significantly 
throughout the study. The data have shown that Gum arabic did not have a statistically 
significant effect on renal haemodynamics and is therefore unlikely to change urinary 
protein excretion. There is a possible suggestion of an effect in the healthy individuals, 
with a drop in urinary protein excretion (p=NS) and a drop in GFR and ERPF. It is 
possible that the study period needed to be longer to see a more significant effect.   
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There is a clear rise in serum acetate following the administration of Gum Arabic in the 
incipient nephropath group (p=0.033), with a fall back to baseline after the washout 
period, however this drop did not reach statistical significance. During the same period 
the serum butyrate levels fell in this group (p=0.031) with a non significant rise back 
towards baseline in the washout period. There was also a rise and subsequent fall in the 
serum formate levels and total amount of short chain fatty acids during this time but 
these did not reach statistical significance. This is clearly different than what happened 
in the group of healthy individuals in which I have shown a rise in the serum butyrate 
levels following the administration of Gum Arabic.  
The rate and amount of individual serum short chain fatty acids is dependent on the 
amounts and species of microflora in the colon, the source of the substrate and also the 
transit time. SCFAs produced in the colon are readily absorbed across the bowel 
mucosa in to the peripheral circulation. It has previously been demonstrated that acetate 
is the principal SCFA in the colon. Acetate is absorbed in to the peripheral circulation 
and has been shown to increase cholesterol synthesis. Propionate on the other hand has 
been shown to be an inhibitor of cholesterol synthesis [168].The changes seen in this 
study suggest a change in production of short chain fatty acids from bowel flora, 
reflected by the changes in serum levels. I have already shown earlier in this chapter 
that in this same cohort of patients there was a small but significant rise in total 
cholesterol but also, more importantly this rise was due largely to an increase in HDL 
cholesterol. It could be postulated that this rise in HDL cholesterol may be due in part 
to the rise in serum acetate. There was no associated fall in the levels of propionate to 
further account for this rise in cholesterol. 
The findings from this study are somewhat similar to what has been previously 
demonstrated. Bourquin et al [165] showed that Gum Arabic lead to a rise in production 
of acetate, propionate and butyrate, with acetate being the greatest. However, this was 
in a study of patients taking a variety of different fibre supplements, Gum Arabic being 
just one of them.  
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This thesis has discussed the fact that Type 2 Diabetes Mellitus is on a global increase 
in prevalence. Type 2 diabetes is associated with significant morbidity and mortality, 
largely as a result of the increase in macrovascular and microvascular complications 
compared to the normal population. This will ultimately result in a worldwide economic 
health burden unless steps are either taken to reduce the risk of developing type 2 
Diabetes Mellitus or to reduce the risks of developing its complications. Diabetic 
nephropathy and the associated increase in cardiovascular risk are two of the causes of 
the increased health and economic burden.  
The pathogenesis of diabetic nephropathy has been studied extensively. There is a lot of 
evidence to suggest a role of various growth factors in the development and progression 
of diabetic nephropathy. In particular TGF-β seems to be a key factor in the final 
common pathway of tissue fibrosis in many tissues, including liver, heart, lung, skin, 
and importantly to the work in this thesis the kidney. However there has been no real 
clinical application to modify TGF-β production in an attempt to reduce the progression 
of diabetic nephropathy. 
Control of glycaemia, the associated hypertension that almost invariably occurs with 
diabetic nephropathy and control of proteinuria, particularly with the use of medications 
that alter the renin angiotensin system have all been shown to reduce the risk of 
progression of diabetic nephropathy. However, the current therapeutic options for 
preventing or even slowing the progression of diabetic nephropathy are largely limited 
to these target areas, that is, strict control of blood pressure, reduction of proteinuria and 
tight glycaemic control. Cardiovascular risk factors must also be addressed and treated 
aggressively 
Dietary fibre has wide reaching health benefits, including a reduction in colorectal 
cancer, an improvement in cardiovascular risk and improvements in blood pressure. 
Dietary fibre intake has also correlated in a reduced risk in the development of type 2 
diabetes and improved glycaemic control.  
The focus of this thesis has been on Gum Arabic, a naturally occurring gum exudate 
from Acacia trees. In particular I have used SuperGumTM, a modified form of Gum 
Arabic designed such that it has a consistent molecular mass. There are anecdotal 
reports of the use of Gum Arabic in patients with end stage renal failure showing that it 
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slowed the progression of disease and reduced the need for dialysis, possibly by non 
renal nitrogen clearance. 
Colonic bacteria produce ureases that hydrolyse urea from dietary proteins to ammonia 
and CO2. The resultant ammonia is then incorporated in to bacterial proteins which are 
then excreted as the bacterial mass fraction of the faeces. The net result is an increase in 
nitrogen in the faeces, and therefore a reduction in the need for the renal clearance of 
these nitrogenous compounds. There is also an increase in bacterial short chain fatty 
acid production which is absorbed in to the systemic circulation in varying proportions. 
Short chain fatty acids have a variety of beneficial effects on health and it may be these 
that could lead to an improvement in renal function, improvements in blood pressure 
and in other metabolic factors associated with cardiovascular risk. Addition of gum 
arabic to the diet has certainly had effects on bowel flora which has resulted in a change 
in short chain fatty acid production. There does seem to be a difference in the way the 
individual patient groups have responded though. The healthy individuals have shown a 
significant increase in the levels of butyrate, whereas the incipient nephropaths have 
shown a significant rise in levels of acetate with a concurrent significant drop in the 
levels of butyrate. This rise in acetate has previously been demonstrated. There was also 
a rise in formate levels but this was not statistically significant. There was an overall 
increase in levels of short chain fatty acids following gum arabic which is likely to be 
secondary to bacterial fermentation of the fibre. Serum butyrate has been shown to 
reduce TGF-β1 production, an important profibrotic cytokine implicated in diabetic 
nephropathy.   
In the group of healthy individuals, following administration of Gum Arabic there was a 
statistically significant drop in GFR and ERPF, with no change in filtration fraction in 
the same period. This could represent a beneficial drop in intraglomerular pressure 
which could translate in to long term benefits on renal health in subjects with type 2 
diabetes. This may well have been due to the rise in serum butyrate.  However, similar 
changes were not seen in the 2 groups of subjects with type 2 diabetes. A rise in serum 
acetate and not butyrate was seen in the incipient nephropaths. It must be noted that the 
vast proportion of these patients were already on appropriate treatment for diabetic 
nephropathy, in particular drugs that block the renin angiotensin system. Further 
improvements to renal haemodynamics may be small and difficult to demonstrate in a 
relatively small population. 
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Evidence suggests one may expect a small drop in serum cholesterol in a diet 
supplemented by soluble fibre, but there is evidence to show that gum arabic may not 
possess this property. This study seems to confirm this, with in fact a statistically 
significant rise in cholesterol and triglycerides in the group of incipient nephropaths. 
Serum acetate was shown to rise in the group of incipient nephropaths and this is 
documented to lead to an increase in hepatic cholesterol synthesis. This is a potentially 
negative effect of the Gum Arabic. All subjects were requested not to change their diet 
during the study period but this was not recorded by means of a food diary. One other 
possible explanation would be that gum arabic has an as yet unrecognised stimulatory 
effect on appetite. If this were the case it could also explain the rise in serum creatinine 
in the same group but this is not supported by an increase in BMI, which remained 
unchanged. Gum arabic did not have any significant effect on HbA1C which has been 
seen in others study of dietary fibre, including soluble fibre. This could reflect the short 
time period over which the study took place or the relatively good diabetic control of 
the patient cohort prior to commencing the study. 
Control of blood pressure has a well established close correlation with progression of 
renal disease and furthermore there is a large body of evidence to suggest that 
aggressive management of hypertension has profound beneficial effects in delaying its 
progression, not to mention its effects on the reduction of overall cardiovascular risk. 
This study has demonstrated several improvements in peripheral blood pressure. 
Healthy individuals showed a drop in systolic blood pressure and incipient nephropaths 
in diastolic blood pressure, with a trend towards a drop in systolic pressure. A drop in 
MAP was shown in the overt nephropath group. These are all short term changes 
demonstrated over a period of 12 weeks and are likely to translate in to marked 
improvement in long term renal and cardiac outcomes if the gum arabic was continued. 
The direct mechanism by which this has occurred is not clear, but data from this study 
would suggest that it is not as a direct result of changes in levels of vascular stiffness. 
Vascular stiffness, in addition to peripheral blood pressure has been shown to be an 
independent predictor of all cause and cardiovascular mortality, in the general, diabetic, 
hypertensive and renal populations [55, 186, 191, 219, 220]. But, despite significant 
reductions in blood pressure in the incipient nephropaths, there have been no changes in 
the measurements of vascular stiffness or in measures of central blood pressure. This 
would therefore suggest the mechanism by which peripheral blood pressure is lowered 
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following dietary supplementation with SuperGumTM is independent of specific 
alterations in vascular stiffness. 
 
5.1 Limitations of the Study 
 
Ideally this study would have been conducted as a randomised controlled double blind 
study, rather than an unblinded study with a washout period and no placebo arm. This 
however would have been prohibitively expensive to have undertaken. Patient 
recruitment to the main study of incipient nephropaths was difficult and resulted in 
smaller patient numbers than what was calculated in the power calculation. Ideally 30 
patients should have been recruited to the follow on study, rather than the 23 that were 
recruited, meaning the study was underpowered. The study required numerous lengthy 
visits for investigations and the requirement to take a supplement every day, both of 
which I believe were barriers to joining the study to some patients. Patient compliance 
with taking the SuperGumTM was very good and the side effects, as discussed, were 
minimal with occasional bloating being the most common symptom. This did not 
however lead to any withdrawals from the study. Attempts were made to record 
compliance by counting the number of foil sachets of gum arabic returned, but 
measuring true compliance is difficult and it is possible that not all patients took all of 
the supplements which again would significantly affect the results. Due to the relatively 
small sample size, it has been difficult to draw conclusions from some of the 
investigations. For instance many of the groups have shown changes in blood pressure 
and renal function (GFR and EPRF) but these have not reached statistical significance 
potentially due to the small numbers. It would have also been beneficial to ask the 
participants in the study to keep a food diary. As discussed, it is possible some of the 
subjects were already taking a high fibre diet and the addition of further fibre may have 
not been of any benefit.  
There appear to have been changes in blood pressure from the first study visit to the 
second visit, following dietary supplementation with gum arabic. Blood pressure was 
only recorded with a sitting office blood pressure. A potential bias has been introduced 
as the subjects’ blood pressures may well have “regressed to the mean” purely by virtue 
of the fact that they could have been more relaxed on a second visit. A potential way 
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around this would be to ideally use 24 hour blood pressure monitoring to measure blood 
pressure, or by means of a randomised placebo controlled study. 
As stated earlier this study was supported by a grant by San-Ei Gen, the company that 
manufacture SuperGumTM and the study could be criticised for this as a potential bias 
could be introduced.  
It is not clear form any studies how long the effects of TGF-β or other profibrotic 
cytokines take to cause a noticeable effect on renal function and indeed how long these 
changes may take to reverse. A period of 12 weeks was taken to supplement the diets 
with SuperGumTM but it is entirely feasible that this study has not allowed sufficient 
time to make meaningful and detectable differences in renal function, particularly the 
benefits that are likely to arise as a result of the potential blood pressure lowering effect 
that has been seen. 
A potential criticism of the study would be that a significance level of p<0.05 was 
chosen for both the primary and secondary outcomes. One could argue that a more 
stringent level of significance would be taken for secondary outcomes, for instance 
p<0.01. This may well be reasonable for some outcomes. However, for changes in short 
chain fatty acids, this was an expected change and key to the hypothesis of the action of 
gum arabic and a significance level of p<0.05 is reasonable. For some of the other 
metabolic parameters, if a level of p<0.01 were chosen, it would have actually meant 
that there were no significant changes in levels of glucose control or of lipid 
metabolism. 
 
5.2 Future directions 
 
There evidence presented in this thesis suggests that dietary supplementation with 
SuperGumTM may have some clinically important effects on renal function and on blood 
pressure in certain populations, which could translate in to long term health benefits. In 
particular it is interesting to note that the healthy individuals were the only group to 
have had a drop in GFR and ERPF, and indeed a change in systolic blood pressure, and 
are also the only group to have had a rise in serum butyrate.  A clinically and 
statistically significant change in diastolic pressure was seen in the incipient 
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nephropaths, a group of individuals with a high cardiovascular risk. I believe there is 
enough evidence to support further investigation in to the use of Gum Arabic 
compounds. The group who are most likely to see a potential benefit are the incipient 
nephropaths. However, a larger sample size would be required and ideally studied for a 
longer period of time. Changes in blood pressure and small changes in renal function 
are only likely to show beneficial effects on outcome in the long term.  
A further study, ideally of a double blind randomised placebo controlled design should 
be undertaken to confirm these potential health benefits. Again, a population of subjects 
with type 2 diabetes and incipient nephropathy should be chosen as I believe these are 
an at risk group who may have the potential to benefit. Combination of the Gum Arabic 
powder in to foodstuffs such as bread and biscuits would make this an easier substance 
to ingest on a regular long term basis. 
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The Effects of Acacia (sen) SUPER GUM™ (Gum Arabic) on 
renal physiology and arterial function in Type II diabetic 
patients 
PATIENT INFORMATION SHEET 
 
You are being invited to take part in a research study. Before you decide to take part it is 
important for you to understand why the study is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with friends, relatives. Ask 
us if there is anything that is not clear or if you would like more information. Take time to 
decide whether or not you wish to take part. 
Consumers for Ethics in Research (CERES) publish a leaflet entitled ‘Health Research and 
You’. The research nurse coordinating this study can give you a copy of this leaflet.  
1. What is the purpose of the study? 
Good control of blood pressure and blood sugar has been shown to help in slowing the 
progression of diabetic kidney disease.  There is also some evidence from laboratory studies 
that the addition of extra fibre in the form of “Gum Arabic” may be able to stabilise kidney 
function. Gum Arabic is used as a stabilising additive in many processed foods and is regarded 
as very safe. 
2. Do I have to take part? 
It is up to you to decide whether or not to take part. If you do decide to take part you will be 
given this information sheet to keep and be asked to sign a consent form. If you decide to take 
part you are still free to withdraw at any time and without giving a reason. This will not affect 
the standard of care you receive. If you decide not to take part, you do not have to give a reason 
and the care you receive now or in the future will not be affected. 
3. What will happen to me if I take part? 
If you agree to take part in this study, the doctor will examine you and take a blood sample to 
make sure you can take part. Each patient will be part of the study for a total of 24 weeks, 12 
weeks of which you will be taking the fibre supplement. At the start of the study there will be a 
screening visit where a doctor will go through the study with you, measure your blood pressure 
and do a basic physical investigation. This screening visit will last approximately 30 minutes. 
This will be followed by a 4 week run in period if the initial examination shows that you are 
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eligible to enroll in the study. During this time you will have to make a visit to the hospital 
when your blood pressure will be monitored and your kidney function assessed to make certain 
that you will be able to take part in the study. This visit will last about 20 minutes. 
After the initial screening visit you will need to attend the Clinical Investigation unit a further 3 
times, at 4 weeks, 12 weeks after that and then after a further 6-8 weeks. 
 
 
 
 
 
 
 
These visits (Test Points) will each take about five hours and we will ask you to bring a 24-hour 
collection of urine with you each time. 
• Test point 1 
This visit will consist of having a thin plastic tube inserted into a vein in your arm, which will 
be used to inject low dose radioactive material into your blood stream. The amount of 
radioactivity in this injection is around the same as you would get from a flight to Rome or a 2 
week holiday in Cornwall. This test measures the blood flow to your kidneys by measuring the 
radioactivity in blood samples (10ml or about 2 teaspoons will be taken on 4 occasions from the 
thin plastic tube). The total amount of blood that will be drawn during each visit will be 
approximately 40 ml (8-10 teaspoons).  We will also take an extra 10 ml of blood for other 
biochemical tests that are necessary for the study. In addition we would also like to assess the 
effects of the study medication on the blood vessels. This is done with a special ultrasound 
machine and does not involve the use of any needles. A probe is placed on an artery at the wrist, 
neck and top of the thigh. Measurements are then made with the help of a computer. The only 
thing you will feel is slight pressure when the probe is placed on the skin and the procedure is 
not painful. It will take about 20 minutes to perform and can be done during the assessment of 
your kidney function. You will also be fitted with a 24 hour blood pressure monitor which will 
check your blood pressure at home every hour automatically. We will provide you with a 
stamped addressed envelope to post this back to us the following day. 
 
You will then be commenced on the Gum Arabic. The study period during which you take the 
Gum Arabic is scheduled to last 12 weeks and during this time you will be given a drink to take 
every morning, which has the Gum Arabic in it. The Gum Arabic is supplied as a dried powder 
and we will provide a bottle to allow you to mix the powder with water and flavour of your 
choice e.g. orange squash. During the study you will be phoned every two weeks by the 
research team coordinating the study who will check that you are alright.   
• Test point 2 
Following taking the Gum Arabic for 12 week period, the same tests as Test Point 1 will be 
done. 
• Test Point 3 
In order to be sure that any effects seen are due to the Gum Arabic a final test of kidney 
function will be arranged 6-8 weeks after you have finished taking the study material.  
The tests performed will be as Test point 1 
4 weeks 
Run in 
12 weeks 
Gum Arabic 
8 weeks 
Wash out 
Screening 
Test point 1 Test point 2 Test point 3 
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To further assess the mechanism behind the potential benefit of the Gum Arabic we would like 
some volunteers to provide a stool sample to be analyzed for chemicals and natural 
microorganisms that are usually present. These may change with the Gum Arabic treatment. We 
would provide a small container for you to collect the sample and then we would send this off 
to Japan for analysis. This part of the study is completely voluntary and if you felt that you were 
unable to help with this particular aspect of the study that would be ok. 
You can decide to stop the study at any time.  This will not affect your future care in any way. 
You may also be taken out of the study by the doctor if he thinks it is necessary. 
4. What are the possible disadvantages and risks of taking part? 
Having a needle in your arm to take blood can be uncomfortable. Apart from this we would not 
expect you to suffer in any way. Gum Arabic is a food additive used in many products which 
are eaten every day, however it is possible that you may feel a bit bloated or have ‘wind’ while 
taking part in the study. In our experience this is usually very mild and infrequent. To the best 
of our knowledge there are no known interactions with your regular medication. 
5. What are the possible benefits of taking part? 
Taking part in this study will not help you directly, however we hope it may help us to 
understand diabetic kidney disease more clearly.  
6. Will my taking part in this study be kept confidential? 
If you agree to take part in the study, any of your medical records may be inspected by the 
investigators carrying out the research. They may also be looked at by people from the 
Regulatory Authorities to check that the study is being carried out correctly. Your name, 
however, will be kept secret outside the hospital. With your permission, your doctor will inform 
your General Practitioner that you are taking part in the study. 
7. What will happen to the results of the research study? 
A report containing the results of this study will be written and submitted for publication in a 
medical journal. Your identity will not be revealed in this report. 
8. Who is organising and funding the research? 
The research is being funded by San-Ei Gen FFI, Osaka, Japan who have provided a grant to the 
Institute of Nephrology to cover a research doctor salary and the cost of all the research study 
tests 
9. Who has reviewed the study? 
This study has been reviewed and approved by the South East Wales Research Ethics 
Committee. 
10. Costs/Reimbursement 
All travel expenses (including parking) will be paid back. 
11. Contact for further information 
Now or during the course of the study, if you have any needs or questions concerning this study 
or your rights as a patient or in case of emergency, you should contact the doctor or nurse at the 
number below. You will be given a copy of the information sheet and a signed consent form to 
keep.  
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Contact:  Dr Dave Glover:  Tel 02920 748435 
  Dr Steve Riley: Tel 02920 748467   
 
Thank you for taking the time to read this information sheet. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
174 
Screening Assessment 
 
 
 
Date: …….//……//……. 
 
  
 
 
 
Type II DM diagnosis date:…………………….. 
 
Microalbuminuria? Yes / No  If yes, diagnosis date…………………… 
 
ACR……………………(>2.5 male, >3.5 female : <30) 
 
DM medications ………………………. 
   ………………………. 
   ………………………. 
   ………………………. 
 Insulin? Yes / No 
 
 
Name: 
 
Address: 
 
Affix label here 
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Medications (Cardiovascular) 
 
Diuretic………………………… Ca channel blocker………………………. 
Beta-blocker…………………… ARB………………………………………  
ACE inh……………………….. Nitrate…………………………………….  
Statin…………………………...       Other……………………………………… 
 
Other Risk Factors 
 
Angina      Y / N 
CABG       Y / N 
FHx of CV disease     Y / N 
Previous CVA / TIA     Y / N 
Hypertension      Y / N 
Previous MI      Y / N 
Dyslipidaemia      Y / N 
Smoker (current or past = Y)    Y / N  PYH……………. 
Retinopathy      Y / N 
Neuropathy      Y / N 
Peripheral Vascular Disease    Y / N 
 
Other Past Medical History 
 
 
 
Relevant Family History 
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Examination 
 
Height…………………. 
Weight………………… 
 
Pulse…………….AF?…  RS 
BP……………………... 
HS……………………... 
JVP……………………. 
Oedema……………….. 
 
 
Abdo 
 
 
Notes / Additional Comments 
 
 
Bloods to do etc. 
 
U+E, bicarb 
HbA1C 
Lipid Profile 
 
24 hour urine protein 
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Sign consent form  (copy x3) 
Fill out expenses form  (copy x3) 
Give instructions on 24 hr urine 
24 hr urine bottles x 2 
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Instructions for 24 hour urine collection 
 
The following are instructions for the proper collection of a 24-hour urine specimen.  
The aim is to collect every all of your urine during the specified 24-hour period. It does 
not matter what the volume of the urine is, so long as it represents all of the urine you 
pass. If you need to have a bowel movement, you must collect the urine separately. If 
unable to do so you should abandon the collection and start again on another day. 
• Begin the collection at the usual time that you awaken.  
• At that time, pass your urine, flush it down the toilet and note the exact time. 
You will now have an empty bladder and an empty bottle. The collection of 
urine will start from this time. 
• Collect all of the urine you pass during the day and night and finish the 
collection by passing urine at exactly the same time the next morning; this 
specimen of urine should also be collected in the bottle. 
• The time you void the last urine specimen should not vary by more than 5 or 10 
minutes from the time of starting the collection the previous day. If you have to 
urinate one hour before the appointed time, drink a full glass of water or more so 
that you can void again at the appropriate time. If you have to urinate 20 
minutes before try and hold the urine until the proper time. This is necessary in 
order to accurately interpret the results of the test. 
• You can store the bottle at normal room temperature for a day or two, but 
ideally hand the sample in to the Institute of Nephrology at the Hospital. The 
bottle should be kept cool or refrigerated for longer periods of time.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
179 
Pulse Wave Analysis / Isotope GFR – Patient Record 
 
 
 
Date: …….//……//……. 
 
 
 
 
Visit:  Initial – after run-in      
   
Post Gum Arabic  
   
Post Washout     Compliance………..(not taken) 
       
      Side effects…………………… 
 
 
 
Medications (Cardiovascular) 
 
Diuretic………………………… Ca channel blocker………………………. 
Beta-blocker…………………… ARB………………………………………  
ACE inh……………………….. Nitrate…………………………………….  
Statin…………………………...       Other……………………………………… 
 
DM medications ………………………. 
   ………………………. 
   ………………………. 
   ………………………. 
 Insulin? Yes / No 
 
 
Notes 
 
 
 
 
 
Name: 
 
Address: 
 
Affix label here 
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Pulse Wave Analysis – AIx 
 
 
BP (average):          ……./…....mmHg   
 
Height:   …………cm 
 
Weight:  …………kg   
 
 
AIx 
(Circle 2 to be used – within 4%) 
 
1:……  2:……  3:……  4:……  5:……  6:…… 
 
 
 
Pulse Wave Velocity 
 
 
BP (average):          ……./…....mmHg   
 
Distances: 
 
Femoral to Umbilicus to Suprasternal notch:....................mm 
 
Radial to Suprasternal notch:……………………………mm 
 
Carotid to Suprasternal notch:…………………………..mm 
 
 
 
PWV (Radial to Carotid) 
(Circle 2 to be used – within 0.5m/sec) 
 
1:……… 2:……… 3:……… 4:……… 5:……… 6:……… 
 
 
PWV (Femoral to Carotid) 
(Circle 2 to be used – within 0.5m/sec) 
 
1:……… 2:……… 3:……… 4:……… 5:……… 6:……… 
 
 
Isotope GFR / ERPF 
 
Time commenced………………………. 
 
